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Oxytocin release within the brain modulates several social behaviours 
in animals and humans. Moreover, low central oxytocin content has been 
linked to neuropsychiatric disorders, such as anxiety and autism. The 
exogenous administration of oxytocin has been proposed for therapeutic 
treatment, but oxytocin does not cross the blood-brain barrier (BBB) in 
physiologically significant amounts. An alternative approach to oxytocin 
administration is to stimulate central oxytocin release using melanocortins. 
Central administration of the naturally occurring melanocortin, 
α-MSH, has been shown to trigger somatodendritic oxytocin release in vitro. 
Unfortunately, endogenous melanocortins also do not penetrate the BBB in 
neuroactive amounts. In this study, I investigated whether systemic 
administration of synthetic melanocortin receptor 3/4 (MC3/4) agonist, 
Melanotan-II (MT-II), affects oxytocin neuronal activity and secretion in 
anaesthetised rats. I hypothesised that systemic administration of MT-II 
directly (centrally) acts on magnocellular oxytocin neurones to trigger 
somatodendritic oxytocin release from neurones of the supraoptic nucleus 
(SON) of the hypothalamus in vivo.   
Firstly, using double immunohistochemistry against Fos protein, a 
widely used marker for neural activity, and oxytocin, I showed that 
intravenous (i.v.; 1 mg/kg), but not intranasal (1 and 30 µg rat), 
administration of MT-II markedly induced Fos expression in magnocellular 
oxytocin neurones of the SON and paraventricular nuclei (PVN) of the 
hypothalamus, and this response was prevented by prior 
intracerebroventricular (i.c.v.) administration of the melanocortin antagonist, 
SHU-9119 (1 µg rat). In addition, brain areas receiving peripheral inputs 
which are involved in the regulation of oxytocin and vasopressin release 
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were also analysed, showing that i.v. MT-II significantly increased Fos 
expression in the nucleus tractus solitarii (NTS), but not in circumventricular 
organs of the anteroventral third ventricle (AV3V) region. MT-II-induced Fos 
in the NTS was not prevented by the i.c.v. melanocortin antagonist.  
Then, using in vivo electrophysiology, I investigated whether i.v. 
administration of MT-II affects the electrical activity of SON neurones. 
Extracellular single-unit recordings from identified magnocellular neurones 
of the SON showed that MT-II significantly increased the firing rate in 
oxytocin neurones, however, no significant changes in firing rate were 
detected in vasopressin neurones.  
Finally, in vivo oxytocin release experiments showed that i.v. 
administration of MT-II did not trigger somatodendritic oxytocin release 
within the SON as measured by microdialysis and subsequent 
radioimmunoassay. Interestingly, the i.c.v. administration of MT-II (1 µg rat) 
also failed to trigger oxytocin release within the SON. The analysis of 
oxytocin content in plasma revealed that the change in oxytocin 
concentration was significantly greater in i.v. MT-II injected rats compared to 
vehicle-injected rats.  
Taken together, these results show that after i.v., but not intranasal, 
administration of MT-II, the activity of magnocellular neurones of the SON is 
increased. As previous studies showed that SON oxytocin neurones are 
inhibited in response to direct application of melanocortin agonists, the 
actions of i.v. MT-II are likely to be mediated, at least in part, indirectly by 






Oxytocin is a hormone produced in the brain and transported to the 
posterior pituitary gland from where is release into the blood to act on 
peripheral organs. However, oxytocin is also released within the brain, 
where it modulates several social behaviours in animals and humans. 
Interestingly, low levels of oxytocin within the brain have been linked to 
neuropsychiatric disorders, including anxiety and autism. Thus 
administration of oxytocin has been proposed for therapeutic treatment, but 
oxytocin cannot penetrate through layers protecting the brain (blood-brain 
barrier). An alternative approach is to stimulate the release of oxytocin 
within the brain using a group of hormones (melanocortins), which have 
been shown to activate the oxytocin system. However, the naturally 
occurring melanocortin α-MSH, which has been shown to activate oxytocin 
neurones, also does not penetrate the blood-brain barrier.  
Here, I study whether injection of the synthetic melanocortin 
Melanotan-II (MT-II) acts on the brain affecting the activity of 
oxytocin-producing neurones resulting in oxytocin release within the brain 
in rats. Using a gene product activated by changes in neuronal activity, I 
showed that intravenous MT-II, affected the activity of oxytocin neurones, 
and this effect was prevented by the administration of an MT-II blocker 
(antagonist). Then, I recorded the firing pattern of oxytocin neurones, 
showing that MT-II enhanced their spontaneous electrical activity. To 
determine whether MT-II induced release of oxytocin within the brain, the 
content of oxytocin was measured in a brain region where a group of these 
neurones are clustered, the supraoptic nucleus of the hypothalamus.  
All our findings indicate that after intravenous administration of MT-
II the activity of oxytocin neurones is increased, but this does not result in 
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oxytocin released within the brain. Hence, MT-II is not an appropriate drug 
for the treatment of neuropsychiatric disorders associated with low levels of 
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Chapter 1  
General introduction  
  
 
1.1. BACKGROUND  
Oxytocin, firstly sequenced by Du Vigneaud et al. (1953b), was 
originally described as a hormone by its uterotonic actions following 
intravenous (i.v.) administration of pituitary extracts (Dale, 1906). 
Nowadays, it is well established that oxytocin also acts within the brain: 
central (i.e. synaptic and somatodendritic) oxytocin release modulates 
pro-social behaviours (Fahrbach et al., 1984; Insel et al., 1998) which are 
elicited by activation of oxytocin receptors (OTR) expressed in structures 
involved in cognitive and emotional processing (Ferguson et al., 2001; 
Keebaugh & Young, 2011).  
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Several reports have linked neuropsychiatric disorders to alterations 
of oxytocin systems, these alterations include mutation in peptide forms and 
receptors, and changes in peripheral and central oxytocin content. 
Interestingly, low content of oxytocin in the cerebrospinal fluid (CSF) has 
been associated with autism, anxiety, depression, and schizophrenia 
(Linkowski et al., 1984; Modahl et al., 1992; Insel et al., 1999; Heim et al., 2009). 
The exogenous administration of oxytocin has been proposed for the 
treatment of neuropsychiatric disorders, but systemically administered 
oxytocin is not able to penetrate the brain in physiologically significant 
amounts (Zaidi & Heller, 1974; Mens et al., 1983; Ermisch et al., 1985). 
Therefore, alternative approaches are required for the treatment of mental 
disorders associated with low central oxytocin levels. The endogenous 
melanocortin alpha-melanocyte stimulating hormone (α-MSH) stimulates 
somatodendritic oxytocin release in vitro while inhibiting peripheral release 
from nerve endings by decreasing electrical activity in vivo (Sabatier et al., 
2003a). Unfortunately, like oxytocin, α-MSH does not penetrate the brain in 
neuroactive amounts (Wilson et al., 1984; Wilson, 1988). 
Melanotan-II (MT-II) is a synthetic α-MSH analogue acting on 
melanocortin receptors isotype 3 (MC3) and 4 (MC4). These receptors are 
expressed in the paraventricular (PVN) and supraoptic nuclei (SON) of the 
hypothalamus (Kishi et al., 2003) which contain large populations of oxytocin 
(and vasopressin) neurones. It is thought that, at least some, MT-II might 
penetrate the blood-brain barrier (BBB) following peripheral administration, 
as suggested by behavioural actions (i.e. stretch and yawning) observed in 
animals and humans (Dorr et al., 1996). Recently, Modi et al. (2015) reported 
that systemic injection of MT-II stimulates pair-bonding in prairie voles by an 
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oxytocin-dependent mechanism, supporting the notion that peripheral 
administration of MT-II might modulate central oxytocin systems.  
Whether MT-II acts centrally (directly) on oxytocin neurones or 
through peripheral pathways following i.v. injections of MT-II is unknown. 
Furthermore, there is no evidence about the effects of i.v. administered MT-II 
on electrical activity and release of SON oxytocin neurones in vivo. In this 
thesis, I investigate these questions which are key to validate new 
therapeutic strategies for the treatment of neuropsychiatric disorders related 
to low central oxytocin levels.   
 
1.2. LITERATURE REVIEW  
1.2.1. Oxytocin system 
1.2.1.1. Oxytocin and vasopressin synthesis  
Oxytocin is a nonapeptide synthesised as part of a large precursor 
containing the carrier peptide neurophysin-I. The structure and sequence of 
oxytocin is closely related to those of the peptide vasopressin, differing at the 
amino-acid residues 3 and 8 (Du Vigneaud et al., 1953a; Du Vigneaud et al., 
1953b); vasopressin is associated to neurophysin-II and the glycopeptide 
copeptin. Oxytocin and vasopressin are synthesised and packaged in vesicles 
in the soma of separate neurones. Then, these peptide-containing large 
dense-cored vesicles (LDCVs) are transported to different neuronal 
compartments to be released. The primary sites of synthesis of oxytocin are 
the SON, and PVN of the hypothalamus (Brownstein et al., 1980).  
The SON contains neurones exclusively with a large cell body, called 
magnocellular neurones. The soma of SON magnocellular neurones are densely 
clustered on the ventral surface of the brain, along the optic chiasm (Swanson 
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& Sawchenko, 1983). These neurones have between one and three dendrites 
(Pow & Morris, 1989) laying parallel to the ventral surface, and intermingled 
within a layer of glial cells, the glia ventral limitans (Yulis et al., 1984). The 
neurones of the SON mainly express either oxytocin or vasopressin, and are 
organised in a distinctive pattern, in which oxytocin neurones are distributed 
in the anterodorsal SON (Sawchenko & Swanson, 1983; Swanson & 
Sawchenko, 1983). Additionally, oxytocin neurones can be found lying on the 
ventral surface of the brain, called the retrochiasmatic part of the SON. 
Virtually all SON neurones project their axons to the posterior pituitary 
(neurohypophysis) (Swanson & Sawchenko, 1983).  
The PVN contains magnocellular neurones, and also neurones with a 
smaller cell body (parvocellular neurones). Oxytocin (and also vasopressin) 
is synthesised in magnocellular and parvocellular neurones of the PVN; 
within these two subpopulations, several anatomical subdivisions have been 
described (Swanson & Kuypers, 1980). As in the SON, magnocellular 
neurones of PVN project to the posterior pituitary, whereas parvocellular 
populations project to distant targets within the central nervous system 
(CNS), including the brainstem and spinal cord (Swanson & Kuypers, 1980; 
Sawchenko & Swanson, 1983), to release their peptides synaptically. The 
PVN also contains neurones expressing other peptides, including 
corticotrophin releasing hormone (CRH), thyrotropin releasing hormone 
(TRH), somatostatin, and enkephalin (Lechan & Jackson, 1982; Sawchenko & 
Swanson, 1982a; Sawchenko et al., 1984).  
In addition to the PVN and SON, oxytocin neurones can be found in 
small clusters of neurones or accessory nuclei, these include the nucleus 
circularis located between the PVN and SON, as well as small groups 
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neurones located in the bed nucleus stria terminalis, and the lateral 
hypothalamic area (Sofroniew & Glasmann, 1981). 
Magnocellular neurones of the SON and the PVN project their axons 
to the posterior pituitary along the hypothalamic-neurohypophyseal tract 
which passes through the internal zone of the median eminence towards the 
posterior pituitary, where the nerve endings release oxytocin and 
vasopressin into the bloodstream (Sawchenko & Swanson, 1983; Swanson & 
Sawchenko, 1983). Parvocellular neurones project their axons to several 
targets within the brain, including the external zone of median eminence, 
amygdala, hippocampus, olfactory bulb, and brainstem (Sawchenko & 
Swanson, 1982a; Yulis & Rodriguez, 1982; Sawchenko & Swanson, 1983; 
Castel & Morris, 1988).  
 
1.2.1.2. Oxytocin receptor 
The human OTR complementary deoxyribonucleic acid (cDNA) was 
first sequenced by Kimura et al. (1992), encoding a 388- amino acid protein 
receptor with seven transmembrane domains. The receptor is highly 
conserved among the mammals, showing a 93 % of the sequence homology 
with the rat OTR (Rozen et al., 1995). 
The OTR is a member of the G-protein coupled receptor (GPCR) 
family, and its seven transmembrane domains are highly conserved among 
the GPCR family. For the OTR, it has been proposed that changes in the 
orientation of transmembrane domains 3 and 6 command the switch between 
the active to inactive conformation, consequently exposing G-protein binding 
sites (Gimpl & Fahrenholz, 2001). In uterine myometrial cells, the OTR is 
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associated with a Gq/11 protein that mediates its actions through the 
phospholipase C pathway, leading to an increase in intracellular calcium 
concentration ([Ca2+]I) (Ku et al., 1995; Sanborn et al., 1998). 
So far, just a single OTR isoform has been reported. However, the 
OTR shows 40 % to 50 % of sequence homology compared to the vasopressin 
V1 and V2 receptors. As a consequence, there are low levels of cross reaction 
between oxytocin and vasopressin. It is believed that between OTR and 
vasopressin receptors there are common and specific contact sites for the 
ligand binding interaction (Gimpl & Fahrenholz, 2001). However, the OTR 
has a 10-fold greater affinity for oxytocin than vasopressin (Baribeau & 
Anagnostou, 2015). 
 
Oxytocin receptor distribution  
In the brain, the OTR is expressed in several regions, including the 
amygdala, brainstem, hippocampus, hypothalamus, and the olfactory system 
(Table 1.1.). The expression and distribution of OTR vary according to the 
species, sex, and age (Insel & Shapiro, 1992; Vaccari et al., 1998; Young, 1999; 
Bale et al., 2001). Peripherally, the receptor is expressed in several tissues, 
including the uterus, mammary gland, ovary, kidney, and heart (Gimpl & 
Fahrenholz, 2001).   
Several factors regulate the expression of the OTR, but oestrogen is 
probably one of the most relevant regulators. In the brain and uterus, 
activation of the oestrogen receptor type alpha (ERα) upregulates cell 
expression of OTR (Alves et al., 1998; Young et al., 1998). Although basal 
synthesis of the OTR has been detected in ERα knock-out mice, ERα is 
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indispensable for the induction of OTR binding in the brain by oestrogen 
(Young et al., 1998).  
 
1.2.1.3. Oxytocin release  
Oxytocin- and vasopressin-containing vesicles can be released from all 
compartments of the magnocellular neurones (i.e. nerve endings, non-dilated 
segments of the axon, axon swellings, soma, and dendrites) (Pow & Morris, 
1989; Morris & Pow, 1991). The release from these compartments is 
differentially regulated in magnocellular neurones.  
 
Peripheral release 
The posterior pituitary stores a large amount of oxytocin and 
vasopressin, which are able to maintain, in steady-state conditions, basal 
plasmatic concentrations for 3-4 weeks. It is estimated that approximately 5 
% of the neuropeptide content is released to the bloodstream in 24 h (Jones & 
Pickering, 1972). However, high demand conditions can dramatically 
increase oxytocin (and vasopressin) release, for instance, 3 days of water 
deprivation can deplete the posterior pituitary stores to only 10 % of its 
normal level. In steady-state conditions, newly-made peptides arrive at the 
posterior pituitary at a rate that closely matches the release and destruction 
of old peptide-containing vesicles, keeping the peptide content roughly 
constant. Nevertheless, under high-demand conditions the increase in release 
is not coupled to the newly-synthesised peptide due to a lag in the peptide 
synthesis, leading to the depletion of the posterior pituitary (Leng et al., 
2012). 
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The release of peptide-containing vesicles from the nerve endings is 
determined by action potentials arriving from the soma of magnocellular 
neurones, which invade the nerve endings, opening voltage-gated Ca2+ 
channels that allows Ca2+ entry, and consequently, leading to the fusion of 
vesicles with the cell membrane (Nordmann, 1983). The amount of oxytocin, 
and also vasopressin, released with each action potential (spike activity) 
increases with the frequency and pattern of activity, and in oxytocin 
neurones, increasing frequencies of action potentials sustain the release of 
larger amounts of peptide into the bloodstream (Bicknell, 1988). In contrast to 
low spike frequencies (which do not invade all the nerve endings, and induce 
a small increase in [Ca2+]I because the voltage-gated Ca2+ channels are opened 
for a very brief period), high spike frequencies result in a greater number of 
nerve endings depolarized, and also induce a larger Ca2+ entry which is 
essential to trigger and facilitate the exocytosis of vesicles (Bourque, 1991).   
 
Central release 
In magnocellular neurones, oxytocin and vasopressin release from the 
dendritic compartment can occur independently or semi-independently of 
peripheral release. The release from dendrites in the hypothalamus and 
nerve endings located in the posterior pituitary can be triggered on different 
time points in response to the same stimulus or can be regulated completely 
independently. For instance, in lactating rats, suckling stimulus evokes 
oxytocin release within the SON that precedes peripheral oxytocin release 
(Moos et al., 1989). On the other hand, systemic osmotic stimulation evokes 
peripheral oxytocin release, but the release within the SON is delayed 
approximately by 1 h (Ludwig et al., 1994). 
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Oxytocin, and vasopressin released from dendrites have autocrine and 
paracrine effects which are mediated by activation of autoreceptors (Freund-
Mercier et al., 1994; Hurbin et al., 2002). Oxytocin itself (and also other 
peptides, such as α-MSH) can elicit dendritic oxytocin release without 
inducing release from nerve endings, and conversely, electrical activity in the 
soma can trigger release from nerve endings without evoking dendritic 
release (Ludwig et al., 2002). Dendritic peptide release has a role in 
autoregulation of the electrical activity of the same neurone from which the 
peptide is released, as shown by direct application of vasopressin which 
results in inhibition of phasic vasopressin neurones (Leng & Mason, 1982; 
Abe et al., 1983; Ludwig & Leng, 1997).  
As described above, dendritic release can occur independently of 
electrical activity. In oxytocin neurones, oxytocin itself stimulates dendritic 
release by mobilising intracellular Ca2+ from thapsigargin-sensitive stores, 
and consequently, rising [Ca2+]i (Lambert et al., 1994) which result in oxytocin 
release without electrical activity (Ludwig et al., 2002). In vasopressin 
neurones, the rise in [Ca2+]I is mediated by combined extracellular Ca2+ entry 
and mobilisation of intracellular Ca2+ from thapsigargin-sensitive stores 
(Ludwig et al., 2005).  
In addition, mobilisation of intracellular Ca2+ stores make dendritic 
(but not nerve endings) oxytocin stores available (priming) for 
activity-dependant release (Ludwig et al., 2002). Priming increases the pool of 
readily-releasable vesicles by relocating vesicles in close proximity to the 
dendritic plasma membrane (Tobin et al., 2004), which results, for example, in 
a larger amount (potentiation) of oxytocin dendritically released in response 
to hypertonic stimulation in thapsigargin-pretreated rats in vivo (Ludwig et 
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al., 2002). Nevertheless, priming effects are not immediate because it requires 
relocation of vesicles, and its effects can be detected 30 min after priming 
stimulation, however, these are long-lasting (+ 90 min), as observed in vitro 
(Ludwig et al., 2002). Hence, priming modifies the level of dendro-dendritic 
communication, increasing the coordination of magnocellular neurones, and 
increasing dramatically the amount of peptide released.  
Finally, oxytocin and vasopressin are also released synaptically from 
parvocellular neurones of the PVN which project to central targets 
(Sawchenko & Swanson, 1982a). However, the parvocellular system contain 
much less peptide than the magnocellular system, and this content does not 
account for CSF concentrations, but because virtually all magnocellular 
neurones project to the posterior pituitary it has been assumed that central 
actions are driven by release from parvocellular neurones (Ludwig & Leng, 
2006).  
 
1.2.1.4. Physiological roles of oxytocin  
1.2.1.4.1. Central roles of oxytocin 
Oxytocin has several behavioural effects when it is centrally released. 
Since peripherally released oxytocin cannot re-enter to the brain in 
significant amounts due to the BBB (Zaidi & Heller, 1974; Mens et al., 1983; 
Ermisch et al., 1985), these behavioural actions are evoked by oxytocin 
released from dendrites of magnocellular neurones and oxytocin synaptically 
released from parvocellular neurones (Neumann, 2007; Stoop, 2012). 
Interestingly, several oxytocin pathways projecting from the PVN to different 
brain areas have been reported, including to the amygdala, lateral septum 
and hippocampus (Buijs, 1978; Buijs & Swaab, 1979).   




The role of oxytocin as a modulator of maternal behaviour was firstly 
reported by Pedersen and Prange (1979), showing that 
intracerebroventricular (i.c.v.) administration of small doses of oxytocin 
elicited full maternal behaviour in virgin rats. Subsequent studies using 
pharmacological blockage of OTR, and optogenetic stimulation of oxytocin 
neurones of the PVN have confirmed that central oxytocin release is crucial 
to evoke maternal behaviour (van Leengoed et al., 1987; Marlin et al., 2015). 
At the end of pregnancy, high levels of prostaglandins increase the 
expression of OTR which combined with large amounts of central (and 
peripheral) oxytocin released during labour (Pedersen et al., 1982) are the key 
factors to initiate recognition and nurturing of the offspring, two key 
components of maternal care.  
The maternal behaviour is mainly regulated by OTR expressed on the 
medial preoptic area and bed nucleus of the stria terminalis, as it has been 
shown by lesioning of these areas (Numan & Young, 2016). Oxytocin 
released from PVN projections during labour, and then during lactation are 
thought to be responsible for activation of neurones located in the medial 
preoptic area (Numan et al., 2006). In addition, Marlin et al. (2015) have 
shown that optogenetically-evoked PVN oxytocin release acting on OTR of 
the left auditory cortex stimulates pup retrieval in virgin mice. 
 
Pair Bonding  
The evidence of the involvement of oxytocin in partner preference has 
been obtained from pharmacological, behavioural, and neuroanatomical 
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studies of non-monogamous and monogamous species of voles (genus 
Microtus). The monogamous prairie voles establish pair bond following 
mating. 
The i.c.v. administration of oxytocin, but not vehicle, strongly induces 
partner preference in virgin female prairie voles cohabiting with a male for 6 
h without mating (Williams et al., 1994). Moreover, partner preference 
induced by mating can be prevented by the administration of an OTR 
antagonist into the nucleus accumbens or into the prefrontal cortex (Young et 
al., 2001).  
Neuroanatomical studies of the distribution of the OTR in 
monogamous and non-monogamous species of voles (i.e. prairie, montane 
and meadow voles) have shown differences in the expression of OTR in 
brain structures involved in cognitive processing. In the monogamous prairie 
vole, high densities of OTR are expressed in the prefrontal cortex, lateral 
amygdala, and nucleus accumbens, whereas in the non-monogamous 
montane vole the expression of OTR is almost absent in the nucleus 
accumbens (Insel & Shapiro, 1992). This indicates that activation of OTR 
expressed in neurones of the nucleus accumbens is responsible for 
monogamous behaviour in voles.    
Genital stimulation during mating has been proposed as the 
mechanism responsible for the release of oxytocin into the nucleus 
accumbens (Ross et al., 2009). In addition to oxytocin, other peptides and 
neurotransmitters are also involved in the establishment of partner 
preference in both sexes, including vasopressin and the neurotransmitter 
dopamine (Young & Wang, 2004).   




Central and systemic oxytocin facilitate sexual behaviour in male and 
female rats, and also others species. Oxytocin exerts its actions on sexual 
behaviour by different pathways that comprises direct innervations of 
genitals and endocrine actions following peripheral and central release 
(Carmichael et al., 1987; Hughes et al., 1987). Oxytocin participates in several 
phases of the sexual behaviour, including sex arousal and sexual satiety 
(Mahalati et al., 1991; Blaicher et al., 1999).    
In male rats, sexual behaviour stimulates oxytocin neurone activity 
and release as part of the facilitation of intromission. Tracing studies have 
shown projections from the penis and sexual accessory glands to 
parvocellular and magnocellular neurones of the PVN (Marson & McKenna, 
1996; Normandin & Murphy, 2011). During mating, increased Fos expression 
in both parvocellular and magnocellular neurones of the PVN, and the SON 
have been reported (Witt & Insel, 1994; Caquineau et al., 2006), as well as 
increased oxytocin release within the PVN as measured by in vivo 
microdialysis (Waldherr & Neumann, 2007). Furthermore, electrical 
stimulation of penile nerves has been shown to excite approximately 50 % of 
the SON and PVN oxytocin neurones (Yanagimoto et al., 1996; Honda et al., 
1999). 
Peripheral oxytocin also participates in sexual behaviour, as shown by 
reduced numbers of erections in hypophysectomized rats. However, 
systemic oxytocin release from the posterior pituitary is not essential to 
induce this behaviour (Argiolas et al., 1989). I.c.v. administration, and direct 
injection of oxytocin into the PVN have been shown to induce penile 
erections in a dose-dependent manner (Argiolas, 1992). Moreover, i.c.v. 
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administration of oxytocin increases intromission latencies and ejaculatory 
behaviour (Arletti et al., 1985; Stoneham et al., 1985). 
In females, central oxytocin also participates in sexual behaviours. 
I.c.v. administration of oxytocin stimulates lordosis postures in female 
rodents, as part of the pro-receptive behaviour. The lordosis posture is 
triggered by activation of OTR located in the ventromedial hypothalamic 
nucleus (Bale et al., 2001), however, oestrogen and progesterone are also 
required to elicit this behaviour (Veening et al., 2015). 
 
1.2.1.4.2. Peripheral roles of oxytocin  
Parturition 
Before the onset of labour, the ratio of progesterone and oestrogen in 
plasma, and their uterine receptors increase, leading to an upregulation of 
OTR expression in myometrial cells, and consequently increasing the 
sensitivity of myoepithelial cells to oxytocin (reviewed by Kota et al., 2013). 
Then, myoepithelial contractions are initiated by locally produced 
prostaglandins which weakly stimulate the contraction of the uterus. These 
initial uterine contractions stimulate sensory afferents pathways projecting 
via the vagus nerve to noradrenergic neurones of the nucleus tractus solitarii 
(NTS) which, in turn, send excitatory projections to magnocellular oxytocin 
neurones, activating them (Douglas et al., 2001). The oxytocin secreted 
enhances the uterotonic actions of prostaglandins by a direct action on the 
myometrium, and also by increasing the synthesis of prostaglandins by the 
endometrium. As delivery progresses, a positive feedback is established 
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(Ferguson reflex) between neuronal afferents and more frequent and strong 
contractions (Ferguson (1941) reviewed by Russell et al. (2003)).     
At the level of the hypothalamic nuclei, magnocellular oxytocin 
neurones fire in intermittent synchronised bursts that release large pulses of 
oxytocin, stimulating the foetus expulsion (Summerlee, 1981). This pulsatile 
release pattern allows myometrial cells to avoid receptor desensitisation 
caused by the sustained increase of oxytocin in plasma (Engstrom et al., 1988; 
Willets et al., 2009). In addition, peripheral oxytocin release is accompanied 
by an increase in the dendritic release of oxytocin which has a role in 
synchronising the intermittent bursts of oxytocin neurones. This dendritic 
release plays a crucial role during delivery, as shown by intra-SON 
administration of an OTR antagonist which attenuated the rise of oxytocin 
release within the SON associated with parturition, resulting in a reduced 
number of pups delivered during the antagonist application (Neumann et al., 
1996).  
Interestingly, transgenic mice null for oxytocin or OTR can give birth 
normally, indicating redundant and compensatory mechanism involved in 
parturition (Nishimori et al., 1996; Young et al., 1996).  
 
Lactation 
Despite the fact that oxytocin is not involved in milk synthesis, it plays 
a crucial role allowing the milk let-down in response to suckling. Oxytocin is 
the only hormone able to trigger the milk ejection reflex, as shown in mice 
null for oxytocin (Young et al., 1996).  
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At the end of pregnancy, OTR expression increases in alveolar 
myoepithelial cells enhancing their sensitivity to oxytocin which causes the 
contraction of these cells, and consequently the ejection of milk due to the 
increased pressure within the mammary alveoli. In lactating rats, when pups 
suckle, milk is ejected every 10 ‒ 20 min (Wakerley & Lincoln, 1971), these 
milk ejections are preceded (~ 10 s) by a very short, and synchronised high-
frequency burst of activity of magnocellular SON and PVN neurones that 
lasts 1 ‒ 3 s, this leads to a large pulse release of oxytocin which is followed 
by a silent period of activity (Wakerley & Lincoln, 1973; Lincoln & Wakerley, 
1974).  
These bursts of activity are synchronised among all the magnocellular 
oxytocin neurones located in the SON and PVN. It is thought that 
communication between magnocellular nuclei have an important role in the 
burst synchronisation (Belin & Moos, 1986), in addition to priming of 
dendritic oxytocin release (Lambert et al., 1993; Rossoni et al., 2008). Oxytocin 
neurones release more oxytocin when spikes occur in bursts than at lower 
frequency (Leng et al., 2012).  
Similarly to uterine contraction during labour, the mammary gland 
responds to high concentrations of oxytocin, but its continuous exposure to 
oxytocin can lead to receptor desensitisation (Smith et al., 2006; Willets et al., 
2009), therefore, pulsatile release allows the cells maintain their 
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1.2.1.5. Oxytocin and neuropsychiatric disorders 
Based on neuroanatomical studies showing projections of oxytocin 
neurones to limbic areas and the prosocial effects observed following central 
administration of oxytocin in animals, several studies have investigated the 
roles of oxytocin and vasopressin in anxiety, stress-coping, and sociality. It is 
commonly accepted that central oxytocin exerts anxiolytic and 
antidepressive effects in rodents (Neumann, 2008; Neumann & Landgraf, 
2012). Moreover, in humans, reports have linked neuropsychiatric disorders 
to alteration of oxytocin system, including changes in CSF and plasma 
oxytocin content. In recent years, an increasing number of publications have 
reported changes in plasma oxytocin content in patients with 
neuropsychiatric disorders, however, as in animals, peripheral oxytocin 
release does not reflect its central release (Kagerbauer et al., 2013). The 
measurement of plasma oxytocin as a biomarker has been used, probably, 
based on the lesser invasiveness of blood sampling compared to CSF 
sampling, however, dissimilar results, and more importantly, inconsistent 
values have been reported (Leng & Sabatier, 2016).  
In CSF, lower oxytocin content has been found in suicide attempters 
compared to healthy volunteers, as well as a significant inverse correlation 
between CSF oxytocin content and suicide intent (Jokinen et al., 2012). 
Women exposed to childhood abuse had lower CSF oxytocin concentrations 
compared to non-exposed women, and an inverse correlation between 
oxytocin content and anxiety was also found (Heim et al., 2009). Similarly, 
Lee et al. (2009) reported an inverse correlation between CSF oxytocin content 
and a life story of aggression in women. In schizophrenic subjects, lower 
levels of neurophysin-I, the oxytocin associated carrier protein, has been 
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detected when compared to control subjects (Linkowski et al., 1984). In 
contrast, other studies have not found significant changes in CSF oxytocin 
content in schizophrenic subjects (Glovinsky et al., 1994; Sasayama et al., 
2012), but the severity of symptoms, measured by the positive and negative 
syndrome scale (PANSS) for schizophrenia, were inversely correlated with 
the oxytocin concentrations in the CSF (Sasayama et al., 2012). Furthermore, 
women suffering depression showed no differences in CSF oxytocin content 
compared to controls (Pitts et al., 1995), but plasma oxytocin content was 
higher in depressed women, probably, due to alteration of oxytocin release 
patterns (Cyranowski et al., 2008). 
Finally, alterations of oxytocin content in plasma have been reported 
in depression (Scantamburlo et al., 2007; Parker et al., 2010), schizophrenia 
(Legros et al., 1992; Goldman et al., 2008; Strauss et al., 2015), borderline 
personality disorder (Jobst et al., 2016), anxiety (Scantamburlo et al., 2007; 
Cyranowski et al., 2008), and autism spectrum disorder (ASD) (Jansen et al., 
2006). Interestingly, in autistic children, low plasma oxytocin content 
(Modahl et al., 1998) was related to alterations of the enzymatic cleavage of 
the oxytocin precursor, leading to an increase of the oxytocin precursor, and 
consequently to the ratio oxytocin precursor/oxytocin (Green et al., 2001). 
Since the exogenous administration of oxytocin is not able to cross the 
BBB in neuroactive amounts (Zaidi & Heller, 1974; Mens et al., 1983; Ermisch 
et al., 1985; Ludwig et al., 2013), an alternative approach for the treatment of 
neuropsychiatric disorders is to stimulate the endogenous oxytocin systems 
using melanocortins which have been shown to induce central oxytocin 
release (Sabatier et al., 2003a).  
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1.2.1.5.1 Melanocortins as a therapeutic tool targeting central 
oxytocin systems 
 The melanocortin α-MSH is a potent stimulus to induce dendritic 
oxytocin release. In SON explants, application of α-MSH mobilised 
intracellular Ca2+ stores, triggering dendritic oxytocin release, and when 
injected i.c.v., it stimulates the expression of Fos protein (the product of the 
immediate early gene c-fos) in magnocellular oxytocin neurones of the SON 
while inhibiting peripheral oxytocin release by decreasing the electrical 
activity of these neurones (Sabatier et al., 2003a). The actions of α-MSH are 
mediated through MC4 which are expressed in the SON and PVN (Mountjoy 
et al., 1994; Kishi et al., 2003). However, like oxytocin, α-MSH is not able to 
penetrate the BBB in neuroactive amounts (Wilson et al., 1984; Wilson, 1988), 
and therefore itself is not useful for systemic administration to stimulate the 
central oxytocin systems. However, in the last years, several synthetic 
melanocortin agonists have been synthesised, some of these molecules (e.g. 
MT-II) are thought to have better brain penetration properties due to their 
shorter amino acid sequence and cyclic structure. 
  
1.2.2. The central melanocortin system 
1.2.2.1. Melanocortin structure and synthesis 
The melanocortins are a group of related peptides derived from the 
proopiomelanocortin (POMC) precursor, which is post-translationally 
processed by successive enzymatic cleavages into the adrenocorticotropic 
hormone (ACTH), and the melanotropins alpha-, beta-, and gamma-
melanocyte-stimulating-hormone (α-, β-, γ-MSH). α-MSH is a 13-amino acid 
peptide cleaved from the N-terminal region of the 39-amino acid ACTH. 
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Additionally, the opioid peptide β-endorphin, and the lipid-mobilizing 
peptides beta-, and gamma-lipotropin (β-, γ-LPH) are also derived from the 
cleavage processing (Cawley et al., 2016). POMC is differentially cleaved by 
tissue and cell-specific processing enzymes to yield different end products 
(Figure 1.1.). 
In the brain, α-MSH and β-endorphin are the main products 
synthesised by the hypothalamic neurones. α-MSH is synthesised in two 
neuronal populations located in the arcuate nuclei and dorsolateral to the 
third ventricle of the hypothalamus (Watson & Akil, 1979; Guy et al., 1980). A 
third population of neurones expressing POMC-related peptides (i.e. ACTH, 
α-MSH, and β-endorphin) have also been identified in the NTS (Joseph et al., 
1983; Palkovits et al., 1987). α-MSH fibres projecting from hypothalamic 
populations have been detected in several brain structures, including the 
amygdala, cortex, hippocampus, hypothalamus, and preoptic and septal 
areas (Jacobowitz & O'Donohue, 1978; Guy et al., 1981). Within the 
hypothalamus, a moderate number of α-MSH, and its precursor ACTH nerve 
fibres have been found in the PVN and SON (Sawchenko et al., 1982).  
Peripherally, melanotropins are synthesised by cells of the 
intermediate pituitary gland from which they are released into the 
bloodstream. Similarly, to the hypothalamus, α-MSH and β-endorphin are 
the end peptide products of the intermediate pituitary. The release of 
melanotropins from the intermediate pituitary is regulated by several 
hypothalamic factors including serotonin and dopamine which stimulate and 
inhibit, respectively, the release of secretory granules containing MSH 
peptides into the bloodstream (Cawley et al., 2016).  
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1.2.2.2. Melanocortin receptors 
Five melanocortin receptor genes have been cloned, encoding the 
melanocortin receptors: MC1, MC2, MC3, MC4, and MC5 (Dores et al., 2016). 
Separate genes encode each receptor isotype; the sequence homologies 
among human melanocortin receptors range from 60 % to 38 % identity. The 
melanocortin receptors belong to the seven-transmembrane domain GPCR 
family. Compared to other G-protein receptors the melanocortin receptors 
are the smallest G-protein receptors, with short amino- and 
carboxyl-terminal ends, and a short extracellular loop. The melanocortin 
receptors are coupled to a Gs protein that activates the cyclic adenosine 
monophosphate (cAMP) signalling pathway (Abdel-Malek, 2001; Yang, 
2011).  
The five receptor subtypes are differentially expressed in the several 
tissues, including peripheral organs and the CNS; they display different 
affinities for their endogenous agonist, and antagonist melanocortin ligands 
(i.e. the agouti-related protein (AgRP), and agouti signalling protein (ASIP)) 
(Dores et al., 2014; Dores et al., 2016).  
 
Central expression of melanocortin receptors  
In the brain, melanocortins exert their actions through activation of 
the MC3 and MC4, which are expressed in different subsets of neurones of the 
hypothalamus and limbic system. MC3 expression has been detected mainly 
in the hypothalamus, whereas MC4 expression has been reported in several 
brain areas, including the olfactory bulb, hypothalamus, hippocampus, and 
brainstem (Roselli-Rehfuss et al., 1993; Kishi et al., 2003) (Table 1.2.). Both 
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receptors participate in the regulation of several functions, including energy 
balance, thermogenesis, and cardiovascular actions (Rowland et al., 2010; do 
Carmo et al., 2013; Monge-Roffarello et al., 2014).  
 
1.2.2.3. Central actions of melanocortins  
Sexual behaviour 
Early studies have shown that i.c.v. administration of ACTH in dogs, 
cats, and rabbits induces penile erection and ejaculation (Bertolini et al., 
1969). Similarly, i.c.v. injections of ACTH or α-MSH elicit penile erections in 
rodents. Furthermore, injections of the synthetic α-MSH analogue MT-II into 
the PVN significantly increases spontaneous erections in urethane 
anaesthetized rats (Giuliano et al., 2006). The actions of melanocortins on 
sexual behaviour are thought to be mediated by MC3 and MC4, however, the 
involvement of the MC3 still remains unclear. Knock-out mice for MC4 
display increased mounting and intromission latency compared to wild-type 
mice, as well as a reduced number of ejaculations over 1 h observation 
period (Van der Ploeg et al., 2002). 
In female rats, i.c.v. administration of α-MSH or ACTH4-10 increased 
lordosis behaviour in non-receptive rats primed with oestradiol and 
progesterone (Thody et al., 1981). Moreover, i.v. injection of MT-II facilitates 
solicitation behaviours, including hop and darts, and ear wiggling, in 
oestradiol and progesterone-primed ovariectomized rats (Rossler et al., 2006). 
A brain site of action for melanocortins has been reported by Cragnolini et al. 
(2000), showing that injections of α-MSH into the ventromedial nucleus of 
the hypothalamus increases lordosis behaviour in rats. 
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Grooming, and stretch and yawning syndrome  
Increased grooming and repeated episodes of stretch and yawning 
were the first behavioural effects observed following central administration 
of melanocortins (Ferrari et al., 1963). Melanocortins elicit all the components 
of grooming behaviour which includes: body and genital grooming, 
scratching, body shakes, paw and tail licking, and face washing. These 
behaviours have been observed in several mammals, including laboratory 
rodents, rabbits, dogs, and cats. According to Bertolini et al. (2009), 
“grooming and scratching usually start after about 10 min from the peptide 
injection and are maximally displayed during the first hour”. This suggests 
the involvement of long-lasting chemical messengers, and interestingly, the 
half-life of α-MSH, and also oxytocin ‒a suggested mediator of melanocortin 
actions (Sabatier et al., 2003b)‒ have been reported to be 30 min 
approximately in the CSF (De Rotte et al., 1980; Jones & Robinson, 1982; Mens 
et al., 1983).  
In rats, i.c.v. injections of low doses of ACTH1–24 increases grooming 
behaviour. Similarly, the injection of α-MSH or ACTH1–24 (1 μg) into 
hypothalamic nuclei of the periventricular region of the third ventricle 
induce grooming, yawning, stretching (Argiolas et al., 2000). The induction of 
grooming behaviour is dose-dependent (Bertolini et al., 1988). Stretch and 
yawning syndrome can also be observed in rats and mice following central 
administration of melanocortins; however, stretching is up to 5 times more 
prevalent than yawning in these animals (Bertolini et al., 1988). 
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Food intake and energy homeostasis  
An early study showed that i.c.v. administration or direct injection 
into the ventromedial hypothalamus of ACTH1–24 in rats fasted for 24 h 
markedly inhibits food intake. In these rats, the central administration of 
ACTH1–24 reduced food intake by approximately 75 % during the first hour 
after injection (Vergoni et al., 1986). Similarly, injections of MT-II into the 
PVN of fasted rats reduced food intake in a dose-dependent manner for up 
to 24 h after the injection. On the other hand, injections of a melanocortin 
antagonist into the PVN increased food intake compared to the control group 
(Giraudo et al., 1998). 
The melanocortin actions on food intake are mediated, at least in part, 
by activation of MC4. In mice, targeted disruption of MC4 leads to develop a 
maturity-onset obesity syndrome in which 15-weeks old homozygous male 
mutants were 50 % heavier than wild-type mice. Hyperphagia, 
hyperglycaemia, and hyperinsulinemia were also observed in these animals 
(Huszar et al., 1997). Furthermore, chronic i.c.v. administration of the 
selective MC4 antagonist HS014, potently increases food intake and body 
weight after 2 weeks, increasing body weight by 20 % when compared to 
saline treated rats (Kask et al., 1999). The role of MC3 in food intake and 
energy balance is still not fully understood. Sutton et al. (2008) reported 
impairment in anticipatory patterns of activity during restricted feeding in 
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1.2.2.4. The synthetic melanocortin agonist Melanotan-II 
(MT-II) 
MT-II, Ac-Nle-c[Asp,DPhe,Arg,Trp,Lys]-NH2, is a synthetic cyclic 
heptapeptide analogue of α-MSH (Al-Obeidi et al., 1989b). MT-II has been 
described as “a superpotent, prolonged acting, enzyme resistant 
melanotropic peptide” (Hadley et al., 1989) when compared to α-MSH 
(Hadley & Haskell-Luevano, 1999); showing 1 and 90 fold higher potency in 
frog and lizard skin bioassays, respectively, relative to α-MSH (Al-Obeidi et 
al., 1989a; Al-Obeidi et al., 1989b).  
The cyclic structure of MT-II is believed to confer better brain 
penetration properties than linear melanocortin agonists (e.g. α-MSH, MT-I), 
as it has been suggested by behavioural actions (i.e. yawning and stretching) 
following subcutaneous administration in human trials (Dorr et al., 1996; 
Wessells et al., 1998; Wessells et al., 2000), and i.v. administration in rats 
(Adan et al., 1999). In mice, after intraperitoneal (i.p.) administration of MT-II 
(1 mg/kg), high plasma concentrations were detected at 30 min after 
injection, to then suffer fast plasmatic clearance at 1 h to 2 h; in brain 
homogenates, low concentrations of MT-II were found, suggesting restricted 
capacity to penetrate the brain (Hatziieremia et al., 2007). 
Trivedi et al. (2003) studied the sites of actions of MT-II, showing that 
systemic injection of (125)Iodo-MT-II penetrated the brain parenchyma in 
low amounts, however, a high concentration of radiolabelled MT-II was 
bound to the circumventricular organs, which are located outside of the BBB, 
and are known to modulate the activity of oxytocin and vasopressin 
neurones of the PVN and SON (Cottrell & Ferguson, 2004; Ferguson, 2014). 
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1.2.3. Circulating melanocortins as potential modulators of 
oxytocin and vasopressin neurone activity  
The BBB controls the passage of blood-borne molecules into the brain, 
including oxytocin (Zaidi & Heller, 1974; Ermisch et al., 1985), and 
endogenous melanocortins, such as α-MSH (Wilson et al., 1984; Wilson, 
1988). Expression of tight junctions between endothelial cells of the brain’s 
capillary system restrict the passage of water-soluble molecules, peptides, 
amino acids, and drugs through the intercellular space into the brain 
parenchyma. Only lipid-soluble molecules (e.g. sexual steroids), water, and 
some gases can cross the BBB by passive diffusion. The passage of restricted 
molecules into the brain is determined by the expression of specific transport 
systems (e.g. amino acids) (Engelhardt & Sorokin, 2009; Banks, 2012).  
In addition, specialised areas of the BBB have been described:  
(i) the blood-CSF barrier which prevents the passage of 
molecules from the vascular system of the choroid plexuses to the 
ventricular system (CSF). Tight junctions expressed on the choroidal 
epithelial cells completely seal the intercellular space, whereas 
fenestrated capillaries are located in the inner structure of the choroid 
plexuses. Similarly to the BBB, specific transport systems mediate the 
entry of compounds, including glucose, prolactin, and others 
molecules (Rodriguez et al., 2010). 
(ii) the blood-circumventricular organs barrier which 
prevent the diffusion of blood-borne molecules from discrete brain 
areas into the ‒deep‒ brain parenchyma. Tight junction proteins are 
expressed in the ependymal cells surrounding these discrete brain 
areas, whereas fenestrated capillaries lay in the inner structure 
(Langlet et al., 2013). The circumventricular organs allow neurones 
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located in these regions to monitor and sense blood-borne molecules 
and to modulate the activity of brain areas protected by the BBB 
(Miyata, 2015).  
 
1.2.3.1. Circumventricular organs 
The subfornical organ (SFO), and organum vasculosum lamina 
terminalis (OVLT) are sensory circumventricular organs located in the rostral 
wall, or lamina terminalis, of the third ventricle. Both brain structures play a 
pivotal role in the regulation of vasopressin and oxytocin neurone activity, as 
exemplified by studies of their role in osmoregulation. This regulation is 
achieved by neurones expressing receptors for several hormones (including 
the MC4; Kishi et al. (2003)), which are present in the bloodstream and diffuse 
into the circumventricular organ milieu. Tracing studies have shown 
retrogradely labelled neurones in both circumventricular organs projecting 
to the PVN and SON (Sawchenko & Swanson, 1983).  
The area postrema (AP) is a sensory circumventricular organ located 
in the brainstem that also expresses receptors for circulating hormones, 
including melanocortins (Kishi et al., 2003; Rowland et al., 2010). The AP has 
extensive connections with the NTS which is known to modulate vasopressin 
and oxytocin neurones (Renaud et al., 1987; Leng et al., 1991; Verbalis et al., 
1991).  
 
The subfornical organ (SFO) 
The SFO is an unpaired structure located in the midline of the dorsal 
third ventricle. Morphologically, an outer shell and ventromedial core can be 
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distinguished in the SFO, the latter displays a high degree of vascularization. 
The SFO regulates cardiovascular, behavioural (i.e. water intake, and salt 
consumption), metabolic, and neuroendocrine functions (Fry & Ferguson, 
2007). Receptors for several hormones, including angiotensin II, and relaxin 
are expressed in the SFO (McKinley et al., 1998). I.v. administration of these 
peptides (e.g. relaxin) have been shown to induce activation of SFO (and also 
OVLT) neurones projecting to the SON and PVN, as shown by expression of 
Fos protein in fluorogold retrolabelled neurones (Sunn et al., 2001). Although 
the expression of MC4 messenger ribonucleic acid (mRNA) has also been 
detected in the SFO (Kishi et al., 2003), its role is unknown.  
The SFO sends direct excitatory projections to oxytocin and 
vasopressin magnocellular neurones of SON and PVN, as well as to 
parvocellular populations of the PVN (Fry & Ferguson, 2007). Contrariwise, 
scarce oxytocin-containing fibres have been detected in the SFO (Buijs, 1978; 
Yulis & Rodriguez, 1982). Neurones of the SFO are intrinsically 
osmosensitive (Anderson et al., 2000), and electrolytic lesioning of SFO has 
been shown to impair the osmoresponsiveness of the oxytocin system (Leng 
et al., 1989). 
 
The organum vasculosum lamina terminalis (OVLT)   
The OVLT is an unpaired structure located in the midline of the 
rostroventral wall of the third ventricle, and dorsal to the optic chiasm. Two 
anatomical areas can be distinguished in the OVLT: a lateral area, and a 
dorsal cap (Fry & Ferguson, 2007). Similarly to the SFO, the OVLT neurones 
express receptors for several circulating hormones, including angiotensin II, 
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relaxin, as well as the MC4 mRNA (Kishi et al., 2003). Interestingly, in 
addition to the MC4, high densities of POMC- and AgRP-immunoreactive 
fibres have been found in the OVLT (Bagnol et al., 1999), but their functional 
role has not been established. 
The OVLT exerts its regulatory actions through direct afferent 
projections to the PVN and SON (Fry & Ferguson, 2007), which are crucial 
for the regulation of vasopressin and oxytocin release. Experimental 
electrolytic lesion of the anteroventral third ventricle region of the 
hypothalamus (AV3V; which includes the OVLT and median preoptic 
nucleus) decreases the basal spontaneous activity of SON neurones, and 
reduces peripheral oxytocin and vasopressin release in response to 
hyperosmotic stimulation (Leng et al., 1989). The osmotic response is 
commanded, at least in part, by activation of OVLT osmosensitive neurones 
expressing the transient receptor potential vanilloid-1 (TRPV1) channels 
(Ciura & Bourque, 2006). Similarly, lesion of the AV3V impairs peripheral 
vasopressin release in response to i.v. administration of angiotensin II.   
 
The area postrema (AP) 
In rats, the AP is a single structure located in the midline of the fourth 
ventricle. It is highly vascularized, displaying similar vascular features than 
the SFO. The AP is well known for its role as chemosensor, detecting toxins 
and triggering emesis. As with other circumventricular organs, the AP 
express receptors for several hormones (McKinley et al., 1998). The AP send 
direct projections to the NTS. In addition, afferent projections from the PVN, 
and NTS to the AP have been described (Shapiro & Miselis, 1985). 
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Experimental lesion of the AP has been shown to decrease basal vasopressin 
concentration in plasma, and attenuate the peripheral vasopressin release in 
response to hypovolemia and hyperosmolality (Arima et al., 1998). Moreover, 
Huang et al. (2000) have reported impaired peripheral oxytocin (and 
vasopressin) release in response to i.v. administration of 1M NaCl in 
AP-lesioned rats, indicating that the AP could be involved in the release 
response of magnocellular neurones to circulating compounds.   
 
1.2.3.2. Nucleus tractus solitarii (NTS) 
The NTS is a complex brain nucleus formed by heterogeneous groups 
of neurones located in the brainstem. The NTS receives visceral afferent 
projections from peripheral organs through the vagus nerve, and also from 
brain structures, such as the AP. Peripherally, changes in parameters of 
cardiovascular, respiratory, or gastrointestinal systems lead to modifications 
in neural activity of different subsets of NTS neurones which, in turn, modify 
other neural systems for an appropriate physiological response. For 
oxytocin-vasopressin systems, most of the current knowledge has been 
obtained from stimuli acting on aortic baro- or chemo-receptors or 
blood-borne molecules, like the gastric peptide cholecystokinin (CCK), which 
activate NTS neurones that in turn activate magnocellular neurones of the 
SON (Zoccal et al., 2014). 
The SON, and both magnocellular and parvocellular populations of 
the PVN receive projections from some neurones of the NTS (A2 cells), and 
the ventrolateral medulla (A1 cells) which are mostly noradrenergic 
(Sawchenko & Swanson, 1982b). Oxytocin and vasopressin neurones are 
equally innervated by noradrenergic afferents in virgin rats, however, in 
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lactating rats the innervation of oxytocin neurones is increased. Remarkably, 
projections from A2 cells of the NTS have been found in the posterior 
pituitary, which are thought to facilitate the release of oxytocin and 
vasopressin. Subsets of noradrenergic neurones also co-express other 
peptides including neuropeptide Y (NPY), and substance P. Moreover, 
several peptides have also been found in non-noradrenergic neurones 
projecting to the magnocellular system, such as inhibin B, somatostatin and 
enkephalin (Leng et al., 1999). 
The excitatory actions of noradrenaline cells on magnocellular 
neurones is potentiated by NPY, as shown by enhanced excitation of SON 
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1.4.  HYPOTHESIS 
Briefly, morphological evidence supports the regulation of central 
oxytocin systems by POMC neurones which synthesise the POMC product 
α-MSH. The direct application of α-MSH to SON explants has been shown to 
trigger somatodendritic oxytocin release in vitro, while i.c.v. administration 
of α-MSH inhibited peripheral oxytocin release by decreasing electrical 
activity of SON oxytocin neurones in vivo (Sabatier et al., 2003a). MT-II is a 
synthetic cyclic analogue of α-MSH that is thought to have better brain 
penetration properties than α-MSH, as suggested by behavioural actions 
following peripheral administration (Dorr et al., 1996; Modi et al., 2015). 
The main hypothesis of this thesis is that: intravenous (i.v.) 
administration of MT-II directly (centrally) acts on oxytocin neurones to 
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1.5.  OBJECTIVES  
 To test this hypothesis, my objectives were as follows:   
1. To determine whether i.v. injection of MT-II induces activation 
of PVN and SON oxytocin neurones, using the product of the 
immediate early gene c-fos, Fos protein, as a marker for neural 
activity by immunohistochemistry.  
2. To determine whether i.v. injection of MT-II activates brain 
regions that are known to modulate oxytocin and vasopressin 
neurone activity, using immunohistochemistry for Fos protein. 
3. To study the electrophysiological responses of oxytocin and 
vasopressin neurones to i.v. administration of MT-II in 
urethane anaesthetized rats.  
4. To evaluate whether i.v. administration of MT-II triggers 
somatodendritic oxytocin within the SON in urethane 
anaesthetized rats, as measured by microdialysis and highly 
sensitive radioimmunoassay (RIA).   
 
I also set an additional objective: 
5. To study the effect of intranasally administered MT-II on neural 
activity of PVN and SON oxytocin neurones, and layers of the 
olfactory bulb, using immunohistochemistry for Fos protein. 
 
 
Figure 1.1. Schematic representation of the processing of the POMC precursor
protein and its related subproducts. Neurones of the arcuate nucleus and cells of
the adenohypophysis synthesize POMC which is differentially processed by tissue‐
specific enzymes leading to different subproducts. POMC ‐ proopiomelanocortin,
ACTH ‐ adrenocorticopic hormone, α‐ β‐ γ‐MSH ‐ alpha‐ beta‐ gamma‐melanocyte
stimulating hormone, CLIP ‐ corticotropin‐like intermediate lobe peptide.
POMC
ACTHγ‐MSH β‐lipotropin




Table 1.1. Detection of oxytocin fibres and oxytocin receptor (OTR) mRNA in the









Anterior olfactory nucleus  + +++ ++
Olfactory bulb + + ?
Olfactory tubercle + +++ + +
Islands of Calleja ND + + +
Entorhinal/perirhinal area + + +
Piriform cortex ++ ?
Cortical areas
Peduncular cortex ? + + +
Insular cortex ? +
Cingulate cortex + + ND
Retrosplenial cortex ? ND
Frontal cortex ++ ++ (+)
Temporal cortex + (+) +
Taenia tecta +++ +++ (+)
Diagonal band of Broca + + ?
Basal nucleus of Meynert ND ND
Basal ganglia
Caudoputamen +++ +++ + +
Ventral pallidum  ++ ++ + + +
Globus pallidus + ND





Anteroventral thalamic nucleus + ND ND
Paraventricular thalamic nucleus + ++ +
Anterior medial preoptic area + +++ ND
Dorsomedial hypothalamic nucleus +
Ventromedial hypothalamic nucleus + +++ + +
Arcuate nucleus + +
Paraventricular nucleus (PVN) + ++ (+)




Posterior hypothalamic area + + ND
Medial tuberal nucleus + ND + +
Supramammillary nucleus + ++ +
Lateral mammillary nucleus + ND +




Lateral septal nucleus + + +
Medial septal nucleus +
Bed nucleus of stria terminalis (BNST) + +++ + + +
Amygdaloid‐hippocampal area +++ +
Central amygdala + +++ + + +
Medial amygdala + ++ +
Basolateral amygdala + +++ +
Parasubiculum and presubiculum ND + +
Dorsal subiculum + +++ (+)
Ventral subiculum + +++ + + +
Brainstem
Substantia nigra pars compacta ++ ++ ND
Ventral and dorsal tegmental area ++ ND
Locus ceruleus +
Central gray + + ND
Dorsal raphe nucleus + + ND
Reticular nuclei + + ND
Medial vestibular nucleus + ND
Hypoglossus nucleus ++ ND
Nucleus of the solitary tract (NTS) ++ ND (+)
Dorsal motor nucleus of the vagus nerve + +++ +
Nucleus ambiguus +
Inferior olive nucleus ND +
Substantia gelatinosa of trigeminal nucleus + +
Pituitary gland
Anterior lobe (lactotrophs) + +
Posterior lobe + (IHC)
Spinal cord + +
Adapted from Bujis et al., (1979, 1980, 1985); Adan et al., (1995); Vaccari et al., (1998);
Gimpl and Fahrenholz (2001). Expression: +++ strong; ++ moderate; + weak; ND = no
detection, blank space = not reported, IHC = immunohistochemistry.
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Table 1.2. Detection of melanocortin receptors mRNA and autoradiographic binding









































Anteroventral preoptic nucleus ++ +
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Anteroventral periventricular nucleus + +++
Dorsomedial hypothalamic nucleus ++











Lateral septal nucleus ++ +++ +
Medial septal nucleus ++







Substantia nigra pars compacta + +
Dorsal tegmental nucleus ++
Locus ceruleus +


























Chapter 2  
General material and methods          
                                                                                                     
 
2.1.  ANIMALS 
Adult male Sprague-Dawley rats weighing 250-350 g, bred in the 
animal unit of the Hugh Robson Building at The University of Edinburgh, 
were used in the studies. The animals were housed in stock cages of 6 rats 
maximum, with ad libitum access to rodent food and water. The animals were 
maintained on a 12-hour light/dark cycle (lights on: 7 h – 19 h), and a room 
temperature of 20 ± 1 °C. All the experiments started at 9:30 h, and lasted a 
maximum of 7 hours (i.e. in vivo microdialysis). Housing, handling, care and 
experimental procedures of animals were conducted in accordance with UK 
Home Office Animals Scientific Procedures Act 1986, and were approved by 
the Ethical Committee of the University of Edinburgh.  
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2.2. ANAESTHESIA AND ANALGESIA  
For non-recovery procedures, rats were briefly anaesthetized under 
isoflurane inhalation (IsoFlo, Abbott Laboratories Ltd., Berkshire, UK) in a 
glass chamber. Then, rats were i.p. injected with 25 % urethane solution 
(ethyl carbamate; SigmaAldrich, Dorset, UK) at a dose 1.25 g/kg. Urethane 
provides a long-lasting stable anaesthesia whereas maintaining the 
physiological functions of SON neurones (Leng & Sabatier, 2014). It has been 
the anaesthetic of choice for in vivo electrophysiology, and microdialysis 
studies, however, urethane is known to induce a mild increase in plasma 
osmolality, and consequently, the expression of Fos protein is increased in 
magnocellular neurones (Leng & Sabatier, 2014). In Fos expression studies, 
rats were anaesthetized with an i.p. injection of sodium pentobarbital (Ceva 
Santé Animale, Libourne, France) at a dose 50 mg/kg, then anaesthesia was 
maintained by i.v. injections of sodium pentobarbital at a dose 25 mg/kg 
every 45 min using an i.v. cannula implanted as described below.  
For recovery experiments, rats were anaesthetised using inhalation 
isoflurane anaesthesia delivered by a continuous-flow anaesthetic machine. 
Briefly, rats were placed in an induction chamber, and 5 % isoflurane in 1.5 l / 
min of oxygen was delivered into the chamber. Anaesthesia was maintained 
using 2.5 % isoflurane in 1.5 l / min of oxygen delivered via an anaesthetic 
mask. For postoperative analgesia, rats were given carprofen (Rimadyl, 
Pfizer Animal Health; Surrey, UK) 5 mg/kg s.c. every 24 h for 2 days.  
For euthanasia, rats were given an i.p. injection of sodium 
pentobarbital (Euthenal, Merial Animal Health Ltd., Harlow, UK) at a dose 
160 mg/kg.  
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2.3. NON-SURGICAL PROCEDURES 
2.3.1. Subcutaneous injections (s.c.) 
The rat was restrained in prone position, then using the thumb and 
index fingers the skin over the flank was gently tented, and a sterile 26-gauge 
needle was inserted into the base of the loose skin and the drug injected. 
Only carprofen for postoperative pain control was injected using this route of 
administration.    
 
2.3.2. Intraperitoneal injections (i.p.) 
The rats were restrained on their back and the abdomen exposed. 
Then, a sterile 23-gauge needle was inserted through the abdominal wall at 
the lower right quadrant of the abdomen in an angle of 45° to the body. The 
syringe was slightly withdrawn to check the correct placement (i.e. outside of 
blood vessels) before injecting the drugs into the peritoneal cavity.  
 
2.4. SURGICAL PROCEDURES  
All procedures were conducted under aseptic conditions, and tools 
and instruments were autoclaved. The incision sites were shaved, and the 
skin disinfected using a chlorhexidine gluconate 4 % w/v solution (Hibiscrub; 
Regent Medical Ltd, Manchester, UK). During recovery procedures, body 
temperature was maintained using a heatmat at 37 °C. In non-recovery 
procedures, body temperature was maintained using a light bulb and a 
cotton cover. Rats were given 1 ml i.v. or i.p. of 0.9 % saline solution for any 
fluid loss associated with the surgical procedures.  
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2.4.1.  I.v. cannula implantation  
Under non-recovery anaesthesia, rats were placed in supine position 
and the left leg extended and secured to the table surface with tape, then 
using a sterile disposable scalpel a 1.5 cm incision was made in the skin over 
an imaginary line between the leg and abdomen. Under a stereomicroscope, 
the connective tissue was gently separated, and the femoral vein, artery, and 
nerve were carefully dissected. Two ligatures (4-0 size silk thread; Fine 
Science Tools GmbH, Heidelberg, Germany) were tied around the vein; the 
ligature located in the distal end of the vein was immediately tightened, the 
proximal end of the vein, close to the abdominal wall, was clamped using a 
stainless steel clamp. A very small incision was made and a polyethene 
cannula (0.5 mm internal diameter; 0.25 mm wall) was inserted into the 
femoral vein. The clamp was removed, the cannula gently pushed further 
into the vein, and the proximal ligature firmly tightened. Finally, the cannula 
was secured to the leg with tape. 
 
2.4.2.  I.c.v. cannula implantation    
Under inhalation isoflurane anaesthesia the rats were placed in a 
digital stereotaxic frame (Stoelting Co., Wood Dale, IL, USA); two 
non-puncture ear bars fixed the head in position to the frame. The head was 
shaved, and a skin incision was made along the midline of the head to 
expose the dorsal surface of the skull. The connective tissue was removed, 
and any bleeding stopped to clearly visualise the bregma and lambda points. 
The level of the skull was adjusted and corrected when necessary using the 
bregma and lambda points. Then a burr hole was drilled through the skull 
(coordinates: 0.6 mm caudal to bregma, 1.5 mm lateral to midline) and a 4.5 
mm long guide cannula (cat. C315G; Plastics One Inc., VA, USA) was 
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positioned into the right cerebral ventricle. The cannula was secured in place 
using two stainless screws fixed to the skull and dental cement (Kemdent, 
Associated Dental Products Ltd., Swindon Wiltshire, UK). A dummy cap 
was inserted into the guide cannula (cat. C315DC; Plastics One Inc., VA, 
USA). Rats were allowed to recover for 4 days. 
 
2.5.  DRUGS 
For i.v. injections, the melanocortin agonists MT-II (American Peptide 
Company, Inc., CA, USA), and TCMC-A01 (kindly provided by Dr Michael 
Callahan; Tensive Controls, Inc., MO, USA) were dissolved at a 
concentration 1 mg/ml in sterile physiological 0.9 % saline solution (B. Braun, 
Melsungen, Germany). For i.c.v. injections, MT-II, and the melanocortin 
antagonist SHU-9119 (Abcam plc, Cambridge, UK) were dissolved at a 
concentration of 0.33 µg/µl in artificial cerebrospinal fluid (aCSF, Tocris 
Bioscience, Bristol, UK). For intranasal MT-II application, 1 µg or 30 µg of 
MT-II was dissolved in 20 µl of aCSF.  
These peptide solutions were prepared in phials. Briefly, the peptides 
and solvent (i.e. 0.9 % saline or aCSF) were vortexed 3 times 45 s each, then 
the solutions were sonicated 3 times 30 s each, and allowed to cool down on 
ice for 1 min between each sonication cycle. Finally, the solutions were 
aliquoted and stored at -80 °C until they were required. As some peptides are 
unstable in solution, only fresh peptide aliquots (i.e. 1 month old maximum) 
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2.6.  DRUG ADMINISTRATION PROCEDURES 
 2.6.1. I.v. injection 
The i.v. cannula was connected to a graduated disposable 1 ml syringe 
filled with heparinised 0.9 % saline solution. Before injections, 0.1 ml of saline 
solution was injected to ensure the fluid is able to flow through the cannula, 
then the syringe was removed and a second syringe containing the drug 
solution connected to the i.v. cannula, and the drug was slowly injected. 
Finally, the syringe was removed and the syringe containing heparinised 
saline reconnected to the cannula and 0.1 ml injected to flush the line.  
 
2.6.2.  I.c.v. injection 
A 10 μl Hamilton syringe was connected to an injection cannula (cat. 
C315I; Plastics One Inc., VA, USA) using a short plastic tubing. The dummy 
cap was removed from the guide cannula previously implanted, and the 
injection cannula inserted into the guide cannula. The drugs were injected at 
1 μl/min rate. Once the injection was completed, the injection cannula was 
removed 1 min after the injection and the dummy cap refitted. 
The correct placement of the i.c.v. cannula into the lateral ventricle 
was checked by histology using coronal sections of the brain (40 µm). 
 
2.6.3.  Intranasal administration  
For intranasal administration, rats were anaesthetized with sodium 
pentobarbital as described above. After a period of 2 h, rats were placed in a 
supine position, with the head supported at 45° to the body and the drug 
given intranasally by slowly pipetting a 10 µl volume into each nostril. 
Inhalation anaesthetics were not used, and all the procedures were 
conducted under air-controlled conditions in a room in the animal unit 
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under positive pressure to avoid stimulation of the olfactory system by 
unspecific odours. 
 
2.7. REAGENTS AND SOLUTIONS  
Reagents for solutions used in these studies were purchased from 
Sigma Aldrich, Dorset, UK unless otherwise stated. Solutions were prepared 
based on conventional protocols and formulas.  
 
2.8. STATISTICAL ANALYSIS 
The data were analysed using Graph Pad Prism 6 (GraphPad 
Software, CA, USA). Statistical tests used in each experiment are described in 
the specific results chapters. All data are presented as means ± S.E.M., and 
statistical significance was set at P < 0.05 unless otherwise stated. Significance 
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Melanocortins regulate the activity of oxytocin neurones when 
injected centrally. These actions are mediated by the activation of MC4 which 
are expressed in neurones of the PVN and SON (Kishi et al., 2003). In virgin 
rats, α-MSH i.c.v. injected or directly applied to the SON increases the 
expression of Fos in magnocellular neurones (Sabatier et al., 2003a), however, 
the α-MSH-induced Fos expression in virgin rats is suppressed during 
pregnancy (Ladyman et al., 2016). Similarly to α-MSH, central administration 
of the synthetic MC3/4 agonist, MT-II, has been shown to induce the 
expression of Fos in SON and PVN neurones (Thiele et al., 1998; Trivedi et al., 
2003; Rowland et al., 2010).  
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Activation of oxytocin neurones by melanocortins has been proposed 
as a putative mediator responsible for a wide range of behavioural and 
physiological effects (Sabatier et al., 2003b), including sexual behaviour, food 
intake and energy homoeostasis (see Chapter 1). Interestingly, the MC4 is 
also expressed in the amygdala where high mRNA receptor densities have 
been detected in the central nucleus (cAMG) (Kishi et al., 2003) and i.c.v. 
administration of the melanocortins ligands, including MT-II, have been 
shown to increase the neural activity, as shown by the expression of Fos 
(Thiele et al., 1998; McMinn et al., 2000; Hagan et al., 2001). The amygdala is a 
complex brain region involved in emotional processing playing a key role in 
fear and rewarding behavioural responses, and these responses are 
commanded by a complex interaction of several neurotransmitters and 
neuropeptides (Janak & Tye, 2015). For example, α-MSH has been shown to 
modulate stress and anxiety behavioural responses via activation of MC4 
(Kokare et al., 2005; Bhorkar et al., 2014). Moreover, the cAMG also expresses 
a high density of OTR (Veinante & Freund-Mercier, 1997; Bale et al., 2001; 
Huber et al., 2005), and evoked release of oxytocin within the cAMG has been 
shown to attenuate fear response in female rats (Knobloch et al., 2012). Thus, 
the administration of a melanocortin agonist makes the cAMG a potential 
site of behavioural actions for melanocortins themselves, or acting indirectly, 
through melanocortin-stimulated central oxytocin release.  
A limitation for drug delivery into the brain is the BBB which restricts 
the passage of hydrophilic molecules (e.g. peptides) into the brain 
extracellular fluid by the expression of tight junctions between endothelial 
cells, and consequently, separating the vascular system from the brain 
parenchyma (Banks, 2016). Unfortunately, exogenous administration of 
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naturally occurring melanocortins, including α-MSH, cannot penetrate the 
BBB in neuroactive amounts (Wilson et al., 1984). α-MSH and other 
endogenous melanocortins, such as ACTH and β-MSH, are cleaved from the 
POMC precursor which is largely synthesized in cells of the intermediate and 
anterior lobe of the pituitary gland, and also in neurones of the arcuate 
nucleus of the hypothalamus, but their physiological roles are controlled by 
the BBB (Hadley & Haskell-Luevano, 1999). However, the synthetic α-MSH 
analogue, MT-II, is thought to have, at least some, brain penetration 
capacities based on its molecular conformation and physiological effects 
(Dorr et al., 1996; Hadley & Dorr, 2006). Similarly, the experimental drug 
TCMC-A01 is a melanocortin ligand with MC3/4 agonist properties, and 
designed with theoretical BBB penetration capacities (Dr M. Callahan, 
Tensive Controls Inc., MO, USA; personal communication).  
In addition, systemic (i.v.) administration of radiolabelled MT-II has 
been reported to bind to circumventricular organs including the SFO and 
OVLT (Trivedi et al., 2003) which are located outside of the BBB, and express 
MC4 (Kishi et al., 2003). Both the SFO and the OVLT play an important role in 
the regulation of oxytocin and vasopressin neurones, serving as relay centres 
that monitor circulating signals (e.g. endogenous peptides like relaxin) 
related to homeostatic and physiological status, and consequently modifying 
the activity of magnocellular neurones via activation of afferents pathways 
projecting to the SON and PVN (Sunn et al., 2002). Another pathway 
regulating the activity of SON and PVN oxytocin neurones is the vagal-NTS 
complex, which has been shown to send excitatory noradrenergic afferents 
inputs from the caudal brainstem to the PVN and SON (Onaka et al., 1995). 
For example, stimulation of vagal afferents by systemic administration of the 
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gut-related peptide CCK has also been shown to regulate the activity of 
oxytocin neurones via brainstem which induces the expression of Fos in PVN 
and SON neurones (Verbalis et al., 1991).  
In recent years, intranasal administration of peptides has been 
proposed as an alternative route to circumvent the BBB, delivering peptides 
directly into the brain by intracellular and extracellular pathways (Balin et al., 
1986; Thorne et al., 2004; Johnson et al., 2010), and several peptides including 
oxytocin, ACTH4-10, and vasopressin have been reported to be found in the 
CSF in variable times following intranasal administration (Born et al., 2002; 
Striepens et al., 2013). Moreover, it has been reported that intranasal 
administration of oxytocin exerts prosocial effects in humans (Meyer-
Lindenberg et al., 2011), however, whether peptides can reach the brain is 
still a matter of debate (Leng & Ludwig, 2016; Quintana & Woolley, 2016). 
Interestingly, the rat olfactory bulb also expresses MC3/4 (Roselli-Rehfuss et 
al., 1993; Kishi et al., 2003), and thus, it may be a potential target for the 
therapeutic use of intranasal MT-II acting on the olfactory bulb itself, which 
has been shown to be involved in social behaviour in animals (Sanchez-
Andrade & Kendrick, 2009), or acting via afferent projections at distant 
targets, such as magnocellular neurones of the SON and PVN (Smithson et 
al., 1989, 1992; Bader et al., 2012).     
This study was aimed to investigate whether systemic (i.v.) and 
intranasal administration of MT-II activates oxytocin neurones using Fos 
expression as a marker for neural activity. Fos protein is part (together with 
Jun protein) of the transcription factor AP-1 which is involved in the 
regulation of target late genes, and it has been widely used as a generic 
marker for activated neuroendocrine cells, including magnocellular oxytocin 
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and vasopressin neurones (Kovacs, 2008). Interestingly, the vasopressin, but 
not oxytocin, gene promoter contains an AP-1 binding site (Yoshida et al., 
2006). The expression of Fos is stimulated by several physiological and 
experimental conditions. However, in osmotically-stimulated SON 
vasopressin neurones the induction of Fos is not required for vasopressin 
transcription (Arima et al., 2010). Fos expression is transient and can be 
immunohistochemically detected 30 min after stimulation, reaching a peak 
after 90 min (Verbalis et al., 1991; Kovacs, 2008). I analysed changes in the 
expression of Fos in neurones of the SON and PVN, and also in brain 
structures involved in the regulation of oxytocin and vasopressin release 
such as the OVLT and SFO, and the NTS. Then, using a pharmacological 
approach, I administered (i.c.v.) a non-selective MC3/4 antagonist to 
determine whether i.v. MT-II acts directly (centrally) on oxytocin neurones or 
through activation of peripheral melanocortin receptors. 
 
3.2. MATERIAL AND METHODS 
3.2.1.  Drug administration 
Rats were briefly anaesthetized using isoflurane and then dosed with 
sodium pentobarbital as previously described (see Chapter 2). After 2 h, 
MT-II (1 mg/ml/kg), TCMC-A01 -another synthetic MC3/4 agonist- (1 
mg/ml/kg), or vehicle (saline 0.9 %; 1 ml/kg) was injected i.v. In the first 
experiment animals were treated with either MT-II or vehicle (n = 6 for each 
treatment) and in the second experiment animals were treated with MT-II, 
TCMC-A01 or vehicle (n = 6 for each treatment). In both experiments the 
researcher was unaware of which animal had received which treatment until 
data collection was completed. For intranasal administration, 1 µg or 30 µg 
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of MT-II dissolved in 20 µl aCSF, or vehicle (aCSF) was given into each 
nostril (10 µl each). These doses were chosen as equimolar doses of intranasal 
oxytocin used in a previous study (Ludwig et al., 2013). In another 
experiment, the melanocortin antagonist SHU-9119 (1 µg/3 µl/rat) or vehicle 
(aCSF; 3 µl/rat) was given i.c.v. and 10 min later, MT-II (1 mg/ml/kg) was 
given i.v. After 90 min, the rats were transcardially perfused as described 
below. 
 
3.2.2. Transcardial perfusion and tissue collection   
Rats were given a terminal i.p. injection of sodium pentobarbital (160 
mg/kg), and then were placed in supine position. Using scissors the 
abdominal wall was cut horizontally close to the thoracic cage, and then the 
diaphragm carefully opened. The ribs were cut using a scissor and the heart 
exposed, then the pericardium was removed, and a short blunt 23-gauge 
needle was inserted through the left ventricle reaching the aortic arc. A cut in 
the right atrium was made to allow the drainage of blood and fixative 
solutions. The rats were perfused with 300 ml of heparinized (20 U/ml) 0.9 % 
saline solution followed by at least 300 ml paraformaldehyde (PFA) 4 % in 
0.1 M phosphate buffer (PB) at a pH of 7.4. Perfusion with 4 % PFA was 
stopped once clearly visible sign of fixations were observed (i.e. limbs). 
Using a guillotine, the head was cut off and the brain carefully removed and 
immersed in a post-fixative solution containing 2 % PFA and 15 % sucrose in 
0.1 M PB at 4 °C overnight. After this, the brains were kept in a solution 
containing 30 % sucrose for at least 72 h.  
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3.2.3. Brain slicing  
The brains were dissected using razor blades between the rostral 
margins of the optic chiasm and pons, and coronal sections (40 µm) were cut 
using a freezing microtome (Leica Microsystems, Wetzlar, Germany). For 
olfactory bulbs, sagittal sections of 40 µm were obtained. The sections 
including the main and accessory olfactory bulb (AOB), the SFO, the OVLT, 
the SON, the PVN, the cAMG, and the NTS were stored in cryoprotectant 
until they were processed for immunohistochemistry. 
 
3.2.4. Immunohistochemistry  
Standard free floating immunochemistry methods were used in this 
study as previously described (Ludwig et al., 2013). Sections were washed 
between steps in 0.1 M PB pH 7.4.  
For Fos protein immunostaining, the endogenous peroxidase activity 
was deactivated by incubating the sections for 20 min in 0.1 M PB containing 
0.3 % H2O2. After this, sections were incubated in a blocking buffer solution 
containing 3 % normal horse serum + 0.3 % Triton X-100 in 0.1 M PB for 1 h 
and were then incubated with c-Fos polyclonal antibody raised in rabbit 
(Ab5, PC38, Calbiochem, EMD Chemicals Inc., CA, USA) diluted at 1 : 20000 
in blocking buffer for 48 h at 4 °C. Following this, sections were incubated 
with biotinylated horse anti-rabbit IgG (Vector Laboratories, Inc., 
Peterborough, UK) diluted 1 : 500 in 0.1 M PB for 1 h at room temperature. 
Then sections were incubated in Vectastain Elite ABC Kit (Vector 
Laboratories, Inc., Peterborough, UK) diluted 1 : 25 in 0.1 M PB for 1 h at 
room temperature. The antigen-antibody complexes were visualised with a 
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solution containing 0.025 % diaminobenzidine, 2.5 % nickel II sulphate, 0.08 
% ammonium chloride and 0.015 % H2O2 in 0.1 M Tris.  
For Fos and oxytocin immunostaining, double immunochemistry was 
performed sequentially. Procedures were conducted as described above. For 
oxytocin immunostaining, sections were incubated in mouse anti-rat PS38 ‒ 
oxytocin-neurophysin monoclonal antibody (Ben-Barak et al., 1985) kindly 
provided by Prof H. Gainer (NIH, Bethesda, MD, USA) diluted 1 : 5000. 
Then, sections were incubated with biotinylated horse anti-mouse IgG 
antibody (Vector Laboratories, Inc., Peterborough, UK) diluted 1 : 500 in 0.1 
M PB for 1 h at room temperature. To visualise the oxytocin immunoreaction 
a solution containing 0.025 % diaminobenzidine and 0.015 % H2O2 in 0.1 M 
Tris was used.  
The immunostained sections were mounted on gelatinized slides, 
air-dried for 12 h, and dehydrated in increasing concentrations of ethanol 
followed by xylene. In some experiments, sections (e.g. brainstem sections) 
were counterstained with nuclear fast red (Vector Laboratories, Inc., 
Peterborough, UK) for 3 min before ethanol dehydration. Finally, the slides 
were cover-slipped using DPX mounting medium (Sigma Aldrich, Dorset, 
UK). 
  
3.2.5. Quantification of Fos-positive neurones  
All quantification was carried out blinded. The number of Fos-positive 
neurones in the brain regions analysed, include the olfactory bulb, the AV3V, 
the PVN and SON of the hypothalamus, the cAMG, and the NTS. In the 
olfactory bulb, Fos-positive neurones were counted in areas of the mitral cell 
layer (MCL) and external plexiform layer (EPL) of the main olfactory bulb, 
Chapter 3 – Results I  
54 
 
and also in the entire accessory olfactory bulb (AOB). In the PVN, 
parvocellular and magnocellular regions were counted separately by 
comparing sections with illustrations of a brain atlas (Paxinos & Watson, 
1998). At the level counted, the parvocellular PVN includes the dorsal cap 
and ventromedial subdivisions. 
In the cAMG, Fos-positive neurones were counted from sections 
spanning from rostral (bregma -1.56 mm) to caudal (bregma -2.28 mm). In 
the NTS, Fos-positive neurones were counted and analysed from sections 
spanning from rostral (bregma -12.0 mm) to caudal (bregma -14.9 mm) 
according to Paxinos and Watson (1998). In the olfactory bulb, Fos-positive 
neurones were counted in dorsal, rostral, and ventral areas (six fields) of each 
cell layer analysed. Images of the regions were acquired using an upright 
Leica microscope (10x objective) attached to Leica digital camera and 
controlled by Leica acquisition software (Leica Microsystems, Wetzlar, 
Germany). Images from at least six regions from every rat in each treatment 
group were acquired. Using ImageJ (NIH, Bethesda, MD, USA) the number 
of Fos-positive neurones was counted using the Count macro, and the 
surface area of each region of interest (ROI) was measured using the ROI 
macro, by comparing the section image with the brain atlas (Paxinos & 
Watson, 1998). The number of Fos-positive neurones within each ROI was 
normalised by the surface area of that ROI to allow comparison. Thus, the 
number of Fos-positive neurones in these regions are expressed as the mean 
± S.E.M. per 104 μm2 (corresponding to an area of 100 × 100 μm). The mean 
number of Fos-positive neurones from every rat in each region was averaged 
and is expressed as the mean ± S.E.M. per region.  
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Oxytocin neurones are densely packed within the SON and cell 
structures in the sections overlap making it difficult to distinguish between 
single neurones which might affect counting Fos-positive nuclei in oxytocin 
stained neurones. Therefore, I also counted a proportion of clearly 
distinguishable oxytocin neurones and oxytocin neurones expressing Fos 
protein directly under the microscope (20x magnification in at least 6 regions 
in every rat); values are expressed as percentage. 
 
3.2.6. Statistical analysis 
Fos expression experiments involving two groups were analysed 
using a two-tailed Mann-Whitney test. Experiments involving three groups 
were analysed using Kruskal-Wallis test followed by post hoc Dunn’s 
multiple comparison test, comparing the treatment groups with the control 
(vehicle) group. P < 0.05 was considered significant. 
 
3.3. RESULTS 
3.3.1. Effect of i.v. MT-II on Fos expression  
The SON of rats injected with MT-II (1 mg/kg) showed a significantly 
higher density of Fos-positive neurones compared with rats injected with 
vehicle (**P = 0.0016; Fig. 3.1A.; Appendix Table A.). In the PVN, MT-II-
treated rats also showed a significantly higher density of Fos-positive 
neurones (*P = 0.0457; Fig. 3.1B.; Appx. Table A.) compared with rats injected 
with vehicle. I.v. administration of TCMC-A01 did not significantly change 
Fos expression either in the SON (P > 0.9999; Fig. 3.1A.), or in the PVN (P = 
0.4499; Fig. 3.1B.; Appx. Table A.). The analysis of magnocellular and 
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parvocellular regions of the PVN (Fig. 3.2A.), showed a higher density of 
Fos-positive neurones in the magnocellular regions of the PVN in the MT-II 
group compared to the vehicle group (***P < 0.001; Fig. 3.2B.; Appx. Table 
A.). I.v. administration of MT-II did not significantly change Fos expression 
in parvocellular regions (P = 0.1326; Fig. 3.2B.; Appx. Table A.). 
Double immunostaining for Fos and oxytocin revealed that both 
oxytocin neurones and non-labelled, putative vasopressin neurones, 
displayed more Fos expression in rats injected with MT-II in the SON 
(oxytocin: *P = 0.0260; non-labelled: *P = 0.0411; Fig. 3.3E.; Appx. Table A.). In 
the PVN, magnocellular and parvocellular oxytocin neurones also showed 
significantly more Fos expression in rats injected with MT-II (magnocellular: 
**P = 0.0087; parvocellular: **P = 0.0043; Fig. 3.3F.; Appx. Table A.). There was 
also more Fos expression in magnocellular and parvocellular non-oxytocin 
neurones, but this did not achieve statistical significance (magnocellular: P = 
0.1775; parvocellular: P = 0.0823; Fig. 3.3F.; Appx. Table A.).  
Oxytocin neurones are densely packed and cells structures overlap 
making difficult to distinguish between single cells, so a proportion of clearly 
distinguishable oxytocin neurones was counted under the microscope. The 
percentage of oxytocin neurones expressing Fos was significantly higher in 
the SON (**P = 0.0022; Fig. 3.4A.; Appx. Table A.), and magnocellular (**P = 
0.0043; Fig. 3.4B.; Appx. Table A.) and parvocellular (**P = 0.0043; Fig. 3.4B.; 
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3.3.1.1.  Fos expression in neurones of the SFO, OVLT   
No significant changes in Fos expression were detected in the 
circumventricular organs, including the OVLT (MT-II vs vehicle: P = 0.8734, 
TCMC-A01 vs vehicle: P > 0.9999) and SFO (MT-II vs vehicle: P > 0.9999, 
TCMC-A01 vs vehicle: P = 0.2623) following i.v. administration of MT-II or 
TCMC-A01 (Fig. 3.5A,D.; Appx. Table A.).  
 
3.3.1.2.  Fos expression in neurones of the cAMG   
The i.v. administration of MT-II or TCMC-A01 did not significantly 
change the expression of Fos in the cAMG (MT-II vs vehicle: P > 0.9999, 
TCMC-A01 vs vehicle: P > 0.9999; Fig. 3.5F.; Appx. Table A.). 
 
3.3.1.3.  Fos expression in the NTS 
The analysis of the NTS showed significantly more Fos expression in 
rats injected with i.v. MT-II than in rats injected with i.v. vehicle (MT-II vs 
vehicle: *P = 0.0482; Fig. 3.6A.; Appx. Table A.). The distribution of Fos-
positive cells within the NTS showed a higher density of Fos expression in 
the caudal part of the NTS (i.e. bregma -14 mm, Paxinos and Watson (1998)) 
but this did not achieve statistical significance (P = 0.3477; Fig. 3.6B.). The i.v. 
administration of TCMC-A01 did not significantly change the expression Fos 
in the NTS (TCMC-A01 vs vehicle: P > 0.9999; Fig. 3.6A.; Appx. Table A.). 
 
  3.3.2. Effect of intranasal MT-II on Fos expression 
In rats intranasally administered with 1 µg or 30 µg of MT-II no 
significant changes in Fos expression were detected in oxytocin neurones 
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(MT-II 1 µg vs vehicle: P = 0.1875, MT-II 30 µg vs vehicle: P = 0.2338) and 
non-labelled, putative vasopressin neurones (MT-II 1 µg vs vehicle: P = 
0.7740, MT-II 30 µg vs vehicle: P > 0.9999) of the SON (Fig. 3.7A.; Appx. Table 
B.), and oxytocin neurones (MT-II 1 µg vs vehicle: P > 0.9999, MT-II 30 µg vs 
vehicle: P = 0.3196) and non-labelled neurones (MT-II 1 µg vs vehicle: P > 
0.9999, MT-II 30 µg vs vehicle: P = 0.3196) of the PVN (Fig. 3.7B.; Appx. 
 Table B.).  
 Intranasal administration of MT-II did not significantly change Fos 
expression in the AOB (MT-II 1 µg vs vehicle: P = 0.9642, MT-II 30 µg vs 
vehicle: P > 0.9999; Appx. Table B.) or cell layers of the main olfactory bulb, 
i.e. the MCL (MT-II 1 µg vs vehicle: P = 0.8981, MT-II 30 µg vs vehicle: P > 
0.9999; Appx. Table B.) and EPL (MT-II 1 µg vs vehicle: P > 0.9999, MT-II 30 
µg vs vehicle: P > 0.9999; Fig. 3.8A,B.; Appx. Table B.). 
 
3.3.3. Effect of i.c.v. melanocortin antagonist administration on 
i.v. MT-II-induced Fos expression  
To determine whether Fos expression induced by MT-II was 
facilitated by activation of central melanocortin receptors, the non-selective 
melanocortin antagonist SHU-9119 was injected centrally (i.c.v.) before 
systemic injection of MT-II (i.v.). The SON of rats injected with the 
melanocortin antagonist had significantly less Fos expression in oxytocin (**P 
= 0.0018), and putative vasopressin (*P = 0.0214) neurones than rats injected 
with vehicle (Fig. 3.9A.; Appx. Table C.), and there was a lower proportion of 
Fos-positive oxytocin neurones in the SON (***P = 0.0002; Fig. 3.10A.; Appx. 
Table C.).  
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In the PVN, there was significantly less MT-II-induced Fos expression 
in both magnocellular (**P = 0.0074) and parvocellular (*P = 0.0379) oxytocin 
neurones in rats injected with i.c.v. antagonist (Fig. 3.9B.; Appx. Table C.). 
There was also less Fos expression in magnocellular (P = 0.0941) and 
parvocellular (P = 0.2256) non-oxytocin neurones, however, this did not 
achieve statistical significance (Fig. 3.9B.; Appx. Table C.). The proportion of 
oxytocin neurones that expressed Fos in rats injected with the antagonist was 
significantly lower in both magnocellular (**P = 0.0016; Fig. 3.10B.; Appx. 
Table C.) and parvocellular neurones of the PVN (**P = 0.0036; Fig. 3.10B.; 
Appx. Table C.). 
 
3.3.3.1.  Fos expression in the NTS 
In the NTS, i.c.v. administration of the antagonist did not change Fos 
expression induced by MT-II (P = 0.3104; Fig. 3.6D.; Appx. Table C.).  
 
3.4. DISCUSSION  
This study was designed to test whether i.v. or intranasal 
administration of the melanocortin agonist MT-II activates oxytocin neurones 
in pentobarbital anaesthetized rats. I demonstrate that i.v., but not intranasal, 
administration of MT-II effectively induces the expression of Fos protein in 
oxytocin neurones of the SON and the PVN. MT-II-induced Fos was 
attenuated by prior i.c.v. administration of the MC3/4 antagonist SHU-9119. 
No significant changes in Fos expression were observed in the 
circumventricular organs SFO and OVLT which are known to monitor 
peripheral signals and modulate oxytocin and vasopressin neurone activity. 
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In contrast, a significant increase in Fos expression was detected in the NTS 
which project to the PVN and SON, and modulate oxytocin and also 
vasopressin neurone activity.  
The naturally occurring melanocortin α-MSH has been shown to 
modulate the activity of magnocellular neurones, as shown by increased 
expression of Fos in PVN and SON neurones when applied centrally 
(Olszewski et al., 2001; Sabatier et al., 2003a). Similarly, central administration 
of the α-MSH analogue, MT-II, increased the expression of Fos in neurones of 
the SON and PVN (Thiele et al., 1998). This action is mediated, at least in 
part, by activation of MC4 which is expressed in the SON and PVN (Kishi et 
al., 2003). Furthermore, activation of MC4 by α-MSH has been reported to 
initiate the ERK-c-fos signalling cascade in hypothalamic rat neurones 
(Ramirez et al., 2015). Fos protein has been widely used as a marker for 
neural activity in neuroendocrine cells. In the magnocellular neurones, a 
large body of evidence has led to the assumption that Fos expression reflects 
well the neurosecretory activity of these cells. After stimulation, c-fos mRNA 
is rapidly expressed in neurones reaching a peak within 30 min, and its 
product Fos between 60 to 90 min, remaining stable for 2 ‒ 5 h (Hoffman et 
al., 1993; Kovacs, 2008).  
A limitation for the peptide delivery into the CNS is the BBB which is 
known to restrict the passage of α-MSH (Wilson et al., 1984; Wilson, 1988). 
However, the cyclic and short amino acid sequence of MT-II is thought to 
result in higher brain penetration when compared to α-MSH (King et al., 
2007). MT-II has been extensively used to study central and peripheral 
melanocortin actions, and some physiological effects induced by systemic 
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administration of MT-II are believed to be, at least in part, mediated by 
activation of central receptors (Giuliano et al., 2006; Klenerova et al., 2008). 
My results show that i.v. injection of MT-II (1 mg/kg) markedly 
induced the expression of Fos in both oxytocin and non-labelled, putative 
vasopressin, magnocellular neurones of the SON and PVN. Similarly, a 
recent study has shown that i.p. injection of MT-II (10 mg/kg) induced the 
expression of EGR-1, another immediate early gene, in oxytocin neurones of 
the PVN in prairie voles (Modi et al., 2015). Conversely, Trivedi et al. (2003) 
did not detect changes in Fos expression in the SON and PVN in response to 
i.v. MT-II. This discrepancy may be related to the different experimental 
conditions of Trivedi et al. (2003) study, namely, use of conscious animals, the 
time (2 h) between i.v. injection and perfusion, as well as possible differences 
in cell counting since this information was not provided.  
In contrast to the effect of MT-II, the i.v. administration of the 
melanocortin agonist TCMC-A01 did not significantly change Fos expression 
in the PVN and SON in this study. TCMC-A01 is an experimental 
melanocortin with theoretical BBB-penetrating capacities designed to bind 
MC3/4 (Dr M. Callahan, personal communication). So here, I administered 
TCMC-A01 and MT-II at the same doses in order to compare their effects on 
Fos expression. Thus, this result suggests that after systemic administration 
TCMC-A01 cannot penetrate the BBB in neuroactive amounts. I then further 
analysed Fos expression in brain areas lacking the BBB (and therefore, 
exposed to high concentration of circulating TCMC-A01), and brain areas 
receiving peripheral inputs (i.e. NTS). However, TCMC-A01 also failed to 
induce any significant change in Fos expression in circumventricular organs 
Chapter 3 – Results I  
62 
 
of the AV3V and the NTS. Thus, the use of TCMC-A01 in further 
experiments was discarded.  
Since TCMC-A01 is currently under development, additional 
experiments are required to determine whether TCMC-A01 is able to induce 
activation of magnocellular neurones, and therefore, validate its systemic use 
(at higher doses than the used here). These experiments may include in vitro 
receptor binding, and receptor activation studies that will allow estimating 
physiologically active doses to be administered. The direct (central) 
administration of different doses of TCMC-A01 should be considered, as this 
route avoids the restriction of the BBB to reach central receptors, and 
therefore, it is possible to determine dose-dependent effects, similarly as it 
has been shown for MT-II after i.c.v. administration (Thiele et al., 1998).   
I did not detect changes in Fos expression in the cAMG in response to 
i.v. administration of MT-II, and TCMC-A01. Conversely, Thiele et al. (1998) 
have shown that i.c.v. administration of 1 µg, but not 0.1 µg, of MT-II 
induces Fos expression in the cAMG, indicating a dose-dependent effect. 
Therefore, it is possible that following i.v. administration, MT-II does not 
reach the cAMG in enough amounts to trigger Fos expression. As Thiele et al. 
(1998) administered MT-II i.c.v., and consequently, reaches other brain 
structures, it is not possible determine whether the effect reported was 
mediated by direct activation of MC4 or indirectly by activation other 
systems that, in turn, activate cAMG neurones. In this context, for example, 
central administration of melanocortin agonists could induce dendritic 
release of oxytocin (Sabatier et al., 2003a) that might act on OTR of the 
amygdala. Remarkably, oxytocin administration has been reported to induce 
changes in Fos expression in the amygdala (Ferguson et al., 2001).   
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Systemic injection of radiolabelled (125)Iodo-MT-II has been reported 
to penetrate the brain parenchyma in low amounts. However, high densities 
of (125)Iodo-MT-II was bound to the circumventricular organs (Trivedi et al., 
2003). This raised the question whether MT-II-induced Fos in SON and PVN 
neurones was a direct effect or mediated indirectly by other brain structures. 
The SFO and OVLT are circumventricular organs in which neurones can 
monitor and sense compounds, including peptides, present in the 
bloodstream (Mimee et al., 2013; Ufnal & Skrzypecki, 2014; Cancelliere et al., 
2015) to, in turn, modulate systemic and central vasopressin and oxytocin 
release by neuronal pathways that connect them with the SON and PVN 
(Miselis et al., 1979; Boudaba et al., 1995; Leng et al., 1999). Interestingly, both 
the SFO and the OVLT express MC4 (Kishi et al., 2003). 
The analysis of the OVLT and SFO did not show any significant 
change in Fos expression induced by systemic MT-II. However, there was a 
significant increase in Fos expression in neurones of the NTS (protected by 
the BBB), which also expresses MC4 (Kishi et al., 2003). In vitro 
electrophysiology studies have shown that direct application of α-MSH has 
excitatory and inhibitory effects on different subsets of NTS neurones 
(Mimee et al., 2014). However, the NTS receives visceral inputs through the 
vagus nerve to modulate gastrointestinal and cardiorespiratory functions, 
and melanocortins have been shown to be involved in modulating these 
functions (Rinne et al., 2012; Campos et al., 2014), so it may be that activation 
of peripheral receptors in response to i.v. MT-II administration contributed 
to the increased Fos expression in the NTS.  
The analysis of sub-regions of the NTS showed a higher density of Fos 
in the caudal part of the NTS which is known to contain noradrenaline 
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neurones that send excitatory projections from the A2 region of the NTS to 
the SON and PVN (Onaka et al., 1995). Furthermore, it has been shown that 
Fos expression in magnocellular oxytocin neurones can be indirectly 
triggered by activation of vagal inputs via brainstem (Verbalis et al., 1991; 
Antonijevic et al., 1995). Hence, possible contributions from the NTS to the 
neural activity of magnocellular neurones observed after systemic MT-II 
should not be dismissed. 
In the second experiment, I investigated whether blockade of central 
melanocortin receptors prevents the central effects of systemically 
administered MT-II. This showed that i.c.v. administration of the 
melanocortin antagonist before i.v. administration of MT-II reduced Fos 
expression induced by MT-II in oxytocin neurones of the SON and PVN, 
consistent with the conclusion that the increase in Fos expression was 
mediated by activation of central receptors. However, it has been reported 
that in a neuronal population of the arcuate nucleus, the antagonist used 
induces hyperpolarization, and consequently, decrease the excitability of this 
neuronal phenotype (Smith et al., 2007). The melanocortin antagonist 
SHU-9119 is structurally related to MT-II, competing for MC3/4 (Hruby et al., 
1995; Yang et al., 2002), and has been extensively used to reverse MT-II 
actions (Fan et al., 1997; Wessells et al., 2003; Rinne et al., 2012). The lack of a 
significant effect on Fos expression in NTS neurones after i.c.v. 
administration of SHU-9119 indicates that when MT-II is systemically 
administered, it acts on peripheral targets which are subsequently signalled 
to the NTS. Hence, the effects of MT-II described in this study appear to be 
mediated by a combination of central and peripheral effects.  
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The antagonist also reduced Fos expression in oxytocin-negative 
neurones in the magnocellular regions of the PVN. These are likely to be 
magnocellular vasopressin neurones, but the subregions of the PVN are not 
entirely homogeneous and contain some parvocellular neurones. However, 
the SON contains only magnocellular neurones, so here, the attenuation of 
Fos expression in non-oxytocin neurones can be definitively associated with 
magnocellular vasopressin neurones. Consistently, the expression of MC4 
mRNA has been described predominantly, but not only, in areas densely 
populated by magnocellular oxytocin neurones in both the PVN and SON 
(Kishi et al., 2003; Siljee et al., 2013). In addition, MC4 expression has also been 
found in parvocellular subregions of the PVN (Kishi et al., 2003; Liu et al., 
2003).     
The intranasal administration of drugs has been proposed as an 
alternative route that can bypass the BBB to deliver drugs directly into the 
brain (Dhuria et al., 2010), however, this is very controversial (Leng & 
Ludwig, 2016; Quintana & Woolley, 2016; Walum et al., 2016). The BBB 
bypassing is theoretically achieved by endocytosis of compounds by 
olfactory or trigeminal neurones, which are then retrogradely transported 
and released into the brain (Johnson et al., 2010). Consistent with this, 
changes in gene expression and behaviour following intranasal 
administration of melanocortin receptor ligands have been reported (Serova 
et al., 2013, 2014). Here, I found that MT-II administered intranasally at two 
different doses did not induce any changes in Fos expression either in the 
olfactory bulbs, or in the PVN and SON. Similarly, Ludwig et al. (2013) 
reported that intranasal administration of equimolar doses of vasopressin 
and oxytocin failed to trigger Fos expression, suggesting that at the doses 
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administered these peptides do not reach the CNS in neuroactive amounts. 
Conversely, it has been reported that low molecular weight compounds, 
such us lidocaine, can be uptaken by the trigeminal nerve from the nose, and 
transported into the brain, reaching deep structures, including the brainstem, 
cerebellum, and spinal cord (Johnson et al., 2010). However, specific 
transport mechanisms have not been reported. It seems unlikely that 
indiscriminate substances can use this entry route, as noxious agents present 
in the air could also get easy access to the brain. Exactly why MT-II failed to 
induce changes in Fos expression in this experiment is unknown, but it is 
possible to conjecture that following intranasal administration, MT-II 
suffered enzymatic degradation, as the nasal mucosa is rich in peptidase and 
protease enzymes (Sarkar, 1992).   
Expression of MC3/4 mRNA (Roselli-Rehfuss et al., 1993; Gelez et al., 
2010) have been detected in the rat olfactory bulb, and high α-MSH content 
extracted from olfactory bulb tissue has also been reported (Loh et al., 1979), 
suggesting that this region is a target for melanocortins. To my knowledge, 
there are no previous studies about the effect of melanocortins on neural 
activity in the olfactory bulb. Here, I report that intranasal administration of 
MT-II failed to induce changes in Fos expression in layers of the main and 
accessory olfactory bulb, suggesting that the receptor is not associated with 
Fos expression, or that MT-II does not reach the olfactory bulb in 
physiologically significant amounts. Consequently, the central (i.c.v. or 
intraparenchymal) administration of MT-II should be critically considered to 
elucidate whether activation of (putative) MC3/4 effectively trigger Fos 
(neural activity) in the olfactory bulb.  
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Since the olfactory bulb is the first neural structure adjacent to the site 
of administration, I inferred that high concentrations of MT-II could be 
reached in the olfactory bulb (which project outside of the BBB through the 
peripheral olfactory nerves). However, whether MT-II can reach this neural 
structure still remains intriguing. Other compounds, including lidocaine, a 
low molecular weight anaesthetic, has been detected in high concentrations 
in the rat olfactory bulb following intranasal administration (Johnson et al., 
2010). Since lidocaine acts directly on neurones blocking sodium channels, it 
seems likely that, at least, some lidocaine may be uptake by peripheral 
olfactory sensory neurones, and then, transported or diffused into the 
olfactory bulb. Nevertheless, compounds with higher molecular weights, for 
example, radiolabeled insulin-like growth factor-I (IGF-I), and IRdye 800 
fluorescent dye (Thorne et al., 2004; Johnson et al., 2010) have also been 
reported to reach the olfactory bulbs, but as for the trigeminal routes, no 
specific transport mechanisms have been reported. An extracellular route 
through intercellular clefts of the olfactory epithelium to the subarachnoid 
space has also been described using horseradish peroxidase administration 
(Balin et al., 1986). The specific mechanisms by which these compounds (or 
even peptides) reach the olfactory bulb still remains to be determined. 
 
Figure 3.1. Fos expression in the SON and PVN after i.v. melanocortin
administration. MT‐II, but not TCMC‐A01, significantly increased the density of
Fos‐positive neurones in the (A) SON, and (B) PVN. Mean + S.E.M. *P < 0.05, **P <
0.01; Kruskal‐Wallis test followed by Dunn’s multiple comparison test. Numbers










































































Figure 3.2. Fos expression in subpopulations of the PVN after i.v. MT‐II. (A)
Representative section showing immunohistochemistry for Fos expression in the
magnocellular and parvocellular regions of the PVN in a MT‐II injected rat. (B)
Density of Fos‐positive neurones within the subpopulations of the PVN. Mean +
S.E.M. ***P < 0.001; Mann‐Whitney test. 3v ‐ third ventricle.
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Figure 3.3. Fos expression in oxytocin neurones of the SON and PVN after i.v.
MT‐II. Representative examples of coronal sections of the hypothalamic (A,C) SON
and (B,D) PVN immunostained for Fos and oxytocin of (A,B) vehicle (saline 0.9 %)
and (C,D) MT‐II injected rats. Density of Fos‐positive oxytocin neurones and
putative vasopressin neurones in the (E) SON, and Fos‐positive oxytocin neurones
and non‐oxytocin neurones in subpopulations of the (F) PVN. Mean + S.E.M. *P <
0.05, **P < 0.01; Mann‐Whitney test. Numbers of animals is shown in bars. OC ‐
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Figure 3.4. Proportion of oxytocin neurones expressing Fos in the SON and PVN
after i.v. MT‐II. (A) MT‐II significantly increased the number of Fos‐positive
neurones within the oxytocin population in the (A) SON, and in magnocellular and




















































































Figure 3.5. Fos expression in the SFO, OVLT and cAMG in response to i.v.
melanocortin administration. Representative examples of the areas analysed in the
(A) SFO, (C) OVLT, and (E) cAMG in a vehicle‐injected rat. No significant changes in
Fos expression in the (B) SFO, (C) OVLT, and (F) cAMG were detected in response to
MT‐II. Mean + S.E.M. Numbers of animals is shown in bars. 3v ‐ third ventricle, P3v

















































































Figure 3.6. Fos expression in the NTS in response to i.v. melanocortin
administration. MT‐II, but not TCMC‐A01, significantly increased the density of
Fos expressing neurones in the (A) NTS, with a higher density of expression (not
significant) in the (B) caudal NTS. (C) Representative examples of Fos expression
in the caudal NTS (bregma ‐14.0 mm). (D) MT‐II‐induced Fos was not reduced by
prior i.c.v application of the melanocortin antagonist SHU‐9119. Mean + S.E.M. *P
< 0.05; Kruskal‐Wallis test followed by Dunn’s multiple comparison test. Numbers
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Figure 3.7. Fos expression in the SON and PVN after intranasal MT‐II
administration. Density of Fos‐positive oxytocin neurones and putative
vasopressin neurones in the (A) SON, and Fos‐positive oxytocin neurones and non‐
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Figure 3.8. Fos expression in the olfactory bulb in response to intranasal MT‐II
administration. (A) Photomontage of a rat olfactory bulb stained for Fos and
nuclear fast red in a vehicle‐injected rat. (B) Number of Fos‐positive neurones (per
104 μm2) in layers of the olfactory system (per area) following low and high doses
of intranasal MT‐II administration. MCL ‐ mitral cell layer, EPL ‐ external
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Figure 3.9. Effect of the melanocortin antagonist on MT‐II induced Fos
expression in the SON and PVN. Intracerebroventricular (i.c.v.) injections of the
melanocortin antagonist, SHU‐9119, reduced Fos expression induced by i.v.
injected MT‐II in the (A) SON and (B) subpopulations of the PVN. Mean + S.E.M.
*P < 0.05, ** P < 0.01; Mann‐Whitney test. Numbers of animals is shown in bars.
76
Chapter 3 – Results I
Figure 3.10. Effect of the melanocortin antagonist on the proportion of SON and
PVN oxytocin neurones expressing Fos in response to i.v. MT‐II. The proportion
of oxytocin neurones expressing Fos in the (A) SON, and in magnocellular and
parvocellular parts of the (B) PVN decreased by prior i.c.v. administration of SHU‐
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Chapter 4  
Changes in the electrical activity of supraoptic oxytocin and 




In Chapter 3, I provided evidence showing that i.v. administration of 
MT-II affects SON oxytocin and vasopressin neurone activity as shown by 
increased expression of Fos protein, and this effect was attenuated by the 
prior i.c.v. administration of a non-selective MC3/4 antagonist. It is commonly 
assumed that Fos expression reflects increased neuronal electrical activity 
(action potentials), but this is not always true (Luckman et al., 1994; Kovacs, 
2008), and direct application of the naturally occurring melanocortin, 
α-MSH, has been shown to inhibit the electrical activity of SON oxytocin 
neurones yet strongly induce Fos expression (Sabatier et al., 2003a). 
Moreover, antidromically evoked action potentials do not induce Fos 
expression in SON neurones (Luckman et al., 1994), showing that “if 
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depolarization per se induced its expression, c-fos should have been detected 
in millions of neurones throughout the brain under basal conditions” 
(Kovacs, 2008). 
The magnocellular neurones of the rat SON, and also the PVN, exhibit 
spontaneous action potentials (spikes) that are driven by the interaction of 
intrinsic membrane properties, and afferent excitatory and inhibitory inputs 
(Li et al., 2007; Brown et al., 2013). These spikes are “stereotypically” fired in 
two discharge patterns. The continuous firing pattern exhibited by oxytocin 
and some vasopressin neurones is characterized by slow spike discharge 
occurring in irregular (slow irregular) or regular (fast continuous) patterns, 
and fired at a frequency (firing rate) of ~ 2 ‒ 4 spikes/s and ~ 4 ‒ 6 spikes/s, 
respectively. The phasic firing pattern is only exhibited by vasopressin 
neurones, and is characterized by periods of intense spike activity, reaching a 
rate of ~ 15 ‒ 25 spikes/s during the first 10 s then decreasing to ~ 6 spikes/s 
for the rest of the activity period; these activity periods alternate with silence 
periods (i.e. non-spike activity) occurring at relatively regular intervals. The 
intervals of activity and silence periods last a minimum of 15 s and 10 s, 
respectively, and their duration is stochastically determined (Fig. 4.1.) 
(Poulain & Wakerley, 1982; Li et al., 2007; Brown et al., 2013). 
The basal firing rate and discharge pattern of magnocellular neurones 
can be modified when a stimulus (e.g. osmolality) is applied to 
magnocellular neurones. For example, in rats, infusion of hypertonic saline 
increases the firing rate in both intrinsically osmosensitive magnocellular 
SON vasopressin and oxytocin neurones (Mason, 1980; Oliet & Bourque, 
1993), as well as transiently modifying the firing pattern of phasic 
vasopressin neurones to a continuous firing pattern (Leng et al., 2001). 
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Similarly, i.v. administration of peptides, including CCK (Leng et al., 1991) 
has been shown to transiently increase the firing rate in oxytocin neurones, 
but has no or an inhibitory effect on vasopressin neurones. CCK is regularly 
used to identify and to distinguish between SON neurones. Interestingly, the 
changes in neuronal electrical “behaviour” can be even more marked under 
certain physiological conditions. During parturition and lactation, oxytocin 
neurones fire in a discharge pattern characterised by a brief (1 ‒ 2 s) high 
frequency (firing rates of ~ 50 ‒ 100 spikes/s) of coordinated bursts which are 
followed by periods of slow irregular background activity lasting ~ 5 min 
(Belin et al., 1984; Belin & Moos, 1986). These changes in firing rate and 
pattern allow magnocellular oxytocin and vasopressin neurones to adapt 
peptide release to sustained physiological activation.   
The electrical activity of magnocellular neurones is closely linked with 
oxytocin and vasopressin release from the nerve endings into the 
bloodstream, and consequently, the firing rate and discharge pattern are key 
factors that determine the amount of peptide peripherally released 
(MacGregor & Leng, 2013). When an action potential reaches the nerve 
endings, the opening of voltage-gated Ca2+ channels results in a Ca2+ influx 
that leads to the classic stimulus-secretion coupling (Nordmann, 1983). The 
spike-associated secretion is, theoretically, not only restricted to the nerve 
endings, as the characteristics of the somatodendritic cell membrane in some 
neuronal phenotypes support the propagation of the action potential to the 
dendritic tree (backpropagation) (Vetter et al., 2001; Casale & McCormick, 
2011). Nevertheless, the backpropagation in magnocellular neurones is not 
completely understood and in addition to action potentials, other factors 
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including changes in intracellular Ca2+ and the actin cytoskeleton, are also 
involved in the release of peptide-containing vesicles (Tobin et al., 2012).  
In this chapter, I study the effect of systemic administration (i.v.) of 
MT-II on the electrical activity of SON oxytocin and vasopressin neurones in 
vivo in urethane anaesthetized rats by using extracellular single-unit 
recordings of antidromically identified SON neurones. The use of in vivo 
electrophysiology allows monitoring dynamic changes in the activity of SON 
neurones accurately whereas preserving the physiological milieu, and 
therefore, the physiological significance of the responses of magnocellular 
neurones (Leng & Sabatier, 2014). 
 
4.2. MATERIAL AND METHODS 
 The following experiments were performed under the direct 
supervision and assistance of Dr Nancy Sabatier. 
 
4.2.1. In vivo preparation and electrophysiological recording 
Adult male Sprague-Dawley rats weighing 350 g approximately were 
anaesthetized with an i.p. injection of urethane (1.25 g/kg); a femoral vein 
was cannulated for drug administration and an endotracheal tube inserted 
into the trachea to keep the airway opened. The rats were placed into a 
stereotaxic frame in supine position, and the right SON and the pituitary 
stalk were exposed transpharyngeally as previously described (Leng & 
Dyball, 1991; Leng & Sabatier, 2014). A glass micropipette (filled with 0.15 M 
NaCl, 20-40 M) was introduced into the SON under direct visual control to 
record the extracellular activity of single neurones. A bipolar stimulating 
electrode (SNEX-200X, Clarke Electromedical Instruments, Reading, UK) was 
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placed on the pituitary stalk and set to deliver single matched biphasic 
pulses (1 ms, < 1 mA peak to peak) for antidromic identification of SON 
neurones. The neuronal electrical activity was amplified using an Axonpatch 
200B amplifier connected to a CV203BU headstage (Molecular Devices Inc., 
Sunnyvale, CA, USA) and the signal filtered using a HumBug 50Hz noise 
eliminator (Quest Scientific Instruments Inc., North Vancouver, BC, Canada). 
The spikes were processed (Digitimer D130; Digitimer Ltd., Welwyn Garden 
City, UK) and interfaced (CED1401; Cambridge Electronic Design Ltd., 
Cambridge, UK) to a personal computer using Spike2 software ver. 7.03 
(Cambridge Electronic Design Ltd., Cambridge, UK).  
 
4.2.2. Identification of vasopressin and oxytocin SON neurones  
SON neurones were identified by antidromic stimulation of the 
pituitary stalk which evokes an action potential in the axon that propagates 
to the cell body. Thus, an antidromic spike occurring at a constant latency (~ 
10 ms for SON neurones) serve as a confirmation for a cell as a SON neurone 
(Fig. 4.2A.). The shape of interspike-interval histogram (which shows the 
distribution of the observed times between spikes) was also checked for 
characteristic firing patterns of SON vasopressin and oxytocin neurones; 
which is highly skewed to the left in vasopressin neurones as previously 
described (Leng et al., 2001; Sabatier et al., 2004); Fig. 4.2B.). Oxytocin 
neurones were also distinguished from vasopressin neurones by their 
discharge pattern (Fig. 4.1.) and by their opposite response to i.v. CCK (20 
µg/kg; cholecystokinin-(26-33)-sulphated, Bachem Ltd., Saffron Walden, 
Essex, UK; Fig. 4.3.), i.e. transient excitatory response of oxytocin neurones 
and no effect or transient inhibition of vasopressin neurones (Sabatier et al., 
2004).  
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4.2.3. Recording protocol  
After a 10 min period of stable baseline recording, CCK was injected 
i.v. and recordings were made until the electrical activity of the neurones 
returned to their previous basal condition. Then, after 20 ‒ 30 min of 
recording under basal conditions, MT-II (1 mg/kg) was given i.v., and in 
most neurones, recordings were made for 40 min after MT-II injection. A 
vehicle (0.2 ml of saline 0.9 %) injection was given to determine potential 
effects of the i.v. injection itself on the SON neurone activity. In the majority 
of the experiments, only one neurone was tested with MT-II in each rat.  
At the end of each experiment, the rats were killed by an overdose of 
sodium pentobarbital (160 mg/kg, i.v.). 
 
4.2.4. Statistical analysis 
The responses to MT-II were analysed by comparing the mean firing 
rate in 10-min intervals after MT-II injection with the basal firing rate 
measured in a 10–20-min control period before MT-II injection. A 10 % 
change in firing rate was set as a threshold to categorise the neurone as a 
responsive to MT-II. For analysis of individual responsive neurones the 
firing rate (in 30-s bins) in the 10-min before MT-II injection was compared 
with the rate in the 10-min after injection for oxytocin neurones, and the 
firing rate 20-min before MT-II was compared with 40-min after injection for 
vasopressin neurones because (in phasic neurones) burst of spikes are long 
and variable when analysed over short periods; these comparisons were 
tested for significance using a one-tailed paired t-test, accepting P < 0.01 as 
significant. 
The mean change in firing rate (spikes/s) in the period 0 to 10 min (in 
30-s bins) after the MT-II injection was tested for the entire population of 
Chapter 4 – Results II  
84 
 
oxytocin neurones recorded to check whether this change was significantly 
different from 0 (baseline), using a two-tailed Wilcoxon signed rank test. For 
vasopressin neurones the period 0 to 40 min (in 10-min bins) after MT-II 
injection was tested; the longer binwidth was required because many 
vasopressin neurones fire phasically, so spike counts are very variable over 
short binwidths. P < 0.05 was considered significant. 
 
4.3. RESULTS 
4.3.1. Effect of i.v. MT-II on the electrical activity of oxytocin 
neurones  
The electrical activity of oxytocin neurones was recorded in seven rats, 
only one rat was double tested with i.v. MT-II. Oxytocin neurones showed a 
consistent excitatory response to MT-II (Fig. 4.4.). 
To analyse the effect of MT-II on the oxytocin population, the mean 
change in firing rate (in 30-s bins) over 10-min after MT-II administration of 
eight oxytocin neurones was tested. The mean basal firing rate of the eight 
oxytocin neurones before injection of MT-II was 2.67 ± 0.69 spikes/s. After 
injection of MT-II, the mean firing rate in these eight neurones was 3.34 ± 0.75 
spikes/s, increasing 0.66 ± 0.16 spikes/s (W = 36.00, Z = 2.521, **P = 0.0078, 
Wilcoxon signed rank test; Fig. 4.5A.) over the 10-min period after MT-II 
administration. This response reached a plateau between 2.5 and 8 min after 
injection, to then rapidly return to the mean basal firing rate (change in firing 
rate > +0.2 spikes/s) in the last 2 min.  
The individual analysis of these neurones showed that the change in 
the firing rate induced by MT-II exceeded the threshold of 10 % in seven of 
the eight neurones (Fig. 4.5B.). In each of these seven responsive neurones, 
MT-II induced a significant increase in firing rate over the 10-min period 
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after injection (**P < 0.01, paired t-test). Two of these responsive neurones 
showed a strong and long-lasting increase in firing rate over a 40-min period 
after administration of MT-II (neurone 1 baseline: 0.11 ± 0.01, after MT-II 10 
min: 0.19 ± 0.02, after MT-II 40 min: 2.33 ± 0.19 spikes/s; neurone 2 baseline: 
0.10 ± 0.02, after MT-II 10 min: 0.94 ± 0.17, after MT-II 40 min: 1.53 ± 0.08 
spikes/s). The non-responsive neurone exhibited a high baseline frequency 
cell which increased 0.27 ± 0.09 spikes/s (baseline: 5.50 ± 0.04, after MT-II 10 
min: 5.77 ± 0.09 spikes/s) over the 10-min period after the injection. 
 
4.3.2. Effect of i.v. MT-II on the electrical activity of vasopressin 
neurones  
The electrical activity of vasopressin neurones was recorded in seven 
rats, only one rat was double tested with i.v. MT-II. A heterogeneous 
response to MT-II was observed in vasopressin neurones, only three of the 
neurones tested were responsive to MT-II (Fig. 4.6.). 
To analyse the effect of MT-II on the vasopressin population, the mean 
change in firing rate (in 10-min bins) over 40-min after the administration of 
MT-II of three continuous- and five phasic-firing neurones was tested. The 
mean basal firing rate in the eight vasopressin neurones before MT-II 
injection was 6.61 ± 0.60 spikes/s. After MT-II injection, the mean firing rate 
in these eight neurones was 7.54 ± 0.51, increasing 0.93 ± 0.59 spikes/s over 
the 40-min period after injection (W = 20.00, Z = 1.400, P = 0.195, Wilcoxon 
signed rank test; Fig. 4.7A.).  
The individual analysis of vasopressin neurones showed that after i.v. 
MT-II, the change in firing rate exceeded 10 % in only three of the eight 
neurones tested (Fig. 4.7B.), and of those three (one continuous- and two 
phasic-firing) responsive neurones, only one (continuous-firing) neurone 
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showed a significant increase in firing rate (**P < 0.01, paired t-test). Three 
phasic-firing neurones showed a transient inhibitory response (~ 2 min) to 
i.v. injection of MT-II. Two continuous-firing neurones showed a short 
transient inhibitory response to MT-II (~ 2 min) immediately after injection 
(Fig. 4.8A.), and also a very brief decrease in spike activity (8 spikes fired in 
10 s) following i.v. injection of vehicle (Fig. 4.8B.). 
 
4.4. DISCUSSION 
This study was aimed to determine whether systemic administration 
of the synthetic MC3/4 agonist, MT-II, affect the electrical activity of SON 
oxytocin and vasopressin neurones in vivo in urethane anaesthetized rats. I 
showed that after systemic administration of MT-II, the activity of oxytocin 
neurones was consistently increased in virtually all the neurones tested. In 
contrast, vasopressin neurones showed a heterogeneous response to MT-II, 
only one-third of the neurones tested were classified as responsive, showing 
an increase in neuronal activity. 
The first evidence of the regulation of the electrical activity of SON 
oxytocin neurones by melanocortins was shown by Sabatier et al. (2003a), 
who reported that, in virgin rats, i.c.v. injection or retrodialysis application of 
the natural melanocortin, α-MSH, decreased the firing rate of oxytocin 
neurones, these actions are thought to be mediated by activation of MC4, as 
the administration of the high-affinity MC4 agonist, MRLOB-0005, exerted 
similar effects in a dose-dependent fashion. Similarly, retrodialysis 
application of α-MSH (7.5 µg/3 µl/min) decreased the firing rate of SON 
oxytocin neurones by 50 % in non-pregnant rats, however, it did not affect 
the response of oxytocin neurones in pregnant rats (Ladyman et al., 2016).  
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Since i.v. injection of the α-MSH analogue, MT-II, triggered Fos 
expression in oxytocin neurones which was prevented by the prior central 
administration of a non-selective melanocortin antagonist (see Chapter 3), I 
assumed that MT-II directly acts on oxytocin neurones, exerting similar 
effects on neuronal electrical activity as i.c.v. α-MSH. In contrast, my 
electrophysiology results show that after i.v. injection of MT-II, the firing rate 
of the SON oxytocin neurones was transiently increased, suggesting that the 
effect of MT-II on electrical activity is predominantly driven by indirect 
pathways. Interestingly, two slow-firing oxytocin neurones showed a 
long-lasting activation after i.v. MT-II that continued for over 40 min. It is 
unknown why these neurones displayed this activation pattern, however, I 
can conjecture that differences in synaptic inputs or intrinsic neurone 
properties may contribute to this neuronal behaviour. 
 In this context, afferent inputs projecting to the SON might increase 
excitatory post-synaptic currents (EPSCs) or decrease post-synaptic 
inhibitory currents (IPSCs). Glutamate and gamma-aminobutyric acid 
(GABA) are the main presynaptic inputs to the SON, playing a major role 
exciting or inhibiting SON neurones, respectively (Brown et al., 2013). The 
main sources of GABA inputs to the SON are thought to originate from 
perinuclear neurones located dorsally to the SON (Theodosis et al., 1986), and 
also from the OVLT (Kolaj et al., 2000). Excitatory glutamate afferents inputs 
to the SON originate from the OVLT, as shown by pharmacological evidence 
indicating glutamate release following electrical stimulation of the OVLT 
(Yang et al., 1994), and this circumventricular organ also expresses MC4 
(Kishi et al., 2003). In addition, noradrenaline inputs from the caudal 
brainstem have been reported to establish synaptic contacts with both 
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oxytocin and vasopressin neurones of the SON to induce depolarization of 
the membrane potential by decreasing the frequency of IPSCs, and 
consequently, increasing the firing rate of SON neurones (Shibuya et al., 
2000). 
In other systems, melanocortins have been shown to induce similar, 
and opposite actions as the described in this preparation. For example, an in 
vitro electrophysiology study has shown that bath application of MT-II (n = 
11), or α-MSH (n = 13) increased the firing rate of mice MC4-green flourescent 
protein (GFP) PVN neurones which co-express oxytocin/vasopressin, and 
also CRH, and this effect was blocked by the administration of the MC3/4 
antagonist SHU-9119 (Ghamari-Langroudi et al., 2011). Consistently with 
this, i.c.v. administration of MT-II significantly increased the firing rate of 
PVN leptin-responsive neurones (n = 11 out of 12) in vivo (Zhang & Felder, 
2004), but the identity of these neurones was not determined. In contrast, 
Fong and Van der Ploeg (2000) reported that administration of α-MSH 
inhibited the firing rate of PVN neurones (n = 5) in a dose-dependent manner 
in vitro. Furthermore, in non-peptidergic systems, i.c.v. administration of 3 
µg, but not 1 µg, of MT-II has shown to induce opposite in vivo electrical 
responses of serotonin neurones of dorsal raphe nucleus and noradrenaline 
neurones of locus coeruleus; exiting the former and inhibiting the latter 
(Kawashima et al., 2003). Similarly, application of α-MSH has been reported 
to have excitatory and inhibitory effects on different subsets of NTS neurones 
in vitro (Mimee et al., 2014). Thus, these dissimilar effects following 
melanocortin administration might depend upon different neuronal 
phenotypes, and therefore, activation of different cellular mechanisms. 
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In SON oxytocin neurones, the mechanism by which α-MSH inhibits 
the firing rate has been linked to the release of endocannabinoids which 
inhibits presynaptic excitatory inputs, as shown by the retrodialysis of a CB1 
cannabinoid receptor antagonist which prevented the inhibition of oxytocin 
neurones in vivo (Sabatier & Leng, 2006). Conversely, in CA1 hippocampal 
neurones, activation of MC4 by MT-II potentiates the postsynaptic response 
to glutamate ex vivo by increasing the expression of ionotropic AMPA 
receptors in dendritic spines (Shen et al., 2013).   
Enhancement of oxytocin neurone activity by peripheral stimuli, 
including pharmacological agents, is a pathway well characterised (Renaud 
et al., 1987; Velmurugan et al., 2010; Scott & Brown, 2011). I.v. injection of the 
gut-related peptide CCK, has been shown to induce a transient activation of 
SON oxytocin neurones (Renaud et al., 1987; Leng et al., 1991) via 
noradrenergic inputs from A2 neurones of the NTS, which in turn, are 
activated by vagal inputs (Onaka et al., 1995). The stimulation of this 
pathway has been used in this study for electrophysiological identification of 
SON neurones in vivo (Leng et al., 2001). Similarly to CCK, when MT-II is 
administered i.v., it is rapidly propelled by the blood flow, reaching virtually 
all the tissues, and consequently, leading to peripheral (and eventually 
central) actions by activation of melanocortin receptors expressed in some of 
these tissues. The expression of MC3/4, which are the main MT-II ligands, 
have been described in several peripheral organs, including the heart and 
intestine (Gantz et al., 1993; Mountjoy et al., 2003) which are innervated by 
the vagus nerve. Moreover, using transgenic mice expressing GPF under the 
control of the MC4 promoter have shown GFP positive fibres in sensory 
afferents of the vagus nerve (Gautron et al., 2010), and MT-II has been shown 
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to modulate spontaneous EPSCs in NTS neurones via presynaptic 
(glutamate) vagal sensory afferents in vitro (Wan et al., 2008). Hence, 
vagotomy or pharmacological desensitisation of vagal afferents by capsaicin 
(an agonist of the TRPV1 which is known to desensitise sensory neurones in 
a dose-dependent fashion (O'Neill et al., 2012)) could be used in further 
experiments to determine the contribution of vagal inputs on oxytocin 
neurone activity following systemic administration of MT-II.   
My results showed that i.v. administration of MT-II did have different 
effects on vasopressin neurone activity, however, one-third of the neurones 
tested in this study exhibited an increase in firing rate over 10 %. A previous 
study has shown excitation of a larger proportion of SON putative 
vasopressin neurones following i.v. administration of the MC3/4 agonist 
γ2-MSH, however, these recorded neurones were identified by histological 
determination of the placement of the recording electrode (Mitchell et al., 
1989). It is known that, in contrast to oxytocin neurones, the population of 
SON vasopressin neurones are heterogeneous in their electrical “behaviour” 
(MacGregor & Leng, 2013, 2016), and consequently, the response observed in 
this study may reflect these phenotypic differences. Interestingly, scattered 
expression of the MC4 in areas of the SON populated by vasopressin 
neurones (i.e. ventromedial SON) has been reported in the rat and human 
hypothalamus (Kishi et al., 2003; Siljee et al., 2013), supporting a possible role 
for melanocortins in the regulation of the activity of some vasopressin 
neurones. Nevertheless, central (i.c.v.) or retrodialysis administration of 
α-MSH or an MC4 agonist did not have an effect on the firing rate of any of 
the SON vasopressin neurones tested in a previous study (Sabatier et al., 
2003a). This apparent conflict between studies on the melanocortin actions on 
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single vasopressin neurones might be related to the administration routes 
used in both studies. Since I administered MT-II i.v., it is possible to infer that 
systemic administration leads to activation of other (peripheral) systems, 
such as the OVLT-glutamate pathway or the vagal-NTS pathway, as 
described above, which may enhance afferents (excitatory) inputs to SON 
vasopressin neurones.  
Immediately after i.v. administration of MT-II we also observed a 
transient inhibition of spike discharge in some phasic- and 
continuous-vasopressin neurones. Vasopressin neurone activity is 
modulated by afferent pathways originating from low- and high-pressure 
stretch receptors of the cardiovascular system, and consequently, 
fluctuations in blood pressure can lead to changes in neurone activity (Leng 
et al., 1999; Grindstaff & Cunningham, 2001). Interestingly, melanocortins are 
known to induce cardiovascular effects (do Carmo et al., 2017), and systemic 
administration of MT-II has been reported to increase the blood pressure and 
heart rate in a dose-dependent manner in conscious and anaesthetized mice 
(Rinne et al., 2012), even at lower doses than the dose administered in the 
present study. Increases in blood pressure have been reported to transiently 
inhibit phasic-vasopressin neurones in rats (Harris, 1979; Leng & Dyball, 
1984). To test whether the spike discharge was affected by the i.v. injection 
itself, we administered a small volume (0.2 ml) of vehicle showing that, in 
some neurones, it induced a very short inhibition of spike activity. Hence, the 
transient inhibition of vasopressin neurones observed here is likely to be 
associated with transitory changes in blood pressure, as well as other 
possible cardiovascular effects including increased heart rate (Rinne et al., 
2012).  
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As described previously, oxytocin and vasopressin release from nerve 
endings is related to spike activity, but the release response is not linear, and 
this is facilitated at certain firing frequencies. According to Brown et al. 
(2013), “frequency facilitation of oxytocin release is most marked between ~ 5 
and 25 Hz, but release continues to increase (albeit with a slower rate of 
increase) beyond ~ 50 Hz. By contrast, frequency facilitation of vasopressin 
release is maximal at ~ 13 Hz and sustained higher frequency stimulation 
actually results in less vasopressin release”. Here I reported that after i.v. 
MT-II administration, half of the oxytocin neurones tested reached a firing 
frequency over 4 Hz, and in the vasopressin neurones tested the frequencies 
observed were less than 10 Hz after stimulation. Thus, my results indicate 
that the increased electrical activity may contribute to changes in peripheral 
oxytocin release.  
Since direct application of α-MSH has been shown to inhibit SON 
oxytocin neurones (Sabatier et al., 2003a; Ladyman et al., 2016), I cannot 
establish whether i.v. MT-II acts on central melanocortin receptors on SON 
neurones. However, the effects observed in this study suggest a possible 




Figure 4.1. Discharge pattern of SON neurones. Representative examples of the



















































Figure 4.2. Identification of supraoptic neurones. (A) SON neurones were identified
by antidromic stimulation of the pituitary stalk (0 ms) which evokes an artificial
action potential (spike) that propagates to the soma at a constant latency (~ 10 ms;
upper panel). The spike collision occurs when an antidromically spike encounters a
descending spontaneous orthodromic spike along the axon, and both are
extinguished (X; lower panel). (B) The descending tails of the inter‐spike interval
distribution can be well fitted using a single negative exponential (red line) in
























y = 148.01e-0.057x y = 360.13e-0.118x
Figure 4.3. Responses of SON neurones to i.v. CCK. I.v. administration of CCK
(20 μg/kg) has opposite effect on oxytocin and vasopressin neurones, increasing











































Figure 4.4. Effect of i.v. administration of MT‐II on the electrical activity of a
SON oxytocin neurone. Representative example showing an increase in the firing
rate (in 30 s‐bins), the instantaneous firing rate recorded, and the inter‐spike
interval distributions (before and after stimulation) of an oxytocin neurone in
































































































Figure 4.5. Effect of i.v. MT‐II on the electrical activity of oxytocin neurones. (A)
Mean change in firing rate (± S.E.M.) in 30 s‐bins from all recorded oxytocin
neurones (n = 8), and change in firing rate over the period analysed (0 ‒ 10 min) in
each neurone recorded (mean ± S.E.M.; right panel). (B) Absolute and percentage
change in firing rate of individual oxytocin neurones in response to MT‐II. **P <
0.01, Wilcoxon signed rank test.
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Figure 4.6. Effect of i.v. administration of MT‐II on the electrical activity of a
responsive SON vasopressin neurone. Example of the increase in firing rate (in 1 s‐
bins), the instantaneous firing rate recorded, and the inter‐spike interval
distributions (before and after stimulation) in a vasopressin neurone in response to


























































































































































Figure 4.7. Effect of i.v. MT‐II on the electrical activity of vasopressin neurones.
(A) Mean change in firing rate (± S.E.M.) in 10 min‐bins from all recorded
vasopressin neurones (n = 8), and change in firing rate over the period analysed (0
‒ 40 min) in each neurone recorded (mean ± S.E.M.; right panel). (B) Absolute and




Figure 4.8. Polygraph tracing (raw voltage traces) of transiently inhibition of
vasopressin neurones following i.v. injection. (A) I.v. administration of MT‐II
induced an inhibition of spike activity of some vasopressin, but not oxytocin,
neurones. (B) I.v. administration of a small volume (0.2 ml) of vehicle (saline 0.9 %)






















Chapter 5  
Central and peripheral oxytocin release following administration 
of Melanotan-II  
 
5.1. INTRODUCTION  
As shown in the previous chapter, i.v. administration of MT-II 
enhanced electrical activity of SON oxytocin neurones, and this has been 
linked to oxytocin release into the bloodstream (peripheral release) from the 
nerve endings located in the posterior pituitary (Bicknell, 1988; Bourque, 
1991). A remarkable feature of oxytocin (and also vasopressin) magnocellular 
neurones is that they can also release oxytocin from other neuronal 
compartments (central release), including the soma, and dendrites (Pow & 
Morris, 1989; Morris & Pow, 1991), and this can be regulated independently 
or semi-independently from peripheral release. 
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The cellular mechanism governing oxytocin release from 
somatodendritic and nerve endings compartments are different (see Chapter 
1). Briefly, when an action potential reaches the nerve endings, the opening 
of voltage-gated Ca2+ lead to an influx of Ca2+ that promotes the release of 
oxytocin vesicles (Douglas & Poisner, 1964; Lemos & Nowycky, 1989). In 
contrast, the somatodendritic release of oxytocin can be wholly regulated by 
mobilisation of intracellular Ca2+ from thapsigargin-sensitive stores (Lambert 
et al., 1994; Ludwig et al., 2002). Interestingly, agents that mobilise Ca2+ from 
intracellular stores can also potentiate the dendritic release of oxytocin in 
response to activity-induced stimulation (Ludwig et al., 2002). Remarkably, 
the direct application of α-MSH or an MC4 agonist (MRLOB-0005) to SON 
explants have been shown to trigger somatodendritic oxytocin release in vitro 
whereas central (i.c.v.) administration of the MC4 agonist inhibited 
peripheral oxytocin release in vivo, and both melanocortin agonists have been 
shown to induce a rise in [Ca2+]I in vitro, even when applied in a medium low 
in extracellular Ca2+ content (Sabatier et al., 2003a)    
When released into the blood, oxytocin acts as a neurohormone 
exerting its classical peripheral effects, which are associated primarily with 
smooth muscle contraction, and these include milk-ejection and uterine 
contraction (see Chapter 1). When released centrally, oxytocin participates in 
the modulation of several behavioural responses (see Chapter 1), as shown 
by a large body of evidence (Neumann, 2007; Veenema & Neumann, 2008; 
Marlin & Froemke, 2017). Although these central actions have been 
classically associated with oxytocin synaptically released from nerve endings 
of PVN parvocellular neurones, magnocellular neurones contain large 
amounts of oxytocin in somatodendritic compartments which effectively 
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account for the high peptide content reported in the CSF (Ludwig & Leng, 
2006). Since oxytocin cannot penetrate the BBB (Zaidi & Heller, 1974; Ermisch 
et al., 1985), and consequently, the BBB prevents the re-entry of peripherally 
released oxytocin, its central measurement (and actions) reflect well the 
release from somatodendritic compartments.   
The use of simultaneous brain microdialysis and blood sampling have 
been a very useful tool to study in vivo the release patterns of central and 
peripheral oxytocin under a wide variety of physiological conditions and 
stimuli (Hattori et al., 1990; Neumann et al., 1993; Bosch et al., 2004; 
Engelmann et al., 2004). The microdialysis allows to study the composition of 
the extracellular fluid of discrete brain areas, as analytes (i.e. oxytocin) 
present in the extracellular fluid pass through a semipermeable membrane 
into a perfusate collected over a predetermined time and volume (Chefer et 
al., 2009). Thus, microdialysis together a sensitive quantification method (e.g. 
RIA) enable studies to determine oxytocin content, as well as monitoring 
changes in release within distinct brain structures, including the sources of 
origin (i.e. SON or PVN) or possible sites of action (e.g. limbic areas). 
 In this chapter, I study the effect of the synthetic MC3/4 agonist, MT-II, 
on central and peripheral oxytocin release in urethane-anaesthetised rats. 
Using combined in vivo microdialysis with blood (plasma) sampling, I 
determine whether i.v. or i.c.v. administration of MT-II induces changes in 
oxytocin content within the SON and plasma compartments. The use of in 
vivo microdialysis has been widely used to determine and monitor dynamic 
changes in somatodendritic release of oxytocin and vasopressin (Landgraf & 
Ludwig, 1991; Ludwig & Landgraf, 1992; Neumann et al., 1993), as well as 
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other neuropeptides and neurotransmitters (Sisk et al., 2001; Engelmann et al., 
2002; Frost et al., 2008). 
 
5.2.  MATERIAL AND METHODS  
5.2.1. In vivo microdialysis preparation  
Rats were anaesthetized with urethane (1.25 g/kg i.p.), and a plastic 
cannula was implanted into the left femoral vein for blood sampling as 
described in Chapter 2. Rats were placed into a stereotaxic frame and an 
in-house design (Horn & Engelmann, 2001) U-shaped microdialysis probe 
(membrane length 2.0 mm, molecular cut-off of 6 kDa; Ludwig and Landgraf 
(1992) was implanted aimed at the right SON using the following 
coordinates: 0.6 mm caudal to bregma, 1.8 mm lateral to midline and 9.4 mm 
deep from the surface of the skull based on the stereotaxic atlas by Paxinos 
and Watson (1998). The microdialysis probe was secured to the skull using 
two jewellers' screws and dental cement.  
The probe was perfused with aCSF (NaCl 138 mM, KCl 3.36 mM, 
NaHCO3 9.52 mM, Na2HPO4 2H2O 0.49 mM, urea 2.16 mM, CaCl2 1.26 mM, 
MgCl2 6H2O 1.18 mM; pH 7.2) using a microinfusion pump (HumBee; 
Bioanalytical system Inc., Lafayette, IN, USA) at a flow rate 3 µl/min. The 
probe was perfused for 2 h without sampling, then consecutive 30-min 
dialysis samples were collected directly into 1.5 ml microcentrifuge tubes, 
which were kept on ice and then immediately stored at -80 °C until assayed 
for oxytocin.  
At the end of the experiments, the rats were killed by an overdose of 
sodium pentobarbital (160 mg/kg) and the brains were removed and stored 
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until sectioning. Coronal sections of the hypothalamus (40 µm) were used for 
reconstruction of the placement of the microdialysis probes (Fig. 5.1.). The 
judgment of successful implantation of the SON was made before analysing 
microdialysis and plasma samples. 
 
5.2.2. Experiments protocol 
 5.2.2.1. Microdialysis  
In experiments where drugs were given i.v., vehicle (0.9 % saline; 1 
ml/kg) or MT-II (1 mg/ml/kg) were injected at the beginning of the fourth 
sample period, as shown in Figure 5.2. For experiments with i.c.v. injections, 
MT-II (1 µg/3 µl/rat) and vehicle (aCSF, 3 µl/rat) were administered at the 
beginning of the third or fifth microdialysis sample period. The sequence of 
the injections was alternated between the successive trials. In both 
experiments, aCSF containing 1 M NaCl was retrodialysed directly into the 
SON during the penultimate microdialysis period and switched back to 
normal aCSF during the last microdialysis period (Fig. 5.2.). Retrodialysis of 
aCSF with high NaCl content served as a positive control to confirm the 
suitability of the microdialysis approach for monitoring dynamic changes in 
the release of oxytocin as described by Landgraf and Ludwig (1991). 
 
5.2.2.2. Blood collection 
Blood samples (0.7 ml) were withdrawn from the femoral vein into 
heparinized tubes, centrifuged (5 min, 2000 g, 4 °C), and the plasma 
separated and stored at - 80 °C for subsequent oxytocin RIA. Blood cells were 
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re-suspended in 0.9 % saline and infused via the femoral cannula. Samples 
were withdrawn as shown in Figure 5.2.  
 
5.2.3. Radioimmunoassay (RIA)  
Microdialysates (90 µl) were kept at -80 °C until evaporation and 
radioimmunological quantification of oxytocin without prior extraction. 
Plasma samples were kept at -80 °C until extraction and subsequent 
radioimmunological quantification of oxytocin. Both plasma extraction and 
RIA were performed by Prof R. Landgraf (RIAgnosis, Sinzing, Germany) as 
described previously (Landgraf et al., 1995; Paiva et al., 2017). The RIA 
detection limit is in the 0.1 ‒ 0.5 pg/sample range, depending on the age of 
the tracer, with typical displacements of 20 ‒ 25 % at 2 pg, 60 ‒ 70 % at 8 pg 
and 90 % at 32 pg of standard neuropeptide (Sigma Aldrich, Germany). 
Cross-reactivities with vasopressin, ring moieties and terminal tripeptides of 
both oxytocin and vasopressin and a wide variety of peptides comprising 13 
(α-MSH) up to 41 (CRH) amino acids are < 0.7 % throughout. All evaporated 
microdialysates and plasma extracts to be compared were treated identically 
and assayed in the same batch at the same time to avoid inter-assay 
variability; intra-assay variability is < 8 %. Serial dilutions of plasma samples 
containing high levels of endogenous oxytocin run strictly parallel to the 
standard curve indicating immunoidentity. 
 
5.2.4. Statistical analysis 
Oxytocin content in microdialysates were analysed using two-way 
ANOVA with treatment and time as variables, followed by post hoc 
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Bonferroni multiple comparison test. Delta changes in plasma oxytocin 
content in experiments using i.v. and i.c.v. administration were analysed 
using two-tailed Mann-Whitney test and two-tailed Wilcoxon matched-pairs 
signed rank test, respectively. P < 0.05 was considered significant. 
 
5.3.  RESULTS 
Plasma samples and SON microdialysates were collected to determine 
peripheral and central oxytocin release in response to i.v. or i.c.v. 
administration of MT-II.  
 
5.3.1 Somatodendritic oxytocin release 
Two-way ANOVA analysis of data obtained after systemic injection of 
MT-II showed a significant effect of factor ‘time’ (F8, 112 = 24.48; ***P < 0.001), 
but no effect of factor ‘treatment’ (F1, 14 = 0.10; P = 0.75), and factor interaction 
(F8, 112 = 0.42; P = 0.91). No significant changes in the oxytocin content in 
microdialysates collected from the SON were detected after systemic 
injection of MT-II (Fig. 5.3.).  
Similarly, two-way ANOVA analysis of data obtained after central 
injection of MT-II showed a significant effect of factor ‘time’ (F7, 56 = 7.67; ***P 
< 0.001), but no effect of factor ‘treatment’ (F1, 8 = 0.07; P = 0.81), and factor 
interaction (F7, 56 = 0.02; P > 0.99). Central administration of MT-II did not 
significantly change the oxytocin content in the subsequent microdialysates 
samples (Fig. 5.4.).  
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The application of direct osmotic stimulation has been used 
previously as a positive control to confirm the correct probe position within 
the SON. The perfusion of the microdialysis probe with hypertonic aCSF (1M 
NaCl) resulted in oxytocin release within the SON during and immediately 
after stimulus application in both previously i.v. and i.c.v. injected rats (*P < 
0.05, last sample period, post hoc test), however, the magnitude of the release 
response was not different between the MT-II and vehicle-injected rats in 
both experiments (Fig. 5.3.; Fig. 5.4.).  
 
5.3.2 Peripheral oxytocin release 
In rats injected with systemic MT-II (baseline 5.3 ± 1.2 pg/ml, MT-II 8.9 
± 1.3 pg/ml, MT-II60min 8.1 ± 1.2 pg/ml) the change in plasma concentration of 
oxytocin was significantly greater (***P < 0.001, Mann-Whitney test) than in 
vehicle-injected rats (baseline 7.3 ± 2.1 pg/ml, saline 6.5 ± 1.9 pg/ml, saline60min 
5.5 ± 1.5 pg/ml) (Fig. 5.5.). Central injection of MT-II (MT-II at 120 min: 
baseline 1.7 ± 0.2 pg/ml, aCSF 2.7 ± 1.2 pg/ml, MT-II 8.5 ± 4.7 pg/ml, MT-II60min 
10.2 ± 5.6 pg/ml; vehicle at 120 min: baseline 1.6 ± 0.5 pg/ml, MT-II 5.7 ± 2.8 
pg/ml, MT-II60min 5.6 ± 3.1 pg/ml, aCSF 5.3 ± 3.1 pg/ml) also tended to increase 
peripheral oxytocin concentrations when compared to vehicle injection, but 
this change did not reach statistical significance (P = 0.06, Wilcoxon 
matched-pairs signed rank test; Fig. 5.6.).  
Retrodialysis of hypertonic aCSF directly into the SON caused an 
increase in peripheral oxytocin release in i.v. (MT-II 12.2 ± 1.5 pg/ml, vehicle 
9.4 ± 1.2 pg/ml) and i.c.v. injected (MT-II at 120 min: 23.4 ± 2.2 pg/ml, vehicle 
at 120 min: 18.0 ± 3.6 pg/ml) rats, with no differences between MT-II and 
vehicle (P > 0.05; Fig. 5.5.; Fig. 5.6.). 
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5.4. DISCUSSION  
This study was designed to test whether systemic or central 
administration of the melanocortin agonist MT-II triggers central and 
peripheral oxytocin release in urethane anaesthetized rats. I show that 
neither systemic nor central administration of MT-II induced oxytocin release 
within the SON, or potentiate (priming) somatodendritic oxytocin release in 
response to direct osmotic stimulation of the SON. However, systemic 
administration of MT-II induced a significant increase of plasma oxytocin 
concentration.  
In oxytocin neurones, the somatodendritic release is not invariably 
coupled with peripheral release. Direct application of the naturally occurring 
MC3/4 agonist, α-MSH, to SON neurones strongly induces oxytocin release 
from the dendrites in vitro whereas it decreases oxytocin release from the 
nerve endings in vivo, and these actions are thought to be mediated by 
activation of MC4 which is expressed in SON neurones (Sabatier et al., 2003a). 
So, based on the ‒empirical‒ capacity of the synthetic MC3/4 agonist MT-II to 
penetrate the BBB (see Chapter 3) (Dorr et al., 1996; Adan et al., 1999; Giuliano 
et al., 2006; Modi et al., 2015), I administered MT-II i.v. However, I found that 
i.v. administration of MT-II (1 mg/kg) fails to trigger central oxytocin release 
(within the SON). Similar findings have been reported in female prairie voles 
in which i.p injection of MT-II (10 mg/kg) did not increase the oxytocin 
content in microdialysates collected from the nucleus accumbens (Modi et al., 
2015), a reported target for central oxytocin actions (Liu & Wang, 2003; Dolen 
et al., 2013). Hence, it seems that MT-II is not able to trigger somatodendritic 
oxytocin release from magnocellular neurones in response to systemic 
administration. 
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These results raise doubts whether the RIAs were sensitive enough 
and comparable between these studies. However, in both studies oxytocin 
content was measured under the same assays conditions, and the detection 
limit of 0.1 ‒ 0.5 pg/sample seems to be sensitive enough to detect changes 
induced by other stimuli, as shown by changes in oxytocin content following 
hypertonic stimulation (Modi et al., 2015; Paiva et al., 2017). The highly 
sensitive RIA used in this study (Prof Rainer Landgraf; RIAgnosis, Sinzig, 
Germany) has become the reference quantification method for the detection 
of changes in central (and peripheral) oxytocin content in a wide range of 
physiological and experimental conditions, and it has been used in previous 
studies (Landgraf et al., 1995; Ross et al., 2009). In contrast, other assays and 
quantification methods have shown inconsistencies in the measurement of 
oxytocin content (Leng & Sabatier, 2016). Additional limiting factors of the in 
vivo microdialysis are the limited time resolution, and relative recovery of an 
analyte (which is inversely proportional to the perfusion rate) (Chefer et al., 
2009). In this preparation, the microdialysis probe was perfused at 3 µl/min, 
and samples were collected every 30 min in order to obtain samples 
containing (basal) oxytocin concentration over the RIA detection limit. 
However, it seems unlikely that the release of a single, very brief and small 
pulse of oxytocin could be detected with the current techniques and 
analytical assay available.     
The result obtained in this study raised the question whether MT-II 
was able to penetrate the BBB, although it is currently accepted that MT-II is 
a brain-penetrating melanocortin (Hruby et al., 2011; Hruby & Cai, 2013). 
Thus, to critically determine the effect of MT-II on oxytocin neurones, I 
directly administered MT-II into the brain (i.c.v.). Unexpectedly, the 
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administration of 1 µg of MT-II did not trigger somatodendritic oxytocin 
release from SON neurones. Sabatier et al. (2003a) reported that the dose of 1 
µg of α-MSH or the synthetic melanocortin agonist MRLOB-0005 triggered 
somatodendritic oxytocin release in vitro from SON explants, and this effect 
was blocked by the addition of the MC4 antagonist MRLOB-0004. 
Consistently with this α-MSH in vitro effect, we have recently reported that 
retrodialysis of α-MSH [167 ng/µl] also induced somatodendritic oxytocin 
release within the SON (Paiva et al., 2017). This melanocortin-induced 
oxytocin release is mediated by mobilization of intracellular Ca2+ from 
thapsigargin-sensitive stores as shown in MC4 transfected HEK293 cells 
(Mountjoy et al., 2001); the increase in [Ca2+]I and subsequent in vitro dendritic 
oxytocin release from SON neurones also occurred when the extracellular 
medium was low in Ca2+ content (Sabatier et al., 2003a). Thus, the differences 
in biological activity observed here might be related to the capabilities of 
melanocortin ligands to mobilise Ca2+ from the intracellular stores.   
Previous studies have shown different changes in [Ca2+]I in response 
to application of melanocortin ligands, including α-MSH, and MT-II. For 
example, in the prolactin and growth hormone secreting GH-3 cell line, the 
application of 0.1 nM, and 1 nM of α-MSH increases [Ca2+]I, whereas MT-II 
does not significantly affect [Ca2+]I when administered at the same or even 
higher dose (Langouche et al., 2001). Furthermore, Ca2+ channels from the 
N-type seem to play a major role in the regulation of somatodendritic 
oxytocin release from SON explants (Tobin et al., 2011). However, in other 
systems, such as transfected HEK293 cells and cultured mouse amygdala 
neurones, activation of MC4 by MT-II has been reported to inhibit N-type 
Ca2+ channels (Agosti et al., 2014).   
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The basis of variations in cellular responses to different melanocortin 
agonist may be related to receptor binding sites bounded by α-MSH, and 
MT-II, and ultimately, the activation of different intracellular pathways. This 
theoretical “agonist-specific trafficking of receptor signalling” (Hermans, 
2003; Kenakin & Christopoulos, 2013) has been reported to naturally occur, 
and be induced, for example, by the pituitary adenylyl cyclase-activating 
polypeptide (PACAP) isoforms 27 and 38 acting on the PACAP type-I 
receptor, where both isoforms induce adenylyl cyclase pathway (cAMP), and 
only PACAP-38 stimulates phospholipase C pathway (Spengler et al., 1993). 
In this context, endogenous melanocortin ligands (i.e. α-MSH) binds GPCRs 
interacting at specific (native) sites of the receptor known as orthosteric sites, 
while synthetic ligands, like MT-II, bind these receptors at sites that could 
potentially be topography distinct (allosteric sites) from the orthosteric sites 
due to variations in the peptide molecular structure (linear versus cyclic 
structure in α-MSH, and MT-II, respectively; Hruby (2016). A recent in vitro 
study has shown that, in immortalised hypothalamic neurones, MT-II, but 
not α-MSH, induces cAMP that persists for at least 1 hour after MT-II 
removal, and this effect cannot be antagonised by the naturally inverse 
agonist, AgRP (Molden et al., 2015). Moreover, substitution of amino acid 
residues in the MT-II molecule has been reported to lead to dramatic changes 
in potency and function, decreasing the formation of cAMP when compared 
to the native MT-II (Bednarek et al., 1999). In other systems, the allosteric 
modulator CPPHA acting on the metabotropic glutamate receptor 5 
(mGluR5) potentiates Ca2+ mobilisation and ERK1/2 phosphorylation 
induced by the endogenous mGluR5 receptor ligand in cortical astrocytes in 
vitro (Zhang et al., 2005). Interestingly, melanocortin receptors can activate 
more than one intracellular signalling pathway depending on the 
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melanocortin ligand (Breit et al., 2011; Hruby et al., 2011). Thus, in vivo studies 
of activation or enhancement of intracellular pathways, such as 
immunohistochemistry and western blot analysis, could be performed to 
compare the effect of MT-II with α-MSH in SON neurones.  
The site of injection (i.c.v., right ventricle) for MT-II delivery is another 
factor that also should be considered. When a drug is delivered i.c.v., high 
drug concentration, if not virtually all, reaches the adjacent structures, but 
then, as the drug diffuses and flows into the ventricular system, the 
concentration decreases. Consequently, there are large concentration 
gradients within the ventricular system which may result in low amounts of 
drug delivered to distant targets, and even lower amounts delivered into 
brain structures located into the brain parenchyma, which are situated at 
variable distances from the ventricular system (Kuo & Smith, 2014). In rats, 
the estimation of the total CSF volume is approximately 90 µl (Pardridge, 
2011), and consequently, the administration of 1 µg/3 µl ([0.33 µg/µl]) i.c.v. is 
largely diluted ([0.01075 µg/µl]), resulting in a concentration 30 times lower 
than the initial concentration delivered (in a non-realistic static system). 
Other factors, such as diffusion into the brain parenchyma, protein binding, 
physicochemical properties, as well as peptide loss by melanocortin receptor 
binding (adsorption) or enzymatic turnover should also be considered (Cook 
et al., 2009; Kuo & Smith, 2014). Hence, once MT-II completely diffuses into 
the CSF, it can be predicted a low peptide concentration reaches the end of 
the ventricular system, and consequently, the SON neurones which are 
bathed by the CSF of the subarachnoid space. This is particularly relevant for 
my preparation, as the oxytocin content released from SON neurones was 
analysed, so the direct application of MT-II by retrodialysis should be 
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considered to definitely confirm the lack of effect of MT-II on 
somatodendritic oxytocin release.   
A remarkable feature of intracellular Ca2-mobilizer agents (i.e. 
thapsigargin and oxytocin itself) acting on oxytocin neurones is that they can 
dramatically increase the amount of peptide dendritically released (priming) 
after activity-evoked stimulation. Priming involves an increase in [Ca2+]I, and 
repositioning of peptide-containing vesicles close to the cell membrane 
(Tobin et al., 2004) that lead to, for instance, a larger dendritic release of 
oxytocin in thapsigargin-primed animals compared to non-primed animals 
in response to hypertonic stimulation (Ludwig et al., 2002). Because α-MSH 
has also been shown to induce a rise in [Ca2+]I (Sabatier et al., 2003a), it has 
been suggested that melanocortins might induce priming of dendritic 
peptide stores. In female prairie voles, it has been reported that i.p. 
administration of MT-II (10 mg/kg) potentiates oxytocin release within the 
nucleus accumbens after hypertonic stimulation (Modi et al., 2015). 
Conversely, I did not detect any potentiation effect in response to hypertonic 
stimulation in MT-II-treated (1 mg/kg) male rats. In both studies, the 
administration of aCSF containing 1M NaCl was applied by retrodialysis, but 
in contrast to Modi et al. (2015), I directly applied the stimulus onto SON 
neurones, increasing the probability of triggering, and detecting changes in 
somatodendritic oxytocin release. This apparent conflict between studies in 
MT-II-induced potentiation of central oxytocin release in response to 
hypertonic stimulus, could be related to the source of oxytocin (e.g. PVN, or 
accessory nuclei in Modi et al. (2015) or differences in the physiological 
responses of the animals (rat and prairie voles) used in both studies. Finally, 
the use of direct evidence, such as electron microscopy to determine 
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relocation of LDCVs should be considered to elucidate whether MT-II 
induces priming in oxytocin neurones   
The plasma oxytocin RIA showed that after i.v. administration of 
MT-II the concentration of oxytocin is increased. Thus, this study shows, for 
first time, that systemic melanocortins may play a role in the regulation of 
peripheral oxytocin release. Previously, it has been reported that i.c.v. 
administration of a selective MC4 agonist decreased plasma oxytocin 
concentrations in vivo (Sabatier et al., 2003a). Since I administered MT-II i.v., 
these actions are likely to be mediated by activation of peripheral inputs 
acting on the magnocellular neurones, such as the vagus nerve-NTS (see 
Chapter 1) or circumventricular organs, or even as a consequence of 
peripheral effects of melanocortin acting on other systems, for example the 
cardiovascular system (Rinne et al., 2012). Interestingly, in this preparation, 
the plasma oxytocin content remained elevated for at least 60 min after MT-II 
injection. As the estimated half-life of oxytocin in plasma is approximately 5 
min (Leng & Ludwig, 2016; Leng & Sabatier, 2016), this result suggests a 
long-lasting effect on oxytocin release from the nerve endings after MT-II 
administration. 
Interestingly, my results show that i.c.v. administration of MT-II (1 
µg) in anaesthetised rats tended to increase peripheral oxytocin release. 
Similarly, i.c.v. injection of α-MSH (1 µg) in conscious rats also tended (not 
significant) to increase peripheral oxytocin release, however, a lower dose of 
an MC4 agonist (MRLOB-0005; 400 ng) significantly decreased oxytocin 
release from the nerve endings in hypertonically stimulated anaesthetized 
rats (Sabatier et al., 2003a). This suggests that, as described previously, 
activation of MC4 by a different melanocortin agonist might induce activation 
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of different intracellular pathways, or act on the MC4 with dissimilar 
potencies (Nickolls et al., 2003). Unfortunately, binding or potency 
parameters of the melanocortins used in these studies, such as the 
concentration of peptide at 50 % specific binding (IC50) or the concentration 
of peptide at 50 % maximum cAMP accumulation (EC50), cannot be 
compared, as these parameter have been provided in different assays using 
cell lines transfected with human or murine MC4 (Adan et al., 1999; Mountjoy 
et al., 2001; Sabatier et al., 2003a). 
Figure 5.1. Judgment of microdialysis probe implantation. Example of a coronal
section counterstained with nuclear fast red, showing the localization of the
microdialysis probe in the dorsomedial SON (arrow) of the hypothalamus. OC ‐
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Figure 5.2. Microdialysis experimental design. Flat open rectangles indicate 30‐
min samples. (A)MT‐II (1 mg/ml/kg) or vehicle (saline 0.9 %, 1 ml/kg) was injected
i.v. at the beginning of the 4th dialysis sample (arrow). (B) Vehicle (aCSF, 3 μl/rat)
and MT‐II (1 μg/3 μl/rat) were injected i.c.v. at the beginning of the 3rd and 5th
dialysis sample (arrows). The sequence of the drug injections was alternated
between the successive trials. The microdialysis medium was changed from
normal aCSF (isotonic medium) to aCSF containing 1 M NaCl (hatched rectangle)
during penultimate dialysis sample. Blood samples were withdrawn at time points
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Figure 5.3. Effect of i.v. MT‐II on central oxytocin release.MT‐II given i.v. did not
trigger somatodendritic oxytocin release from SON neurones measured by
microdialysis. However, oxytocin release was increased in the vehicle and MT‐II
treated rats in response to microdialysis administration (retrodialysis) of
hypertonic (1 M NaCl) aCSF directly into the SON. Means ± S.E.M. *P < 0.05; Two‐
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Figure 5.4. Effect of i.c.v. MT‐II on central oxytocin release. I.c.v. administration
of MT‐II did not trigger somatodendritic oxytocin release from SON neurones
measured by microdialysis. However, oxytocin release was increased in the vehicle
and MT‐II treated rats in response to microdialysis administration (retrodialysis)
of hypertonic (1 M NaCl) aCSF directly into the SON. Means ± S.E.M. *P < 0.05;
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Figure 5.5. Effect of i.v. MT‐II on peripheral oxytocin release. Delta change in
plasma oxytocin concentration following i.c.v. MT‐II, vehicle, and direct osmotic
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Figure 5.6. Effect of i.c.v. MT‐II on peripheral oxytocin release. Delta change in
plasma oxytocin concentration following i.c.v. MT‐II, vehicle, and direct osmotic













Chapter 6  




In this thesis, I proposed that systemic administration of the 
(theoretical) BBB-penetrating melanocortin agonist MT-II would stimulate 
central (magnocellular) oxytocin systems resulting in the dendritic release of 
oxytocin as an alternative approach for the potential treatment of 
neuropsychiatric disorders associated with low central oxytocin release. To 
test this, I investigated Fos protein immunoreactivity in the PVN and SON 
(and also brain areas modulating PVN and SON magnocellular neurones), 
the electrical activity of SON neurones in vivo, and central (within the SON) 
and peripheral oxytocin release in vivo in response to systemic 
administration of MT-II in anaesthetized adult male rats. 
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In the first experiment (Chapter 3), evidence was obtained for the 
efficacy of i.v., but not intranasally, administered MT-II to trigger Fos 
expression in PVN and SON neurones, similarly to previous studies using 
i.v. and i.c.v. administration routes (Thiele et al., 1998; Modi et al., 2015). The 
systemic dose of 1 mg/kg was effective in inducing Fos expression in 
oxytocin and also non-labelled (putative vasopressin) neurones of the SON 
and PVN. MT-II also induced Fos in neurones of the NTS, which is known to 
modulate the activity of PVN and SON magnocellular neurones by relaying 
peripheral inputs. Although this finding provided evidence supporting the 
use of MT-II as a starting point for this study, it does not prove that these 
effects were mediated by activation of central melanocortin receptors. Thus, I 
then administered the melanocortin antagonist SHU-9119 centrally, to 
determine whether MT-II was able to cross the BBB to mediate its effects by 
activation of central receptors (Chapter 3). This experiment showed that prior 
blockade of central melanocortin receptors prevented systemically 
MT-II-induced Fos expression in the SON and PVN, but not in the NTS, 
indicating that, in magnocellular neurones, these actions were mediated by 
central receptors. As could be expected after systemic administration, 
peripheral effects were also signalled to the brain (NTS), possibly, via the 
vagus nerve. Thus, taken together, these pieces of evidence provided support 
for systemically administered MT-II acting on oxytocin neurones via central 
MC3/4, supporting the initial hypothesis established. 
Since Fos expression has been shown to be a marker for changes in 
neural activity rather than an indicator of excitation or inhibition of neurones 
(Kovacs, 2008) I then investigated the effect of i.v. MT-II on the electrical 
activity in vivo, expecting to observe an inhibition of SON oxytocin neurones, 
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as found after i.c.v. α-MSH (Sabatier et al., 2003a; Ladyman et al., 2016). 
However, systemic administration of MT-II resulted in a consistent, strong, 
and transient increase in electrical activity of the oxytocin neurones (Chapter 
4), suggesting that this effect might be mediated by indirect pathways, for 
example, via the NTS (Chapter 3). Systemic administration of other non 
BBB-penetrating peptides have been shown to activate SON oxytocin 
neurones via this pathway (Leng et al., 1991; Way & Leng, 1992; Scott & 
Brown, 2011). Hence, this result should be interpreted as the result of MT-II 
peripheral actions, for instance, cardiovascular effects (Rinne et al., 2012) as 
also suggested by observations (i.e. transient inhibition) in some vasopressin 
neurones tested in this experiment. However, this evidence does not 
preclude central actions of systemic MT-II on oxytocin neurones that could, 
for example, evoke simultaneously central and peripheral oxytocin release, 
or prime the dendritic oxytocin stores for activity-dependant release. It is 
important to highlight that this result indicates, for first time, a potential role 
for circulating melanocortins in the regulation of the activity of 
magnocellular neurones.  
To determine whether systemic MT-II triggers somatodendritic 
oxytocin release, and consequently, validate or reject the hypothesis stated, I 
analyse the OT content within the SON and also the plasma. I found that i.v. 
MT-II neither triggered central oxytocin release nor primed dendritic 
oxytocin stores for activity-evoked release. As predicted (by the 
electrophysiology results), i.v. MT-II increased peripheral oxytocin release 
(Chapter 5). In consequence, I have to reject the hypothesis originally stated.  
In the light of this outcome, two questions arise which are relevant for 
an appropriate interpretation of these results: is this lack of effect a 
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consequence of poor BBB penetration (in physiologically active amounts) of 
MT-II? And also, does MT-II have similar agonistic effects than the natural 
α-MSH in vivo? Thus, to empirically answer these questions I centrally 
administered a dose of 1 µg of MT-II which is known to induce changes in 
neural activity in the SON and PVN, as well as other behavioural effects 
(Thiele et al., 1998; Rowland et al., 2010). Surprisingly, i.c.v. MT-II did not 
stimulate central oxytocin release nor potentiate its activity-evoked release, 
indicating differences in agonistic properties between MT-II and α-MSH that 
are crucial to exerting similar neuronal effects. In addition, another factor 
that cannot be excluded is possible sex differences in response to direct 
application of melanocortin agonists, as here I studied the effect of 
melanocortin administration on male rats with the expectation to observe 
similar effects as previous studies using female rats (Sabatier et al., 2003a; 
Ladyman et al., 2016). Whether i.v. MT-II was able to penetrate the BBB in 
physiologically active amounts still remains unsolved.  
Overall, the effects of systemic MT-II on oxytocin neurones described 
in this study appear to be mediated by a combination of central and 
peripheral effects; the apparent predominance of the latter results in an 
increased peripheral oxytocin release by enhanced spike activity (action 
potentials). In the next lines, I will expand on the main experimental gaps 
and interpretation caveats of this study.     
A major limitation for the pharmacological targeting of the CNS is the 
BBB, which prevents the entry of water-soluble substances (e.g. peptides). 
Only lipophilic molecules or substances having specific transporters can 
readily cross the BBB (Banks, 2012). To my knowledge, potential BBB 
transport mechanisms have not been described for MT-II, so far. 
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Nevertheless, some drugs do penetrate the BBB, and drug transfer can also 
occur via the blood-CSF barrier (BBB located at the choroid plexuses) at a 
rate inversely related to the molecular weight of the drugs. This difference in 
permeability is based on intrinsic properties of epithelial/endothelial barriers, 
which makes the blood-CSF barrier leakier than the BBB (Pardridge, 2011). 
This is exemplified by the antiretroviral drug zidovudine (AZT) which has 
been shown to cross through the choroid plexuses by passive diffusion 
(Masereeuw et al., 1994).  
In this study, i.v. MT-II activated PVN and SON neurones, but not 
neurones in the cAMG. Interestingly, Thiele et al. (1998) have shown a 
dose-dependent effect of i.c.v. MT-II in the cAMG, but not in the PVN and 
SON (which were activated by low and high doses). Since this route (i.c.v.) 
emulates secretion or leakage by choroid plexuses (as the drug is directly 
placed in the CSF) it is possible that, in my experiments, at least some MT-II 
penetrated the brain via this route. In this context, the CSF may act as a 
neuroendocrine signalling pathway (Rodriguez, 1976; Skipor & Thiery, 2008) 
allowing the diffusion of MT-II into the CSF, reaching the PVN and SON 
(which are bathed by the CSF) in neuroactive amounts, but not the cAMG 
which is relatively distant from the ventricular system. 
In view of the combined evidence obtained in this study, an intriguing 
observation is the effect (Fos attenuation) of the melanocortin antagonist 
SHU-9119. In particular, the electrophysiology results are hard to reconcile 
with the Fos immunohistochemistry study, where the melanocortin 
antagonist blocked the i.v. MT-II-induced Fos expression. One possibility 
that I did not investigate is that SHU-9119 has actions when given alone, 
either by blocking the effects of endogenous melanocortins or by acting as an 
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inverse agonist at constitutively active melanocortin receptors. Whether 
SHU-9119 acted as a competitive antagonist blocking binding sites for MT-II 
or as an inverse agonist reducing the excitability of SON neurones to, for 
example, putative noradrenergic inputs arising from the caudal NTS is 
unknown. This antagonist was originally described as a potent MC3/4 
competitive antagonist based on the lack of effect on cAMP formation in 
human MC4, and a very little agonist activity on human MC3 (Hruby et al., 
1995; Yang et al., 2002). However, an in vitro electrophysiology study has 
shown that, in neurones of the arcuate nucleus identified by the rat insulin 2 
promoter (RIPCre) expressing MC3/4, the antagonist SHU-9119 acts as an 
inverse agonist inducing a hyperpolarization of this neuronal phenotype 
(Smith et al., 2007). This suggests that the biological activity of this antagonist 
depends upon the cell-specific features or physiological contexts rather than 
being attributable to the peptide intended design. Consequently, the role of 
SHU-9119 on SON neurones should be investigated in vivo to draw a more 
precise conclusion about the capacity of MT-II to penetrate the brain. If 
SHU-9119 acts as competitive antagonist, this strongly indicates that i.v. 
MT-II triggered Fos by activation of central MC3/4, reinforcing the conclusion 
drawn in Chapter 3. Conversely, an inverse agonist effect of SHU-9119 
would not provide evidence for MT-II brain penetration (but would not 
disprove it either).  
Regarding the agonistic properties of MT-II, in Chapter 5 I discussed 
possible explanations of these differences. Interestingly, it has been recently 
reported that the MC3 and MC4 can heterodimerize in vitro, and i.c.v. 
administration of the bivalent melanocortin agonist ligand CJL-1-87 led to 
different physiological effects (energy homeostasis) in mice when compared 
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to a monovalent ligand. However, the co-expression of MC3 and MC4 in 
neurones remains to be shown (Lensing et al., 2017). Thus, it might be that 
i.c.v. administration of MT-II leads to activation of both MC3 and MC4, which 
results in activation of different molecular mechanism than the mechanism 
activated by the endogenous melanocortin ligands. 
The current evidence indicates that, to elicit dendritic oxytocin release, 
mobilisation of Ca2+ from intracellular stores is crucial (Lambert et al., 1994; 
Ludwig et al., 2002; Sabatier et al., 2003a). Therefore, any pharmacological 
agent used to trigger oxytocin release must achieve this neuronal 
prerequisite. Langouche et al. (2001) have reported that α-MSH and MT-II 
induce different changes in [Ca2+]I in the prolactin and growth hormone 
secreting GH-3 cell line: α-MSH induces a clear increase in [Ca2+]I, but MT-II 
did not change [Ca2+]I. Although this effect could be influenced by the cell 
phenotype and influenced by the milieu context (in vitro), we have recently 
reported (Paiva et al., 2017) that direct (retrodialysis) application of α-MSH 
onto the SON triggers somatodendritic oxytocin release in vivo, replicating 
previous in vitro results (Sabatier et al., 2003a). Hence, oxytocin neurones 
seem to preserve their capacity to respond to α-MSH in vitro and in vivo. The 
retrodialysis administration of MT-II onto the SON, or even better, the direct 
application of MT-II to single SON neurones to determine [Ca2+]I changes by 
Ca2+ imaging should be considered to determine the (lack of) effect of MT-II 
on intracellular Ca2+ mobilisation.  
 
6.1.1. Limitations of this study  
One limitation of this study is related to the determination of central 
oxytocin release, as this was restricted to the SON. This nucleus was selected 
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based on it homogenous composition (magnocellular neurones only), and to 
provide direct mechanistic evidence about the potential origin of oxytocin. 
However, in contrast to neurotransmitters, neuropeptides exert its actions on 
distant targets that, some cases, are none or scarcely innervated by 
peptide-containing fibres. Consequently, activation of brain areas containing 
high densities of OTR could account better for possible behavioural actions. 
In this line, Modi et al. (2015) reported a potentiation of central oxytocin 
release within the nucleus accumbens induced by i.p. MT-II in response to 
direct hypertonic stimulation. The nucleus accumbens is mainly innervated 
by a subset of oxytocin neurones from the PVN. Although this is a 
supraphysiological stimulus, it suggests possible MT-II effects on other 
oxytocin sources.   
I thus cannot exclude possible differential contributions from other 
oxytocin sources (i.e. PVN or nucleus circularis), or even, potential 
differences between PVN and SON magnocellular oxytocin neurones. 
Supporting this notion, a morphological study of oxytocin afferents 
innervating the nucleus accumbens has shown similar densities of fibres 
among rodent species; but, in prairie voles, most of these afferents originated 
from PVN neurones, and only a few from SON neurones, as shown by 
fluorogold retrogradely-labelled oxytocin fibres (Ross et al., 2009). Thus, it 
might be that, regarding behavioural actions, the PVN could be a better site 
to explore the effects of MT-II. Moreover, although PVN and SON 
magnocellular neurones seem to share similar morphological and 
physiological characteristics, evidence suggests that there may be functional 
differences in somatodendritic oxytocin release responses between the 
hypothalamic nuclei. For example, in the naturally vasopressin-null 
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Brattleboro rat, oxytocin release within the PVN, but not in the SON, was 
detected in response to 10-min forced swimming session, and subsequent 
osmotic stimulation (Zelena et al., 2009; Zelena et al., 2013). So, further studies 
await to investigate possible differential effects of MT-II on PVN 
magnocellular neurones. 
Regarding oxytocin released by parvocellular neurones which have 
been classically described to be responsible for central actions of oxytocin. I 
cannot neglect the role of targeted synaptic release of oxytocin, as the Fos 
evidence also supports MT-II actions on this population. However, the 
amount of oxytocin in these neurones is small, and they do not account for 
the oxytocin content found in CSF, which is thought to be largely released by 
magnocellular neurones (Ludwig & Leng, 2006). Whether the synaptic 
release of oxytocin by these neurones can be detected by current methods is 
unknown (see Chapter 5). Furthermore, although the vast majority of the 
axons of magnocellular neurones project to the posterior pituitary, axon 
collaterals from these neurones have also been reported (Mason et al., 1984; 
Hatton et al., 1985), and evoked release of oxytocin within the cAMG from 
collaterals originating mostly from PVN magnocellular neurones have been 
shown to reduce fear response in rats (Knobloch et al., 2012). Hence, in vivo 
microdialysis of other brain areas should be critically considered, as they 
might account for possible behavioural effects, as well as reflect release 
activity of parvocellular, but also magnocellular neurones of the PVN. 
Another limitation is the very limited range of melanocortin agents 
currently available with BBB penetrating properties to validate this 
approach. Here, I tested MT-II based on its previously reported effects and 
its commercial availability. I also tested TCMC-A01 (kindly provided by Dr 
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M. Callahan, Tensive Controls Inc.) with theoretical BBB penetration 
properties which is currently under development. Experimental data using 
other melanocortin agonists (e.g. Pf-446687, and PT-141) have also been 
published (Molinoff et al., 2003; Modi et al., 2015), however, their use is 
restricted as they are currently under development. Whether these 
melanocortin compounds can penetrate the BBB has been assumed based on 
empirical (indirect) evidence, including behavioural effects and 
pharmacological evidence. The best method would be CSF sampling to 
detect contents after systemic drug administration. Unfortunately, there are 
technical limitations related to the amount of CSF sample required, 
appropriated detection method for the compound, and the lower limit of 
detection.   
 
6.1.2. Complementary experiments 
Other experiments would help to refine and complement the results 
obtained in this thesis: 
In vivo electrophysiology of SON neurones in response to i.v. MT-II 
after desensitisation of vagal afferents by, for example, capsaicin would 
confirm that the enhanced electrical activity reported here was mediated by 
activation of peripheral receptors, which were signalled via NTS. In addition, 
the use of the natural (non BBB-penetrating) α-MSH could be considered to 
compare peripherally-induced responses to MT-II responses.    
A comparative in vivo microdialysis study applying MT-II on female 
rats could be performed to determine whether the lack of effect on 
somatodendritic oxytocin release from SON neurones observed in this study 
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is related to sex differences. In addition, the expression of receptors for 
sexual steroids ‒and their possible interactions with the expression of 
melanocortin receptors‒ on SON oxytocin neurones could be analysed in 
both males and females to elucidate the mechanisms involved in this possible 
sex-related difference. 
Brain areas expressing high OTR densities could be analysed by in 
vivo microdialysis to determine changes in oxytocin release that might lead 
to, or account for behavioural responses. These areas might include, for 
example, the cAMG (Knobloch et al., 2012), lateral septum (Zoicas et al., 
2014), and prefrontal cortex (Young et al., 2014).  
Activation patterns and circuits (Gorges et al., 2017) of, for example, 
limbic areas in response to systemic MT-II in conscious animals could be 
investigated by functional magnetic resonance imaging (fMRI). These brain 
areas might be of interest to study the release of oxytocin or even 
neurotransmitters which could be subsequently analysed using other 
methods (e.g. Fos activation patterns, simultaneous microdialysis).  
In the case of hypothetical oxytocin release in other brain areas, 
behavioural tests should be performed to elucidate the role of 
pharmacologically-evoked central oxytocin release in normal animals and 
models of neuropsychiatric disorders. These tests could, for example include 
social recognition (Engelmann et al., 2011) and anxiety tests (e.g. elevated 
plus maze) (Pellow et al., 1985; Walf & Frye, 2007), as well as 
pharmacological studies (e.g. blockade of OTR) in conscious animals to 
confirm the effects of endogenous oxytocin release as a strategy to ameliorate 
neuropsychiatric disorders.   
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6.1.3. Clinical limitations and perspectives  
Since the melanocortin system is widespread throughout the body 
and is involved in such a wide range of physiological functions, it is possible 
to predict that systemic routes lead to peripheral effects that, based on my 
evidence, prevail over central effects. In this study, I selected MT-II based on 
its theoretical BBB penetrating capacity, and agonist potency (Hruby, 2016). 
In mammals, after systemic administration of MT-II several effects have been 
reported, including feeding suppression and weight loss, penile erection, and 
sexual motivation (Wessells et al., 2000; Pierroz et al., 2002). Moreover, 
systemic MT-II induces yawning and stretching in humans (Dorr et al., 1996; 
Wessells et al., 2000), two well-known effects of central administration of 
melanocortin agonists in other species (Bertolini et al., 2009).  
Despite these collateral effects, MT-II has been extensively used for 
research purposes, and a molecule derivate from MT-II (Bremelanotide, 
former PT-141) with less side effects is currently under development and 
testing for use in humans (King et al., 2007; Clayton et al., 2016). A major 
challenge for the development and use of melanocortin agonists is the 
limited receptor binding specificity, which leads to activation of non-targeted 
receptors, and ultimately, non-desired effects (e.g. skin tanning induced by 
MT-II). For example, MT-II is a potent MC3/4 agonist, and also an MC5 agonist 
(Grieco et al., 2007), and this receptor is also expressed in several tissues, 
including exocrine glands and the brain (Fathi et al., 1995; Chen et al., 1997). 
The consequences of simultaneous actions on other receptors, or tissues 
expressing these receptors are unknown, but for therapeutic use, the 
secondary effects should be reduced to the minimum possible. The use of the 
intranasal route as a “focused” delivery of drugs into the brain, in theory, 
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avoid to some extent, these limitations, but the feasibility of this route 
remains to be proven.  
Considering all these factors and the evidence obtained in this study, 
the clinical use of melanocortins seems not to be the best strategy, or at least, 
is severely restricted (with the current drugs available) for the enhancement 
of central oxytocin release, and when used the effects must be carefully 
examined and considered during drug testing. As this strategy requires the 
manipulation of two systems, i.e. the melanocortin and oxytocin systems, it 
may be more efficient and precise use an OTR agonist with BBB capacities. For 
example, the non-peptide OTR agonist WAY-267464 is thought to penetrate 
the BBB to exert behavioural effects (Ring et al., 2010; Hicks et al., 2012). 
To my knowledge, this study shows for first time a potential role of 
circulating melanocortins in the regulation of magnocellular oxytocin (and 
also vasopressin) neurone activity. Whether the MT-II-induced peripheral 
oxytocin release could be used for other clinical applications or health 
conditions should be considered.     
 
6.2. CONCLUSION  
As previous studies have shown that SON oxytocin neurones release 
oxytocin from somatodendritic compartments in vitro, and they are 
electrically inhibited in vivo in response to direct application of the 
melanocortin agonist α-MSH (Sabatier et al., 2003a; Ladyman et al., 2016), the 
actions observed in this study following intravenous (i.v.) administration of 
MT-II are likely to be mediated, at least in part, indirectly, probably via 
activation of peripheral inputs which are relayed in the NTS, where MT-II 
also increased Fos expression (Fig. 6.1.). 
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6.3. SUMMARY  
The following findings and results were obtained from this study: 
Chapter 3 (Fos expression studies)  
 Intravenous (i.v.) administration of MT-II (1 mg/kg) induces the 
expression of Fos protein in oxytocin, and non-labelled, neurones of 
the supraoptic (SON) and paraventricular (PVN) nuclei of the 
hypothalamus. 
 The expression of Fos in the central amygdala (cAMG) is not changed 
by intravenous (i.v.) administration of MT-II.  
 Intravenous (i.v.) administration of MT-II does not change Fos 
expression in the circumventricular organs of the anteroventral third 
ventricle region (i.e. the subfornical organ (SFO)), and the organum 
vasculosum lamina terminalis (OVLT).  
 The expression of Fos in the nucleus tractus solitarii (NTS) is increased 
in response to intravenous (i.v.) administration of MT-II. 
 The prior central (i.c.v.) administration of the melanocortin antagonist 
SHU-9119 (1 µg/rat) prevents Fos expression induced by intravenous 
(i.v.) MT-II in the supraoptic (SON) and paraventricular (PVN) nuclei 
of the hypothalamus, but not in the nucleus tractus solitarii (NTS). 
 Intranasal administration of MT-II (1 µg and 30 µg) fails to induce 
changes in Fos expression in the supraoptic (SON) and 
paraventricular (PVN) nuclei of the hypothalamus, and also in cell 
layers of the olfactory bulb. 
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Chapter 4 (in vivo electrophysiology study) 
 Intravenous (i.v.) administration of MT-II (1 mg/kg) increases the 
firing rate of supraoptic (SON) oxytocin neurones in vivo in 
urethane-anaesthetised rats. 
 The firing rate of supraoptic (SON) vasopressin neurones is not 
significantly changed in response to intravenous (i.v.) administration 
of MT-II, however, single vasopressin neurones show heterogeneous 
responses to MT-II. 
 
Chapter 5 (in vivo SON microdialysis and plasma oxytocin studies) 
 Neither intravenous (i.v.; 1 mg/kg), nor intracerebroventricular (i.c.v.; 
1 µg/rat) administration of MT-II trigger (central) oxytocin release 
within the supraoptic (SON) nucleus of the hypothalamus. 
 Intravenous (i.v.) administration of MT-II stimulates peripheral 
oxytocin release. 





Figure 6.1. Schematic (interpretative) representation of the effects of systemic
administered MT‐II. I.v. administration of MT‐II activates peripheral
melanocortin receptors that are subsequently signalled to the NTS (Fos evidence)
which, in turn, activates magnocellular oxytocin (and vasopressin; Fos evidence)
neurones, as shown by enhanced Fos, electrical activity, and peripheral secretion.
The melanocortin antagonist SHU‐9119 prevented MT‐II‐induced Fos, suggesting
BBB‐penetrant capabilities of MT‐II. Segmented arrows = potential
pathways/effects based on previous reports, X = no evidence found (Callahan et al.,






























List of references  
Abdel-Malek ZA. (2001). Melanocortin receptors: their functions and regulation by 
physiological agonists and antagonists. Cell Mol Life Sci 58, 434-441. 
 
Abe H, Inoue M, Matsuo T & Ogata N. (1983). The effects of vasopressin on 
electrical activity in the guinea-pig supraoptic nucleus in vitro. J Physiol 337, 
665-685. 
 
Adan RA, Szklarczyk AW, Oosterom J, Brakkee JH, Nijenhuis WA, Schaaper WM, 
Meloen RH & Gispen WH. (1999). Characterization of melanocortin receptor 
ligands on cloned brain melanocortin receptors and on grooming behavior in 
the rat. Eur J Pharmacol 378, 249-258. 
 
Adan RA, Van Leeuwen FW, Sonnemans MA, Brouns M, Hoffman G, Verbalis JG & 
Burbach JP. (1995). Rat oxytocin receptor in brain, pituitary, mammary 
gland, and uterus: partial sequence and immunocytochemical localization. 
Endocrinology 136, 4022-4028. 
 
Agosti F, Lopez Soto EJ, Cabral A, Castrogiovanni D, Schioth HB, Perello M & 
Raingo J. (2014). Melanocortin 4 receptor activation inhibits presynaptic N-
type calcium channels in amygdaloid complex neurons. Eur J Neurosci 40, 
2755-2765. 
 
Al-Obeidi F, Castrucci AM, Hadley ME & Hruby VJ. (1989a). Potent and prolonged 
acting cyclic lactam analogues of alpha-melanotropin: design based on 
molecular dynamics. J Med Chem 32, 2555-2561. 
 
Al-Obeidi F, Hadley ME, Pettitt BM & Hruby VJ. (1989b). Design of a New Class of 
Superpotent Cyclic alpha-Melanotropins Based on Quenched Dynamic 
Simulations. J Am Chem Soc 111, 3413-3416. 
 
Alves SE, Lopez V, McEwen BS & Weiland NG. (1998). Differential colocalization of 
estrogen receptor beta (ERbeta) with oxytocin and vasopressin in the 
paraventricular and supraoptic nuclei of the female rat brain: an 
immunocytochemical study. Proc Natl Acad Sci U S A 95, 3281-3286. 
 
Anderson JW, Washburn DL & Ferguson AV. (2000). Intrinsic osmosensitivity of 
subfornical organ neurons. Neuroscience 100, 539-547. 
 
List of references  
140 
 
Antonijevic IA, Leng G, Luckman SM, Douglas AJ, Bicknell RJ & Russell JA. (1995). 
Induction of uterine activity with oxytocin in late pregnant rats replicates the 
expression of c-fos in neuroendocrine and brain stem neurons as seen during 
parturition. Endocrinology 136, 154-163. 
 
Argiolas A. (1992). Oxytocin stimulation of penile erection. Pharmacology, site, and 
mechanism of action. Ann N Y Acad Sci 652, 194-203. 
 
Argiolas A, Melis MR, Mauri A & Gessa GL. (1989). Oxytocin-induced penile 
erection and yawning in male rats: effect of neonatal monosodium glutamate 
and hypophysectomy. Psychopharmacology (Berl) 97, 383-387. 
 
Argiolas A, Melis MR, Murgia S & Schioth HB. (2000). ACTH- and alpha-MSH-
induced grooming, stretching, yawning and penile erection in male rats: site 
of action in the brain and role of melanocortin receptors. Brain Res Bull 51, 
425-431. 
 
Arima H, Baler R & Aguilera G. (2010). Fos proteins are not prerequisite for osmotic 
induction of vasopressin transcription in supraoptic nucleus of rats. Neurosci 
Lett 486, 5-9. 
 
Arima H, Kondo K, Murase T, Yokoi H, Iwasaki Y, Saito H & Oiso Y. (1998). 
Regulation of vasopressin synthesis and release by area postrema in rats. 
Endocrinology 139, 1481-1486. 
 
Arletti R, Bazzani C, Castelli M & Bertolini A. (1985). Oxytocin improves male 
copulatory performance in rats. Horm Behav 19, 14-20. 
 
Bader A, Klein B, Breer H & Strotmann J. (2012). Connectivity from OR37 expressing 
olfactory sensory neurons to distinct cell types in the hypothalamus. Front 
Neural Circuits 6, 84. 
 
Bagnol D, Lu XY, Kaelin CB, Day HE, Ollmann M, Gantz I, Akil H, Barsh GS & 
Watson SJ. (1999). Anatomy of an endogenous antagonist: relationship 
between Agouti-related protein and proopiomelanocortin in brain. J Neurosci 
19, RC26. 
 
List of references  
141 
 
Bale TL, Davis AM, Auger AP, Dorsa DM & McCarthy MM. (2001). CNS region-
specific oxytocin receptor expression: importance in regulation of anxiety 
and sex behavior. J Neurosci 21, 2546-2552. 
 
Balin BJ, Broadwell RD, Salcman M & el-Kalliny M. (1986). Avenues for entry of 
peripherally administered protein to the central nervous system in mouse, 
rat, and squirrel monkey. J Comp Neurol 251, 260-280. 
 
Banks WA. (2012). Brain meets body: the blood-brain barrier as an endocrine 
interface. Endocrinology 153, 4111-4119. 
 
Banks WA. (2016). From blood-brain barrier to blood-brain interface: new 
opportunities for CNS drug delivery. Nat Rev Drug Discov 15, 275-292. 
 
Baribeau DA & Anagnostou E. (2015). Oxytocin and vasopressin: linking pituitary 
neuropeptides and their receptors to social neurocircuits. Front Neurosci 9, 
335. 
 
Bednarek MA, Silva MV, Arison B, MacNeil T, Kalyani RN, Huang RR & Weinberg 
DH. (1999). Structure-function studies on the cyclic peptide MT-II, lactam 
derivative of alpha-melanotropin. Peptides 20, 401-409. 
 
Belin V & Moos F. (1986). Paired recordings from supraoptic and paraventricular 
oxytocin cells in suckled rats: recruitment and synchronization. J Physiol 377, 
369-390. 
 
Belin V, Moos F & Richard P. (1984). Synchronization of oxytocin cells in the 
hypothalamic paraventricular and supraoptic nuclei in suckled rats: direct 
proof with paired extracellular recordings. Exp Brain Res 57, 201-203. 
 
Ben-Barak Y, Russell JT, Whitnall MH, Ozato K & Gainer H. (1985). Neurophysin in 
the hypothalamo-neurohypophysial system. I. Production and 
characterization of monoclonal antibodies. J Neurosci 5, 81-97. 
 
Bertolini A, Poggioli R & Vergoni AV. (1988). Cross-species comparison of the 
ACTH-induced behavioral syndrome. Ann N Y Acad Sci 525, 114-129. 
 
List of references  
142 
 
Bertolini A, Tacchi R & Vergoni AV. (2009). Brain effects of melanocortins. Pharmacol 
Res 59, 13-47. 
 
Bertolini A, Vergoni W, Gessa GL & Ferrari W. (1969). Induction of sexual 
excitement by the action of adrenocorticotrophic hormone in brain. Nature 
221, 667-669. 
 
Bhorkar AA, Dandekar MP, Nakhate KT, Subhedar NK & Kokare DM. (2014). 
Involvement of the central melanocortin system in the effects of caffeine on 
anxiety-like behavior in mice. Life Sci 95, 72-80. 
 
Bicknell RJ. (1988). Optimizing release from peptide hormone secretory nerve 
terminals. J Exp Biol 139, 51-65. 
 
Blaicher W, Gruber D, Bieglmayer C, Blaicher AM, Knogler W & Huber JC. (1999). 
The role of oxytocin in relation to female sexual arousal. Gynecol Obstet Invest 
47, 125-126. 
 
Born J, Lange T, Kern W, McGregor GP, Bickel U & Fehm HL. (2002). Sniffing 
neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5, 
514-516. 
 
Bosch OJ, Kromer SA, Brunton PJ & Neumann ID. (2004). Release of oxytocin in the 
hypothalamic paraventricular nucleus, but not central amygdala or lateral 
septum in lactating residents and virgin intruders during maternal defence. 
Neuroscience 124, 439-448. 
 
Boudaba C, Tasker JG & Poulain DA. (1995). Connections from the subfornical 
organ to the oxytocin and vasopressin systems in the lactating rat. A study 
using electrical stimulations, lesions and electrophysiological recordings. 
Brain Res 672, 1-13. 
 
Bourque CW. (1991). Activity-dependent modulation of nerve terminal excitation in 
a mammalian peptidergic system. Trends Neurosci 14, 28-30. 
 
Breit A, Buch TR, Boekhoff I, Solinski HJ, Damm E & Gudermann T. (2011). 
Alternative G protein coupling and biased agonism: new insights into 
melanocortin-4 receptor signalling. Mol Cell Endocrinol 331, 232-240. 
List of references  
143 
 
Brown CH, Bains JS, Ludwig M & Stern JE. (2013). Physiological regulation of 
magnocellular neurosecretory cell activity: integration of intrinsic, local and 
afferent mechanisms. J Neuroendocrinol 25, 678-710. 
 
Brownstein MJ, Russell JT & Gainer H. (1980). Synthesis, transport, and release of 
posterior pituitary hormones. Science 207, 373-378. 
 
Buijs R, De Vries G & Van Leeuwen F. (1985). The distribution and synaptic release 
of oxytocin in the central nervous system. Oxytocin: Clinical and laboratory 
studies 666, 77-86. 
 
Buijs RM. (1978). Intra- and extrahypothalamic vasopressin and oxytocin pathways 
in the rat. Pathways to the limbic system, medulla oblongata and spinal 
cord. Cell Tissue Res 192, 423-435. 
 
Buijs RM. (1980). Immunocytochemical demonstration of vasopressin and oxytocin 
in the rat brain by light and electron microscopy. J Histochem Cytochem 28, 
357-360. 
 
Buijs RM & Swaab DF. (1979). Immuno-electron microscopical demonstration of 
vasopressin and oxytocin synapses in the limbic system of the rat. Cell Tissue 
Res 204, 355-365. 
 
Callahan MF, Cunningham JT, Kirby RF, Johnson AK & Gruber KA. (1988). Role of 
the anteroventral third ventricle (AV3V) region of the rat brain in the pressor 
response to gamma 2-melanocyte-stimulating hormone (gamma 2-MSH). 
Brain Res 444, 177-180. 
 
Campos CA, Shiina H & Ritter RC. (2014). Central vagal afferent endings mediate 
reduction of food intake by melanocortin-3/4 receptor agonist. J Neurosci 34, 
12636-12645. 
 
Cancelliere NM, Black EA & Ferguson AV. (2015). Neurohumoral Integration of 
Cardiovascular Function by the Lamina Terminalis. Curr Hypertens Rep 17, 
93. 
 
Caquineau C, Leng G, Guan XM, Jiang M, Van der Ploeg L & Douglas AJ. (2006). 
Effects of alpha-melanocyte-stimulating hormone on magnocellular oxytocin 
List of references  
144 
 
neurones and their activation at intromission in male rats. J Neuroendocrinol 
18, 685-691. 
 
Carmichael MS, Humbert R, Dixen J, Palmisano G, Greenleaf W & Davidson JM. 
(1987). Plasma oxytocin increases in the human sexual response. J Clin 
Endocrinol Metab 64, 27-31. 
 
Casale AE & McCormick DA. (2011). Active action potential propagation but not 
initiation in thalamic interneuron dendrites. J Neurosci 31, 18289-18302. 
 
Castel M & Morris JF. (1988). The neurophysin-containing innervation of the 
forebrain of the mouse. Neuroscience 24, 937-966. 
 
Cawley NX, Li Z & Loh YP. (2016). 60 YEARS OF POMC: Biosynthesis, trafficking, 
and secretion of pro-opiomelanocortin-derived peptides. J Mol Endocrinol 56, 
T77-97. 
 
Chefer VI, Thompson AC, Zapata A & Shippenberg TS. (2009). Overview of brain 
microdialysis. Curr Protoc Neurosci Chapter 7, Unit7 1. 
 
Chen W, Kelly MA, Opitz-Araya X, Thomas RE, Low MJ & Cone RD. (1997). 
Exocrine gland dysfunction in MC5-R-deficient mice: evidence for 
coordinated regulation of exocrine gland function by melanocortin peptides. 
Cell 91, 789-798. 
 
Ciura S & Bourque CW. (2006). Transient receptor potential vanilloid 1 is required 
for intrinsic osmoreception in organum vasculosum lamina terminalis 
neurons and for normal thirst responses to systemic hyperosmolality. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 26, 
9069-9075. 
 
Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, 
Kaminetsky J, Spana C, Lucas J, Jordan R & Portman DJ. (2016). 
Bremelanotide for female sexual dysfunctions in premenopausal women: a 
randomized, placebo-controlled dose-finding trial. Womens Health (Lond) 12, 
325-337. 
 
Cook AM, Mieure KD, Owen RD, Pesaturo AB & Hatton J. (2009). 
Intracerebroventricular administration of drugs. Pharmacotherapy 29, 832-845. 
List of references  
145 
 
Cottrell GT & Ferguson AV. (2004). Sensory circumventricular organs: central roles 
in integrated autonomic regulation. Regul Pept 117, 11-23. 
 
Cragnolini A, Scimonelli T, Celis ME & Schioth HB. (2000). The role of melanocortin 
receptors in sexual behavior in female rats. Neuropeptides 34, 211-215. 
 
Cyranowski JM, Hofkens TL, Frank E, Seltman H, Cai HM & Amico JA. (2008). 
Evidence of dysregulated peripheral oxytocin release among depressed 
women. Psychosom Med 70, 967-975. 
 
Dale HH. (1906). On some physiological actions of ergot. J Physiol 34, 163-206. 
 
De Rotte AA, Bouman HJ & van Wimersma Greidanus TB. (1980). Relationships 
between alpha-MSH levels in blood and in cerebrospinal fluid. Brain Res Bull 
5, 375-381. 
 
Dhuria SV, Hanson LR & Frey WH, 2nd. (2010). Intranasal delivery to the central 
nervous system: mechanisms and experimental considerations. J Pharm Sci 
99, 1654-1673. 
 
do Carmo JM, da Silva AA, Rushing JS, Pace B & Hall JE. (2013). Differential control 
of metabolic and cardiovascular functions by melanocortin-4 receptors in 
proopiomelanocortin neurons. Am J Physiol Regul Integr Comp Physiol 305, 
R359-368. 
 
do Carmo JM, da Silva AA, Wang Z, Fang T, Aberdein N, Perez de Lara CE & Hall 
JE. (2017). Role of the brain melanocortins in blood pressure regulation. 
Biochim Biophys Acta 1863, 2508-2514. 
 
Dolen G, Darvishzadeh A, Huang KW & Malenka RC. (2013). Social reward requires 
coordinated activity of nucleus accumbens oxytocin and serotonin. Nature 
501, 179-184. 
 
Dores RM, Liang L, Davis P, Thomas AL & Petko B. (2016). 60 YEARS OF POMC: 
Melanocortin receptors: evolution of ligand selectivity for melanocortin 
peptides. J Mol Endocrinol 56, T119-133. 
 
List of references  
146 
 
Dores RM, Londraville RL, Prokop J, Davis P, Dewey N & Lesinski N. (2014). 
Molecular evolution of GPCRs: Melanocortin/melanocortin receptors. J Mol 
Endocrinol 52, T29-42. 
 
Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ & Hadley ME. (1996). 
Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a 
pilot phase-I clinical study. Life Sci 58, 1777-1784. 
 
Douglas A, Scullion S, Antonijevic I, Brown D, Russell J & Leng G. (2001). Uterine 
contractile activity stimulates supraoptic neurons in term pregnant rats via a 
noradrenergic pathway. Endocrinology 142, 633-644. 
 
Douglas WW & Poisner AM. (1964). Stimulus-Secretion Coupling in a 
Neurosecretory Organ: The Role of Calcium in the Release of Vasopressin 
from the Neurohypophysis. J Physiol 172, 1-18. 
 
Du Vigneaud V, Lawler H & Popenoe E. (1953a). Enzymatic cleavage of 
glycinamide from vasopressin and a proposed structure for this pressor-
antidiuretic hormone of the posterior pituitary. Journal of the American 
Chemical Society 75, 4880-4881. 
 
Du Vigneaud V, Ressler C & Trippett S. (1953b). The sequence of amino acids in 
oxytocin, with a proposal for the structure of oxytocin. J Biol Chem 205, 949-
957. 
 
Engelhardt B & Sorokin L. (2009). The blood-brain and the blood-cerebrospinal fluid 
barriers: function and dysfunction. Semin Immunopathol 31, 497-511. 
 
Engelmann M, Bull PM, Brown CH, Landgraf R, Horn TF, Singewald N, Ludwig M 
& Wotjak CT. (2004). GABA selectively controls the secretory activity of 
oxytocin neurons in the rat supraoptic nucleus. Eur J Neurosci 19, 601-608. 
 
Engelmann M, Hadicke J & Noack J. (2011). Testing declarative memory in 
laboratory rats and mice using the nonconditioned social discrimination 
procedure. Nat Protoc 6, 1152-1162. 
 
Engelmann M, Wolf G & Horn TF. (2002). Release patterns of excitatory and 
inhibitory amino acids within the hypothalamic supraoptic nucleus in 
List of references  
147 
 
response to direct nitric oxide administration during forced swimming in 
rats. Neurosci Lett 324, 252-254. 
 
Engstrom T, Atke A & Vilhardt H. (1988). Oxytocin receptors and contractile 
response of the myometrium after long term infusion of prostaglandin F2 
alpha, indomethacin, oxytocin and an oxytocin antagonist in rats. Regul Pept 
20, 65-72. 
 
Ermisch A, Barth T, Ruhle HJ, Skopkova J, Hrbas P & Landgraf R. (1985). On the 
blood-brain barrier to peptides: accumulation of labelled vasopressin, 
DesGlyNH2-vasopressin and oxytocin by brain regions. Endocrinol Exp 19, 
29-37. 
 
Fahrbach SE, Morrell JI & Pfaff DW. (1984). Oxytocin induction of short-latency 
maternal behavior in nulliparous, estrogen-primed female rats. Horm Behav 
18, 267-286. 
 
Fan W, Boston BA, Kesterson RA, Hruby VJ & Cone RD. (1997). Role of 
melanocortinergic neurons in feeding and the agouti obesity syndrome. 
Nature 385, 165-168. 
 
Fathi Z, Iben LG & Parker EM. (1995). Cloning, expression, and tissue distribution of 
a fifth melanocortin receptor subtype. Neurochem Res 20, 107-113. 
 
Ferguson AV. (2014). Circumventricular Organs: Integrators of Circulating Signals 
Controlling Hydration, Energy Balance, and Immune Function. In 
Neurobiology of Body Fluid Homeostasis: Transduction and Integration, ed. De 
Luca LA, Jr., Menani JV & Johnson AK. Boca Raton (FL). 
 
Ferguson JKW. (1941). A study of the motility of the intact uterus at term. Surg 
Gynecol Obstet 73, 359-366. 
 
Ferguson JN, Aldag JM, Insel TR & Young LJ. (2001). Oxytocin in the medial 
amygdala is essential for social recognition in the mouse. J Neurosci 21, 8278-
8285. 
 
Ferrari W, Gessa GL & Vargiu L. (1963). Behavioral effects induced by 
intracisternally injected ACTH and MSH. Ann N Y Acad Sci 104, 330-345. 
List of references  
148 
 
Fong TM & Van der Ploeg LH. (2000). A melanocortin agonist reduces neuronal 
firing rate in rat hypothalamic slices. Neurosci Lett 283, 5-8. 
 
Freund-Mercier MJ, Stoeckel ME & Klein MJ. (1994). Oxytocin receptors on oxytocin 
neurones: histoautoradiographic detection in the lactating rat. J Physiol 480 ( 
Pt 1), 155-161. 
 
Frost SI, Keen KL, Levine JE & Terasawa E. (2008). Microdialysis methods for in 
vivo neuropeptide measurement in the stalk-median eminence in the Rhesus 
monkey. J Neurosci Methods 168, 26-34. 
 
Fry M & Ferguson AV. (2007). The sensory circumventricular organs: brain targets 
for circulating signals controlling ingestive behavior. Physiol Behav 91, 413-
423. 
 
Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, Watson SJ, DelValle J 
& Yamada T. (1993). Molecular cloning of a novel melanocortin receptor. J 
Biol Chem 268, 8246-8250. 
 
Gautron L, Lee C, Funahashi H, Friedman J, Lee S & Elmquist J. (2010). 
Melanocortin-4 receptor expression in a vago-vagal circuitry involved in 
postprandial functions. J Comp Neurol 518, 6-24. 
 
Gelez H, Poirier S, Facchinetti P, Allers KA, Wayman C, Bernabe J, Alexandre L & 
Giuliano F. (2010). Neuroanatomical distribution of the melanocortin-4 
receptors in male and female rodent brain. J Chem Neuroanat 40, 310-324. 
 
Ghamari-Langroudi M, Srisai D & Cone RD. (2011). Multinodal regulation of the 
arcuate/paraventricular nucleus circuit by leptin. Proc Natl Acad Sci U S A 
108, 355-360. 
 
Gimpl G & Fahrenholz F. (2001). The oxytocin receptor system: structure, function, 
and regulation. Physiol Rev 81, 629-683. 
 
Giraudo SQ, Billington CJ & Levine AS. (1998). Feeding effects of hypothalamic 
injection of melanocortin 4 receptor ligands. Brain Res 809, 302-306. 
 
List of references  
149 
 
Giuliano F, Clement P, Droupy S, Alexandre L & Bernabe J. (2006). Melanotan-II: 
Investigation of the inducer and facilitator effects on penile erection in 
anaesthetized rat. Neuroscience 138, 293-301. 
 
Glovinsky D, Kalogeras KT, Kirch DG, Suddath R & Wyatt RJ. (1994). Cerebrospinal 
fluid oxytocin concentration in schizophrenic patients does not differ from 
control subjects and is not changed by neuroleptic medication. Schizophr Res 
11, 273-276. 
 
Goldman M, Marlow-O'Connor M, Torres I & Carter CS. (2008). Diminished plasma 
oxytocin in schizophrenic patients with neuroendocrine dysfunction and 
emotional deficits. Schizophr Res 98, 247-255. 
 
Gorges M, Roselli F, Muller HP, Ludolph AC, Rasche V & Kassubek J. (2017). 
Functional Connectivity Mapping in the Animal Model: Principles and 
Applications of Resting-State fMRI. Front Neurol 8, 200. 
 
Green L, Fein D, Modahl C, Feinstein C, Waterhouse L & Morris M. (2001). Oxytocin 
and autistic disorder: alterations in peptide forms. Biol Psychiatry 50, 609-613. 
 
Grieco P, Cai M, Han G, Trivedi D, Campiglia P, Novellino E & Hruby VJ. (2007). 
Further structure-activity studies of lactam derivatives of MT-II and SHU-
9119: their activity and selectivity at human melanocortin receptors 3, 4, and 
5. Peptides 28, 1191-1196. 
 
Grindstaff RR & Cunningham JT. (2001). Cardiovascular regulation of vasopressin 
neurons in the supraoptic nucleus. Exp Neurol 171, 219-226. 
 
Guy J, Leclerc R, Vaudry H & Pelletier G. (1980). Identification of a second category 
of alpha-melanocyte-stimulating hormone (alpha-MSH) neurons in the rat 
hypothalamus. Brain Res 199, 135-146. 
 
Guy J, Vaudry H & Pelletier G. (1981). Differential projections of two 
immunoreactive alpha-melanocyte stimulating hormone (alpha-MSH) 
neuronal systems in the rat brain. Brain Res 220, 199-202. 
 
Hadley ME & Dorr RT. (2006). Melanocortin peptide therapeutics: historical 
milestones, clinical studies and commercialization. Peptides 27, 921-930. 
List of references  
150 
 
Hadley ME & Haskell-Luevano C. (1999). The proopiomelanocortin system. Ann N 
Y Acad Sci 885, 1-21. 
 
Hadley ME, Marwan MM, al-Obeidi F, Hruby VJ & Castrucci AM. (1989). Linear 
and cyclic alpha-melanotropin [4-10]-fragment analogues that exhibit 
superpotency and residual activity. Pigment Cell Res 2, 478-484. 
 
Hagan MM, Benoit SC, Rushing PA, Pritchard LM, Woods SC & Seeley RJ. (2001). 
Immediate and prolonged patterns of Agouti-related peptide-(83--132)-
induced c-Fos activation in hypothalamic and extrahypothalamic sites. 
Endocrinology 142, 1050-1056. 
 
Harris MC. (1979). Effects of chemoreceptor and baroreceptor stimulation on the 
discharge of hypothalamic supraoptic neurones in rats. J Endocrinol 82, 115-
125. 
 
Hatton GI, Cobbett P & Salm AK. (1985). Extranuclear axon collaterals of 
paraventricular neurons in the rat hypothalamus: intracellular staining, 
immunocytochemistry and electrophysiology. Brain Res Bull 14, 123-132. 
 
Hattori T, Morris M, Alexander N & Sundberg DK. (1990). Extracellular oxytocin in 
the paraventricular nucleus: hyperosmotic stimulation by in vivo 
microdialysis. Brain Res 506, 169-171. 
 
Hatziieremia S, Kostomitsopoulos N, Balafas V & Tamvakopoulos C. (2007). A 
liquid chromatographic/tandem mass spectroscopic method for 
quantification of the cyclic peptide melanotan-II. Plasma and brain tissue 
concentrations following administration in mice. Rapid Commun Mass 
Spectrom 21, 2431-2438. 
 
Heim C, Young LJ, Newport DJ, Mletzko T, Miller AH & Nemeroff CB. (2009). 
Lower CSF oxytocin concentrations in women with a history of childhood 
abuse. Mol Psychiatry 14, 954-958. 
 
Hermans E. (2003). Biochemical and pharmacological control of the multiplicity of 
coupling at G-protein-coupled receptors. Pharmacol Ther 99, 25-44. 
 
Hicks C, Jorgensen W, Brown C, Fardell J, Koehbach J, Gruber CW, Kassiou M, 
Hunt GE & McGregor IS. (2012). The nonpeptide oxytocin receptor agonist 
List of references  
151 
 
WAY 267,464: receptor-binding profile, prosocial effects and distribution of 
c-Fos expression in adolescent rats. J Neuroendocrinol 24, 1012-1029. 
 
Hoffman GE, Smith MS & Verbalis JG. (1993). c-Fos and related immediate early 
gene products as markers of activity in neuroendocrine systems. Front 
Neuroendocrinol 14, 173-213. 
 
Honda K, Yanagimoto M, Negoro H, Narita K, Murata T & Higuchi T. (1999). 
Excitation of oxytocin cells in the hypothalamic supraoptic nucleus by 
electrical stimulation of the dorsal penile nerve and tactile stimulation of the 
penis in the rat. Brain Res Bull 48, 309-313. 
 
Horn TF & Engelmann M. (2001). In vivo microdialysis for nonapeptides in rat 
brain--a practical guide. Methods 23, 41-53. 
 
Hruby VJ. (2016). Design of cyclic peptides with biological activities from 
biologically active peptides: the case of peptide modulators of melanocortin 
receptors. Biopolymers 106, 884-888. 
 
Hruby VJ & Cai M. (2013). Design of peptide and peptidomimetic ligands with 
novel pharmacological activity profiles. Annu Rev Pharmacol Toxicol 53, 557-
580. 
 
Hruby VJ, Cai M, Cain J, Nyberg J & Trivedi D. (2011). Design of novel melanocortin 
receptor ligands: multiple receptors, complex pharmacology, the challenge. 
Eur J Pharmacol 660, 88-93. 
 
Hruby VJ, Lu D, Sharma SD, Castrucci AL, Kesterson RA, al-Obeidi FA, Hadley ME 
& Cone RD. (1995). Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-
cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-
NH2 with bulky aromatic amino acids at position 7 show high antagonist 
potency and selectivity at specific melanocortin receptors. J Med Chem 38, 
3454-3461. 
 
Huang W, Sved AF & Stricker EM. (2000). Vasopressin and oxytocin release evoked 
by NaCl loads are selectively blunted by area postrema lesions. Am J Physiol 
Regul Integr Comp Physiol 278, R732-740. 
 
List of references  
152 
 
Huber D, Veinante P & Stoop R. (2005). Vasopressin and oxytocin excite distinct 
neuronal populations in the central amygdala. Science 308, 245-248. 
 
Hughes AM, Everitt BJ, Lightman SL & Todd K. (1987). Oxytocin in the central 
nervous system and sexual behaviour in male rats. Brain Res 414, 133-137. 
 
Hurbin A, Orcel H, Alonso G, Moos F & Rabie A. (2002). The vasopressin receptors 
colocalize with vasopressin in the magnocellular neurons of the rat 
supraoptic nucleus and are modulated by water balance. Endocrinology 143, 
456-466. 
 
Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, 
Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P 
& Lee F. (1997). Targeted disruption of the melanocortin-4 receptor results in 
obesity in mice. Cell 88, 131-141. 
 
Insel TR, O'Brien DJ & Leckman JF. (1999). Oxytocin, vasopressin, and autism: is 
there a connection? Biol Psychiatry 45, 145-157. 
 
Insel TR & Shapiro LE. (1992). Oxytocin receptor distribution reflects social 
organization in monogamous and polygamous voles. Proc Natl Acad Sci U S 
A 89, 5981-5985. 
 
Insel TR, Winslow JT, Wang Z & Young LJ. (1998). Oxytocin, vasopressin, and the 
neuroendocrine basis of pair bond formation. Adv Exp Med Biol 449, 215-224. 
 
Jacobowitz DM & O'Donohue TL. (1978). alpha-Melanocyte stimulating hormone: 
immunohistochemical identification and mapping in neurons of rat brain. 
Proc Natl Acad Sci U S A 75, 6300-6304. 
 
Janak PH & Tye KM. (2015). From circuits to behaviour in the amygdala. Nature 517, 
284-292. 
 
Jansen LM, Gispen-de Wied CC, Wiegant VM, Westenberg HG, Lahuis BE & van 
Engeland H. (2006). Autonomic and neuroendocrine responses to a 
psychosocial stressor in adults with autistic spectrum disorder. J Autism Dev 
Disord 36, 891-899. 
 
List of references  
153 
 
Jobst A, Padberg F, Mauer MC, Daltrozzo T, Bauriedl-Schmidt C, Sabass L, Sarubin 
N, Falkai P, Renneberg B, Zill P, Gander M & Buchheim A. (2016). Lower 
Oxytocin Plasma Levels in Borderline Patients with Unresolved Attachment 
Representations. Front Hum Neurosci 10, 125. 
 
Johnson NJ, Hanson LR & Frey WH. (2010). Trigeminal pathways deliver a low 
molecular weight drug from the nose to the brain and orofacial structures. 
Mol Pharm 7, 884-893. 
 
Jokinen J, Chatzittofis A, Hellstrom C, Nordstrom P, Uvnas-Moberg K & Asberg M. 
(2012). Low CSF oxytocin reflects high intent in suicide attempters. 
Psychoneuroendocrinology 37, 482-490. 
 
Jones CW & Pickering BT. (1972). Intra-axonal transport and turnover of 
neurohypophysial hormones in the rat. J Physiol 227, 553-564. 
 
Jones PM & Robinson IC. (1982). Differential clearance of neurophysin and 
neurohypophysial peptides from the cerebrospinal fluid in conscious guinea 
pigs. Neuroendocrinology 34, 297-302. 
 
Joseph SA, Pilcher WH & Bennett-Clarke C. (1983). Immunocytochemical 
localization of ACTH perikarya in nucleus tractus solitarius: evidence for a 
second opiocortin neuronal system. Neurosci Lett 38, 221-225. 
 
Kagerbauer SM, Martin J, Schuster T, Blobner M, Kochs EF & Landgraf R. (2013). 
Plasma oxytocin and vasopressin do not predict neuropeptide 
concentrations in human cerebrospinal fluid. J Neuroendocrinol 25, 668-673. 
 
Kask A, Pahkla R, Irs A, Rago L, Wikberg JE & Schioth HB. (1999). Long-term 
administration of MC4 receptor antagonist HS014 causes hyperphagia and 
obesity in rats. Neuroreport 10, 707-711. 
 
Kawashima N, Chaki S & Okuyama S. (2003). Electrophysiological effects of 
melanocortin receptor ligands on neuronal activities of monoaminergic 
neurons in rats. Neurosci Lett 353, 119-122. 
 
Keebaugh AC & Young LJ. (2011). Increasing oxytocin receptor expression in the 
nucleus accumbens of pre-pubertal female prairie voles enhances 
List of references  
154 
 
alloparental responsiveness and partner preference formation as adults. 
Horm Behav 60, 498-504. 
 
Kenakin T & Christopoulos A. (2013). Signalling bias in new drug discovery: 
detection, quantification and therapeutic impact. Nat Rev Drug Discov 12, 
205-216. 
 
Kimura T, Tanizawa O, Mori K, Brownstein MJ & Okayama H. (1992). Structure and 
expression of a human oxytocin receptor. Nature 356, 526-529. 
 
King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW & Wessells H. 
(2007). Melanocortin receptors, melanotropic peptides and penile erection. 
Curr Top Med Chem 7, 1098-1106. 
 
Kishi T, Aschkenasi CJ, Lee CE, Mountjoy KG, Saper CB & Elmquist JK. (2003). 
Expression of melanocortin 4 receptor mRNA in the central nervous system 
of the rat. J Comp Neurol 457, 213-235. 
 
Klenerova V, Krejci I, Sida P, Hlinak Z & Hynie S. (2008). Effects of melanotan II, a 
melanocortin agonist, on grooming and exploration in rats after repeated 
restraint/immobilization. Neurosci Lett 432, 202-205. 
 
Knobloch HS, Charlet A, Hoffmann LC, Eliava M, Khrulev S, Cetin AH, Osten P, 
Schwarz MK, Seeburg PH, Stoop R & Grinevich V. (2012). Evoked axonal 
oxytocin release in the central amygdala attenuates fear response. Neuron 73, 
553-566. 
 
Kokare DM, Dandekar MP, Chopde CT & Subhedar N. (2005). Interaction between 
neuropeptide Y and alpha-melanocyte stimulating hormone in amygdala 
regulates anxiety in rats. Brain Res 1043, 107-114. 
 
Kolaj M, Yang CR & Renaud LP. (2000). Presynaptic GABA(B) receptors modulate 
organum vasculosum lamina terminalis-evoked postsynaptic currents in rat 
hypothalamic supraoptic neurons. Neuroscience 98, 129-133. 
 
Kota SK, Gayatri K, Jammula S, Kota SK, Krishna SV, Meher LK & Modi KD. (2013). 
Endocrinology of parturition. Indian J Endocrinol Metab 17, 50-59. 
 
List of references  
155 
 
Kovacs KJ. (2008). Measurement of immediate-early gene activation- c-fos and 
beyond. J Neuroendocrinol 20, 665-672. 
 
Ku CY, Qian A, Wen Y, Anwer K & Sanborn BM. (1995). Oxytocin stimulates 
myometrial guanosine triphosphatase and phospholipase-C activities via 
coupling to G alpha q/11. Endocrinology 136, 1509-1515. 
 
Kuo A & Smith MT. (2014). Theoretical and practical applications of the 
intracerebroventricular route for CSF sampling and drug administration in 
CNS drug discovery research: a mini review. J Neurosci Methods 233, 166-171. 
 
Ladyman SR, Augustine RA, Scherf E, Phillipps HR, Brown CH & Grattan DR. 
(2016). Attenuated hypothalamic responses to alpha-melanocyte stimulating 
hormone during pregnancy in the rat. J Physiol 594, 1087-1101. 
 
Lambert RC, Dayanithi G, Moos FC & Richard P. (1994). A rise in the intracellular 
Ca2+ concentration of isolated rat supraoptic cells in response to oxytocin. J 
Physiol 478 ( Pt 2), 275-287. 
 
Lambert RC, Moos FC & Richard P. (1993). Action of endogenous oxytocin within 
the paraventricular or supraoptic nuclei: a powerful link in the regulation of 
the bursting pattern of oxytocin neurons during the milk-ejection reflex in 
rats. Neuroscience 57, 1027-1038. 
 
Landgraf R & Ludwig M. (1991). Vasopressin release within the supraoptic and 
paraventricular nuclei of the rat brain: osmotic stimulation via microdialysis. 
Brain Res 558, 191-196. 
 
Landgraf R, Neumann I, Holsboer F & Pittman QJ. (1995). Interleukin-1 beta 
stimulates both central and peripheral release of vasopressin and oxytocin in 
the rat. Eur J Neurosci 7, 592-598. 
 
Langlet F, Mullier A, Bouret SG, Prevot V & Dehouck B. (2013). Tanycyte-like cells 
form a blood-cerebrospinal fluid barrier in the circumventricular organs of 
the mouse brain. J Comp Neurol 521, 3389-3405. 
 
Langouche L, Roudbaraki M, Pals K & Denef C. (2001). Stimulation of intracellular 
free calcium in GH3 cells by gamma3-melanocyte-stimulating hormone. 
Involvement of a novel melanocortin receptor? Endocrinology 142, 257-266. 
List of references  
156 
 
Lechan RM & Jackson IM. (1982). Immunohistochemical localization of thyrotropin-
releasing hormone in the rat hypothalamus and pituitary. Endocrinology 111, 
55-65. 
 
Lee R, Ferris C, Van de Kar LD & Coccaro EF. (2009). Cerebrospinal fluid oxytocin, 
life history of aggression, and personality disorder. Psychoneuroendocrinology 
34, 1567-1573. 
 
Legros JJ, Gazzotti C, Carvelli T, Franchimont P, Timsit-Berthier M, von Frenckell R 
& Ansseau M. (1992). Apomorphine stimulation of vasopressin- and 
oxytocin-neurophysins. Evidence for increased oxytocinergic and decreased 
vasopressinergic function in schizophrenics. Psychoneuroendocrinology 17, 
611-617. 
 
Lemos JR & Nowycky MC. (1989). Two types of calcium channels coexist in peptide-
releasing vertebrate nerve terminals. Neuron 2, 1419-1426. 
 
Leng G, Blackburn RE, Dyball RE & Russell JA. (1989). Role of anterior peri-third 
ventricular structures in the regulation of supraoptic neuronal activity and 
neurohypophysical hormone secretion in the rat. J Neuroendocrinol 1, 35-46. 
 
Leng G, Brown CH, Bull PM, Brown D, Scullion S, Currie J, Blackburn-Munro RE, 
Feng J, Onaka T, Verbalis JG, Russell JA & Ludwig M. (2001). Responses of 
magnocellular neurons to osmotic stimulation involves coactivation of 
excitatory and inhibitory input: an experimental and theoretical analysis. J 
Neurosci 21, 6967-6977. 
 
Leng G, Brown CH & Russell JA. (1999). Physiological pathways regulating the 
activity of magnocellular neurosecretory cells. Prog Neurobiol 57, 625-655. 
 
Leng G & Dyball R. (1984). Altered baroreceptor inputs to the supraoptic nucleus of 
the Brattleboro rat. Exp Brain Res 54, 571-574. 
 
Leng G & Dyball R. (1991). Functional identification of magnocellular 
neuroendocrine neurones. In Neuroendocrine Research Methods, ed. Greenstein 
B, pp. 769-791. Harwood Academic Publishers GmbH, Chur, Switzerland. 
 
Leng G & Ludwig M. (2016). Intranasal Oxytocin: Myths and Delusions. Biol 
Psychiatry 79, 243-250. 
List of references  
157 
 
Leng G, Ludwig M & Douglas AJ. (2012). Neural Control of the Posterior Pituitary 
Gland (Neurohypophysis). In Handbook of neuroendocrinology, ed. Fink G, 
Pfaff DW & J.E L, pp. 39–155. Academic Press, Elsevier, London, Waltham, 
San Diego. 
 
Leng G & Mason WT. (1982). Influence of vasopressin upon firing patterns of 
supraoptic neurons: a comparison of normal and Brattleboro rats. Ann N Y 
Acad Sci 394, 153-158. 
 
Leng G & Sabatier N. (2014). Electrophysiology of Magnocellular Neurons in Vivo. 
In Neurophysiology of Neuroendocrine Neurons, ed. Armstrong WE & Tasker 
JG, pp. 1-28. John Wiley & Sons, Ltd., Chichester, UK. 
 
Leng G & Sabatier N. (2016). Measuring Oxytocin and Vasopressin: Bioassays, 
Immunoassays and Random Numbers. J Neuroendocrinol 28. 
 
Leng G, Way S & Dyball RE. (1991). Identification of oxytoxin cells in the rat 
supraoptic nucleus by their response to cholecystokinin injection. Neurosci 
Lett 122, 159-162. 
 
Lensing CJ, Adank DN, Wilber SL, Freeman KT, Schnell SM, Speth RC, Zarth AT & 
Haskell-Luevano C. (2017). A Direct in Vivo Comparison of the 
Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH2 versus the 
Bivalent Agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH2: A 
Bivalent Advantage. ACS Chem Neurosci 8, 1262-1278. 
 
Li C, Tripathi PK & Armstrong WE. (2007). Differences in spike train variability in 
rat vasopressin and oxytocin neurons and their relationship to synaptic 
activity. J Physiol 581, 221-240. 
 
Lincoln DW & Wakerley JB. (1974). Electrophysiological evidence for the activation 
of supraoptic neurones during the release of oxytocin. J Physiol 242, 533-554. 
 
Lindblom J, Schioth HB, Larsson A, Wikberg JE & Bergstrom L. (1998). 
Autoradiographic discrimination of melanocortin receptors indicates that the 
MC3 subtype dominates in the medial rat brain. Brain Res 810, 161-171. 
 
List of references  
158 
 
Linkowski P, Geenen V, Kerkhofs M, Mendlewicz J & Legros JJ. (1984). 
Cerebrospinal fluid neurophysins in affective illness and in schizophrenia. 
Eur Arch Psychiatry Neurol Sci 234, 162-165. 
 
Liu H, Kishi T, Roseberry AG, Cai X, Lee CE, Montez JM, Friedman JM & Elmquist 
JK. (2003). Transgenic mice expressing green fluorescent protein under the 
control of the melanocortin-4 receptor promoter. J Neurosci 23, 7143-7154. 
 
Liu Y & Wang ZX. (2003). Nucleus accumbens oxytocin and dopamine interact to 
regulate pair bond formation in female prairie voles. Neuroscience 121, 537-
544. 
 
Loh YP, Zucker L, Verspaget H & Van Wimersma Greidanus TB. (1979). 
Melanotropic peptides: presence in brain of normal and hypophysectomized 
rats, and subcellularly localized in synaptosomes. J Neurosci Res 4, 147-156. 
 
Luckman SM, Dyball RE & Leng G. (1994). Induction of c-fos expression in 
hypothalamic magnocellular neurons requires synaptic activation and not 
simply increased spike activity. J Neurosci 14, 4825-4830. 
 
Ludwig M, Bull PM, Tobin VA, Sabatier N, Landgraf R, Dayanithi G & Leng G. 
(2005). Regulation of activity-dependent dendritic vasopressin release from 
rat supraoptic neurones. J Physiol 564, 515-522. 
 
Ludwig M, Callahan MF, Neumann I, Landgraf R & Morris M. (1994). Systemic 
osmotic stimulation increases vasopressin and oxytocin release within the 
supraoptic nucleus. J Neuroendocrinol 6, 369-373. 
 
Ludwig M & Landgraf R. (1992). Does the release of vasopressin within the 
supraoptic nucleus of the rat brain depend upon changes in osmolality and 
Ca2+/K+? Brain Res 576, 231-234. 
 
Ludwig M & Leng G. (1997). Autoinhibition of supraoptic nucleus vasopressin 
neurons in vivo: a combined retrodialysis/electrophysiological study in rats. 
Eur J Neurosci 9, 2532-2540. 
 
Ludwig M & Leng G. (2006). Dendritic peptide release and peptide-dependent 
behaviours. Nat Rev Neurosci 7, 126-136. 
List of references  
159 
 
Ludwig M, Sabatier N, Bull PM, Landgraf R, Dayanithi G & Leng G. (2002). 
Intracellular calcium stores regulate activity-dependent neuropeptide release 
from dendrites. Nature 418, 85-89. 
 
Ludwig M, Tobin VA, Callahan MF, Papadaki E, Becker A, Engelmann M & Leng G. 
(2013). Intranasal application of vasopressin fails to elicit changes in brain 
immediate early gene expression, neural activity and behavioural 
performance of rats. J Neuroendocrinol 25, 655-667. 
 
MacGregor DJ & Leng G. (2013). Spike triggered hormone secretion in vasopressin 
cells; a model investigation of mechanism and heterogeneous population 
function. PLoS Comput Biol 9, e1003187. 
 
MacGregor DJ & Leng G. (2016). Modeling Spiking and Secretion in the 
Magnocellular Vasopressin Neuron. In Computational Neuroendocrinology, ed. 
MacGregor DJ & Leng G, pp. 166-205. John Wiley & Sons, Ltd., Chichester, 
UK. 
 
Mahalati K, Okanoya K, Witt DM & Carter CS. (1991). Oxytocin inhibits male sexual 
behavior in prairie voles. Pharmacol Biochem Behav 39, 219-222. 
 
Marlin BJ & Froemke RC. (2017). Oxytocin modulation of neural circuits for social 
behavior. Dev Neurobiol 77, 169-189. 
 
Marlin BJ, Mitre M, D'Amour J A, Chao MV & Froemke RC. (2015). Oxytocin 
enables maternal behaviour by balancing cortical inhibition. Nature 520, 499-
504. 
 
Marson L & McKenna KE. (1996). CNS cell groups involved in the control of the 
ischiocavernosus and bulbospongiosus muscles: a transneuronal tracing 
study using pseudorabies virus. J Comp Neurol 374, 161-179. 
 
Masereeuw R, Jaehde U, Langemeijer MW, de Boer AG & Breimer DD. (1994). In 
vitro and in vivo transport of zidovudine (AZT) across the blood-brain 
barrier and the effect of transport inhibitors. Pharm Res 11, 324-330. 
 
Mason WT. (1980). Supraoptic neurones of rat hypothalamus are osmosensitive. 
Nature 287, 154-157. 
List of references  
160 
 
Mason WT, Ho YW & Hatton GI. (1984). Axon collaterals of supraoptic neurones: 
anatomical and electrophysiological evidence for their existence in the lateral 
hypothalamus. Neuroscience 11, 169-182. 
 
McKinley MJ, Allen AM, Burns P, Colvill LM & Oldfield BJ. (1998). Interaction of 
circulating hormones with the brain: the roles of the subfornical organ and 
the organum vasculosum of the lamina terminalis. Clin Exp Pharmacol Physiol 
Suppl 25, S61-67. 
 
McMinn JE, Wilkinson CW, Havel PJ, Woods SC & Schwartz MW. (2000). Effect of 
intracerebroventricular alpha-MSH on food intake, adiposity, c-Fos 
induction, and neuropeptide expression. Am J Physiol Regul Integr Comp 
Physiol 279, R695-703. 
 
Mens WB, Witter A & van Wimersma Greidanus TB. (1983). Penetration of 
neurohypophyseal hormones from plasma into cerebrospinal fluid (CSF): 
half-times of disappearance of these neuropeptides from CSF. Brain Res 262, 
143-149. 
 
Meyer-Lindenberg A, Domes G, Kirsch P & Heinrichs M. (2011). Oxytocin and 
vasopressin in the human brain: social neuropeptides for translational 
medicine. Nat Rev Neurosci 12, 524-538. 
 
Mimee A, Kuksis M & Ferguson AV. (2014). alpha-MSH exerts direct postsynaptic 
excitatory effects on NTS neurons and enhances GABAergic signaling in the 
NTS. Neuroscience 262, 70-82. 
 
Mimee A, Smith PM & Ferguson AV. (2013). Circumventricular organs: targets for 
integration of circulating fluid and energy balance signals? Physiol Behav 121, 
96-102. 
 
Miselis RR, Shapiro RE & Hand PJ. (1979). Subfornical organ efferents to neural 
systems for control of body water. Science 205, 1022-1025. 
 
Mitchell LD, Callahan MF, Wilkin LD, Gruber KA & Johnson AK. (1989). Activation 
of supraoptic magnocellular neurons by gamma 2-melanocyte stimulating 
hormone (gamma 2-MSH). Brain Res 480, 388-392. 
 
List of references  
161 
 
Miyata S. (2015). New aspects in fenestrated capillary and tissue dynamics in the 
sensory circumventricular organs of adult brains. Front Neurosci 9, 390. 
 
Modahl C, Fein D, Waterhouse L & Newton N. (1992). Does oxytocin deficiency 
mediate social deficits in autism? J Autism Dev Disord 22, 449-451. 
 
Modahl C, Green L, Fein D, Morris M, Waterhouse L, Feinstein C & Levin H. (1998). 
Plasma oxytocin levels in autistic children. Biol Psychiatry 43, 270-277. 
 
Modi ME, Inoue K, Barrett CE, Kittelberger KA, Smith DG, Landgraf R & Young LJ. 
(2015). Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent 
Partner Preference Formation in the Prairie Vole. Neuropsychopharmacology 
40, 1856-1865. 
 
Molden BM, Cooney KA, West K, Van Der Ploeg LH & Baldini G. (2015). Temporal 
cAMP Signaling Selectivity by Natural and Synthetic MC4R Agonists. Mol 
Endocrinol 29, 1619-1633. 
 
Molinoff PB, Shadiack AM, Earle D, Diamond LE & Quon CY. (2003). PT-141: a 
melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad 
Sci 994, 96-102. 
 
Monge-Roffarello B, Labbe SM, Roy MC, Lemay ML, Coneggo E, Samson P, Lanfray 
D & Richard D. (2014). The PVH as a site of CB1-mediated stimulation of 
thermogenesis by MC4R agonism in male rats. Endocrinology 155, 3448-3458. 
 
Moos F, Poulain DA, Rodriguez F, Guerne Y, Vincent JD & Richard P. (1989). 
Release of oxytocin within the supraoptic nucleus during the milk ejection 
reflex in rats. Exp Brain Res 76, 593-602. 
 
Morris JF & Pow DV. (1991). Widespread release of peptides in the central nervous 
system: quantitation of tannic acid-captured exocytoses. Anat Rec 231, 437-
445. 
 
Mountjoy KG, Jenny Wu CS, Dumont LM & Wild JM. (2003). Melanocortin-4 
receptor messenger ribonucleic acid expression in rat cardiorespiratory, 
musculoskeletal, and integumentary systems. Endocrinology 144, 5488-5496. 
 
List of references  
162 
 
Mountjoy KG, Kong PL, Taylor JA, Willard DH & Wilkison WO. (2001). 
Melanocortin receptor-mediated mobilization of intracellular free calcium in 
HEK293 cells. Physiol Genomics 5, 11-19. 
 
Mountjoy KG, Mortrud MT, Low MJ, Simerly RB & Cone RD. (1994). Localization of 
the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic 
control circuits in the brain. Mol Endocrinol 8, 1298-1308. 
 
Neumann I, Douglas AJ, Pittman QJ, Russell JA & Landgraf R. (1996). Oxytocin 
released within the supraoptic nucleus of the rat brain by positive feedback 
action is involved in parturition-related events. J Neuroendocrinol 8, 227-233. 
 
Neumann I, Ludwig M, Engelmann M, Pittman QJ & Landgraf R. (1993). 
Simultaneous microdialysis in blood and brain: oxytocin and vasopressin 
release in response to central and peripheral osmotic stimulation and 
suckling in the rat. Neuroendocrinology 58, 637-645. 
 
Neumann ID. (2007). Stimuli and consequences of dendritic release of oxytocin 
within the brain. Biochem Soc Trans 35, 1252-1257. 
 
Neumann ID. (2008). Brain oxytocin: a key regulator of emotional and social 
behaviours in both females and males. J Neuroendocrinol 20, 858-865. 
 
Neumann ID & Landgraf R. (2012). Balance of brain oxytocin and vasopressin: 
implications for anxiety, depression, and social behaviors. Trends Neurosci 35, 
649-659. 
 
Nickolls SA, Cismowski MI, Wang X, Wolff M, Conlon PJ & Maki RA. (2003). 
Molecular determinants of melanocortin 4 receptor ligand binding and 
MC4/MC3 receptor selectivity. J Pharmacol Exp Ther 304, 1217-1227. 
 
Nishimori K, Young LJ, Guo Q, Wang Z, Insel TR & Matzuk MM. (1996). Oxytocin is 
required for nursing but is not essential for parturition or reproductive 
behavior. Proc Natl Acad Sci U S A 93, 11699-11704. 
 
Nordmann JJ. (1983). Stimulus-secretion coupling. Prog Brain Res 60, 281-304. 
 
List of references  
163 
 
Normandin JJ & Murphy AZ. (2011). Somatic genital reflexes in rats with a nod to 
humans: anatomy, physiology, and the role of the social neuropeptides. 
Horm Behav 59, 656-665. 
 
Numan M, Fleming A & Levy F. (2006). Maternal Behavior. In Knobil and Neill’s 
Physiology of Reproduction, ed. JD. N, pp. 1921–1993. Academic Press, United 
States of America. 
 
Numan M & Young LJ. (2016). Neural mechanisms of mother-infant bonding and 
pair bonding: Similarities, differences, and broader implications. Horm Behav 
77, 98-112. 
 
O'Neill J, Brock C, Olesen AE, Andresen T, Nilsson M & Dickenson AH. (2012). 
Unravelling the mystery of capsaicin: a tool to understand and treat pain. 
Pharmacol Rev 64, 939-971. 
 
Oliet SH & Bourque CW. (1993). Mechanosensitive channels transduce 
osmosensitivity in supraoptic neurons. Nature 364, 341-343. 
 
Olszewski PK, Wirth MM, Shaw TJ, Grace MK, Billington CJ, Giraudo SQ & Levine 
AS. (2001). Role of alpha-MSH in the regulation of consummatory behavior: 
immunohistochemical evidence. Am J Physiol Regul Integr Comp Physiol 281, 
R673-680. 
 
Onaka T, Luckman SM, Antonijevic I, Palmer JR & Leng G. (1995). Involvement of 
the noradrenergic afferents from the nucleus tractus solitarii to the 
supraoptic nucleus in oxytocin release after peripheral cholecystokinin 
octapeptide in the rat. Neuroscience 66, 403-412. 
 
Paiva L, Sabatier N, Leng G & Ludwig M. (2017). Effect of Melanotan-II on Brain Fos 
Immunoreactivity and Oxytocin Neuronal Activity and Secretion in Rats. J 
Neuroendocrinol 29: n/a. doi:10.1111/jne.12454 
 
Palkovits M, Mezey E & Eskay RL. (1987). Pro-opiomelanocortin-derived peptides 
(ACTH/beta-endorphin/alpha-MSH) in brainstem baroreceptor areas of the 
rat. Brain Res 436, 323-338. 
 
Pardridge WM. (2011). Drug transport in brain via the cerebrospinal fluid. Fluids 
Barriers CNS 8, 7. 
List of references  
164 
 
Parker KJ, Kenna HA, Zeitzer JM, Keller J, Blasey CM, Amico JA & Schatzberg AF. 
(2010). Preliminary evidence that plasma oxytocin levels are elevated in 
major depression. Psychiatry Res 178, 359-362. 
 
Paxinos G & Watson C. (1998). The rat brain in stereotaxic coordinates. Academic Press, 
San Diego, CA. 
 
Pedersen CA, Ascher JA, Monroe YL & Prange AJ, Jr. (1982). Oxytocin induces 
maternal behavior in virgin female rats. Science 216, 648-650. 
 
Pedersen CA & Prange AJ, Jr. (1979). Induction of maternal behavior in virgin rats 
after intracerebroventricular administration of oxytocin. Proc Natl Acad Sci U 
S A 76, 6661-6665. 
 
Pellow S, Chopin P, File SE & Briley M. (1985). Validation of open:closed arm entries 
in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci 
Methods 14, 149-167. 
 
Pierroz DD, Ziotopoulou M, Ungsunan L, Moschos S, Flier JS & Mantzoros CS. 
(2002). Effects of acute and chronic administration of the melanocortin 
agonist MTII in mice with diet-induced obesity. Diabetes 51, 1337-1345. 
 
Pitts AF, Samuelson SD, Meller WH, Bissette G, Nemeroff CB & Kathol RG. (1995). 
Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and 
oxytocin concentrations in treated patients with major depression and 
controls. Biol Psychiatry 38, 330-335. 
 
Poulain DA & Wakerley JB. (1982). Electrophysiology of hypothalamic 
magnocellular neurones secreting oxytocin and vasopressin. Neuroscience 7, 
773-808. 
 
Pow DV & Morris JF. (1989). Dendrites of hypothalamic magnocellular neurons 
release neurohypophysial peptides by exocytosis. Neuroscience 32, 435-439. 
 
Quintana DS & Woolley JD. (2016). Intranasal Oxytocin Mechanisms Can Be Better 
Understood, but Its Effects on Social Cognition and Behavior Are Not to Be 
Sniffed At. Biol Psychiatry 79, e49-50. 
 
List of references  
165 
 
Ramirez D, Saba J, Carniglia L, Durand D, Lasaga M & Caruso C. (2015). 
Melanocortin 4 receptor activates ERK-cFos pathway to increase brain-
derived neurotrophic factor expression in rat astrocytes and hypothalamus. 
Mol Cell Endocrinol 411, 28-37. 
 
Renaud LP, Tang M, McCann MJ, Stricker EM & Verbalis JG. (1987). 
Cholecystokinin and gastric distension activate oxytocinergic cells in rat 
hypothalamus. Am J Physiol 253, R661-665. 
 
Ring RH, Schechter LE, Leonard SK, Dwyer JM, Platt BJ, Graf R, Grauer S, 
Pulicicchio C, Resnick L, Rahman Z, Sukoff Rizzo SJ, Luo B, Beyer CE, Logue 
SF, Marquis KL, Hughes ZA & Rosenzweig-Lipson S. (2010). Receptor and 
behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor 
agonist. Neuropharmacology 58, 69-77. 
 
Rinne P, Tikka S, Makela S, Streng T & Savontaus E. (2012). Hemodynamic actions 
and mechanisms of systemically administered alpha-MSH analogs in mice. 
Peptides 38, 150-158. 
 
Rodriguez EM. (1976). The cerebrospinal fluid as a pathway in neuroendocrine 
integration. J Endocrinol 71, 407-443. 
 
Rodriguez EM, Blazquez JL & Guerra M. (2010). The design of barriers in the 
hypothalamus allows the median eminence and the arcuate nucleus to enjoy 
private milieus: the former opens to the portal blood and the latter to the 
cerebrospinal fluid. Peptides 31, 757-776. 
 
Roselli-Rehfuss L, Mountjoy KG, Robbins LS, Mortrud MT, Low MJ, Tatro JB, 
Entwistle ML, Simerly RB & Cone RD. (1993). Identification of a receptor for 
gamma melanotropin and other proopiomelanocortin peptides in the 
hypothalamus and limbic system. Proc Natl Acad Sci U S A 90, 8856-8860. 
 
Ross HE, Cole CD, Smith Y, Neumann ID, Landgraf R, Murphy AZ & Young LJ. 
(2009). Characterization of the oxytocin system regulating affiliative 
behavior in female prairie voles. Neuroscience 162, 892-903. 
 
Rossler AS, Pfaus JG, Kia HK, Bernabe J, Alexandre L & Giuliano F. (2006). The 
melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in 
the female rat. Pharmacol Biochem Behav 85, 514-521. 
List of references  
166 
 
Rossoni E, Feng J, Tirozzi B, Brown D, Leng G & Moos F. (2008). Emergent 
synchronous bursting of oxytocin neuronal network. PLoS Comput Biol 4, 
e1000123. 
 
Rowland NE, Schaub JW, Robertson KL, Andreasen A & Haskell-Luevano C. (2010). 
Effect of MTII on food intake and brain c-Fos in melanocortin-3, 
melanocortin-4, and double MC3 and MC4 receptor knockout mice. Peptides 
31, 2314-2317. 
 
Rozen F, Russo C, Banville D & Zingg HH. (1995). Structure, characterization, and 
expression of the rat oxytocin receptor gene. Proc Natl Acad Sci U S A 92, 200-
204. 
 
Russell JA, Leng G & Douglas AJ. (2003). The magnocellular oxytocin system, the 
fount of maternity: adaptations in pregnancy. Front Neuroendocrinol 24, 27-61. 
 
Sabatier N, Brown CH, Ludwig M & Leng G. (2004). Phasic spike patterning in rat 
supraoptic neurones in vivo and in vitro. J Physiol 558, 161-180. 
 
Sabatier N, Caquineau C, Dayanithi G, Bull P, Douglas AJ, Guan XM, Jiang M, Van 
der Ploeg L & Leng G. (2003a). Alpha-melanocyte-stimulating hormone 
stimulates oxytocin release from the dendrites of hypothalamic neurons 
while inhibiting oxytocin release from their terminals in the 
neurohypophysis. J Neurosci 23, 10351-10358. 
 
Sabatier N, Caquineau C, Douglas AJ & Leng G. (2003b). Oxytocin released from 
magnocellular dendrites: a potential modulator of alpha-melanocyte-
stimulating hormone behavioral actions? Ann N Y Acad Sci 994, 218-224. 
 
Sabatier N & Leng G. (2006). Presynaptic actions of endocannabinoids mediate 
alpha-MSH-induced inhibition of oxytocin cells. Am J Physiol Regul Integr 
Comp Physiol 290, R577-584. 
 
Sanborn BM, Dodge K, Monga M, Qian A, Wang W & Yue C. (1998). Molecular 
mechanisms regulating the effects of oxytocin on myometrial intracellular 
calcium. Adv Exp Med Biol 449, 277-286. 
 
Sanchez-Andrade G & Kendrick KM. (2009). The main olfactory system and social 
learning in mammals. Behav Brain Res 200, 323-335. 
List of references  
167 
 
Sarkar MA. (1992). Drug metabolism in the nasal mucosa. Pharm Res 9, 1-9. 
 
Sasayama D, Hattori K, Teraishi T, Hori H, Ota M, Yoshida S, Arima K, Higuchi T, 
Amano N & Kunugi H. (2012). Negative correlation between cerebrospinal 
fluid oxytocin levels and negative symptoms of male patients with 
schizophrenia. Schizophr Res 139, 201-206. 
 
Sawchenko PE & Swanson LW. (1982a). Immunohistochemical identification of 
neurons in the paraventricular nucleus of the hypothalamus that project to 
the medulla or to the spinal cord in the rat. J Comp Neurol 205, 260-272. 
 
Sawchenko PE & Swanson LW. (1982b). The organization of noradrenergic 
pathways from the brainstem to the paraventricular and supraoptic nuclei in 
the rat. Brain Res 257, 275-325. 
 
Sawchenko PE & Swanson LW. (1983). The organization of forebrain afferents to the 
paraventricular and supraoptic nuclei of the rat. J Comp Neurol 218, 121-144. 
 
Sawchenko PE, Swanson LW & Joseph SA. (1982). The distribution and cells of 
origin of ACTH(1-39)-stained varicosities in the paraventricular and 
supraoptic nuclei. Brain Res 232, 365-374. 
 
Sawchenko PE, Swanson LW & Vale WW. (1984). Co-expression of corticotropin-
releasing factor and vasopressin immunoreactivity in parvocellular 
neurosecretory neurons of the adrenalectomized rat. Proc Natl Acad Sci U S A 
81, 1883-1887. 
 
Scantamburlo G, Hansenne M, Fuchs S, Pitchot W, Marechal P, Pequeux C, Ansseau 
M & Legros JJ. (2007). Plasma oxytocin levels and anxiety in patients with 
major depression. Psychoneuroendocrinology 32, 407-410. 
 
Scott V & Brown CH. (2011). Kisspeptin activation of supraoptic nucleus neurons in 
vivo. Endocrinology 152, 3862-3870. 
 
Serova LI, Laukova M, Alaluf LG & Sabban EL. (2013). Intranasal infusion of 
melanocortin receptor four (MC4R) antagonist to rats ameliorates 
development of depression and anxiety related symptoms induced by single 
prolonged stress. Behav Brain Res 250, 139-147. 
List of references  
168 
 
Serova LI, Laukova M, Alaluf LG & Sabban EL. (2014). Blockage of melanocortin-4 
receptors by intranasal HS014 attenuates single prolonged stress-triggered 
changes in several brain regions. J Neurochem 131, 825-835. 
 
Shapiro RE & Miselis RR. (1985). The central neural connections of the area 
postrema of the rat. J Comp Neurol 234, 344-364. 
 
Shen Y, Fu WY, Cheng EY, Fu AK & Ip NY. (2013). Melanocortin-4 receptor 
regulates hippocampal synaptic plasticity through a protein kinase A-
dependent mechanism. J Neurosci 33, 464-472. 
 
Shibuya I, Kabashima N, Ibrahim N, Setiadji SV, Ueta Y & Yamashita H. (2000). Pre- 
and postsynaptic modulation of the electrical activity of rat supraoptic 
neurones. Exp Physiol 85 Spec No, 145S-151S. 
 
Sibbald JR, Wilson BK & Day TA. (1989). Neuropeptide Y potentiates excitation of 
supraoptic neurosecretory cells by noradrenaline. Brain Res 499, 164-168. 
 
Siljee-Wong JE. (2011). Melanocortin MC(4) receptor expression sites and local 
function. Eur J Pharmacol 660, 234-240. 
 
Siljee JE, Unmehopa UA, Kalsbeek A, Swaab DF, Fliers E & Alkemade A. (2013). 
Melanocortin 4 receptor distribution in the human hypothalamus. Eur J 
Endocrinol 168, 361-369. 
 
Sisk CL, Richardson HN, Chappell PE & Levine JE. (2001). In vivo gonadotropin-
releasing hormone secretion in female rats during peripubertal development 
and on proestrus. Endocrinology 142, 2929-2936. 
 
Skipor J & Thiery JC. (2008). The choroid plexus--cerebrospinal fluid system: 
undervaluated pathway of neuroendocrine signaling into the brain. Acta 
Neurobiol Exp (Wars) 68, 414-428. 
 
Smith MA, Hisadome K, Al-Qassab H, Heffron H, Withers DJ & Ashford ML. 
(2007). Melanocortins and agouti-related protein modulate the excitability of 
two arcuate nucleus neuron populations by alteration of resting potassium 
conductances. J Physiol 578, 425-438. 
 
List of references  
169 
 
Smith MP, Ayad VJ, Mundell SJ, McArdle CA, Kelly E & Lopez Bernal A. (2006). 
Internalization and desensitization of the oxytocin receptor is inhibited by 
Dynamin and clathrin mutants in human embryonic kidney 293 cells. Mol 
Endocrinol 20, 379-388. 
 
Smithson KG, Weiss ML & Hatton GI. (1989). Supraoptic nucleus afferents from the 
main olfactory bulb--I. Anatomical evidence from anterograde and 
retrograde tracers in rat. Neuroscience 31, 277-287. 
 
Smithson KG, Weiss ML & Hatton GI. (1992). Supraoptic nucleus afferents from the 
accessory olfactory bulb: evidence from anterograde and retrograde tract 
tracing in the rat. Brain Res Bull 29, 209-220. 
 
Sofroniew MV & Glasmann W. (1981). Golgi-like immunoperoxidase staining of 
hypothalamic magnocellular neurons that contain vasopressin, oxytocin or 
neurophysin in the rat. Neuroscience 6, 619-643. 
 
Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH & Journot L. 
(1993). Differential signal transduction by five splice variants of the PACAP 
receptor. Nature 365, 170-175. 
 
Stoneham MD, Everitt BJ, Hansen S, Lightman SL & Todd K. (1985). Oxytocin and 
sexual behaviour in the male rat and rabbit. J Endocrinol 107, 97-106. 
 
Stoop R. (2012). Neuromodulation by oxytocin and vasopressin. Neuron 76, 142-159. 
 
Strauss GP, Keller WR, Koenig JI, Gold JM, Frost KH & Buchanan RW. (2015). 
Plasma oxytocin levels predict social cue recognition in individuals with 
schizophrenia. Schizophr Res 162, 47-51. 
 
Striepens N, Kendrick KM, Hanking V, Landgraf R, Wullner U, Maier W & 
Hurlemann R. (2013). Elevated cerebrospinal fluid and blood concentrations 
of oxytocin following its intranasal administration in humans. Sci Rep 3, 
3440. 
 
Summerlee AJ. (1981). Extracellular recordings from oxytocin neurones during the 
expulsive phase of birth in unanaesthetized rats. J Physiol 321, 1-9. 
 
List of references  
170 
 
Sunn N, Egli M, Burazin TC, Burns P, Colvill L, Davern P, Denton DA, Oldfield BJ, 
Weisinger RS, Rauch M, Schmid HA & McKinley MJ. (2002). Circulating 
relaxin acts on subfornical organ neurons to stimulate water drinking in the 
rat. Proc Natl Acad Sci U S A 99, 1701-1706. 
 
Sunn N, McKinley MJ & Oldfield BJ. (2001). Identification of efferent neural 
pathways from the lamina terminalis activated by blood-borne relaxin. J 
Neuroendocrinol 13, 432-437. 
 
Sutton GM, Perez-Tilve D, Nogueiras R, Fang J, Kim JK, Cone RD, Gimble JM, 
Tschop MH & Butler AA. (2008). The melanocortin-3 receptor is required for 
entrainment to meal intake. J Neurosci 28, 12946-12955. 
 
Swanson LW & Kuypers HG. (1980). The paraventricular nucleus of the 
hypothalamus: cytoarchitectonic subdivisions and organization of 
projections to the pituitary, dorsal vagal complex, and spinal cord as 
demonstrated by retrograde fluorescence double-labeling methods. J Comp 
Neurol 194, 555-570. 
 
Swanson LW & Sawchenko PE. (1983). Hypothalamic integration: organization of 
the paraventricular and supraoptic nuclei. Annu Rev Neurosci 6, 269-324. 
 
Theodosis DT, Paut L & Tappaz ML. (1986). Immunocytochemical analysis of the 
GABAergic innervation of oxytocin- and vasopressin-secreting neurons in 
the rat supraoptic nucleus. Neuroscience 19, 207-222. 
 
Thiele TE, van Dijk G, Yagaloff KA, Fisher SL, Schwartz M, Burn P & Seeley RJ. 
(1998). Central infusion of melanocortin agonist MTII in rats: assessment of 
c-Fos expression and taste aversion. Am J Physiol 274, R248-254. 
 
Thody AJ, Wilson CA & Everard D. (1981). alpha-Melanocyte stimulating hormone 
stimulates sexual behaviour in the female rat. Psychopharmacology (Berl) 74, 
153-156. 
 
Thorne RG, Pronk GJ, Padmanabhan V & Frey WH, 2nd. (2004). Delivery of insulin-
like growth factor-I to the rat brain and spinal cord along olfactory and 
trigeminal pathways following intranasal administration. Neuroscience 127, 
481-496. 
 
List of references  
171 
 
Tobin V, Leng G & Ludwig M. (2012). The involvement of actin, calcium channels 
and exocytosis proteins in somato-dendritic oxytocin and vasopressin 
release. Front Physiol 3, 261. 
 
Tobin VA, Douglas AJ, Leng G & Ludwig M. (2011). The involvement of voltage-
operated calcium channels in somato-dendritic oxytocin release. PLoS One 6, 
e25366. 
 
Tobin VA, Hurst G, Norrie L, Dal Rio FP, Bull PM & Ludwig M. (2004). 
Thapsigargin-induced mobilization of dendritic dense-cored vesicles in rat 
supraoptic neurons. Eur J Neurosci 19, 2909-2912. 
 
Trivedi P, Jiang M, Tamvakopoulos CC, Shen X, Yu H, Mock S, Fenyk-Melody J, 
Van der Ploeg LH & Guan XM. (2003). Exploring the site of anorectic action 
of peripherally administered synthetic melanocortin peptide MT-II in rats. 
Brain Res 977, 221-230. 
 
Ufnal M & Skrzypecki J. (2014). Blood borne hormones in a cross-talk between 
peripheral and brain mechanisms regulating blood pressure, the role of 
circumventricular organs. Neuropeptides 48, 65-73. 
 
Vaccari C, Lolait SJ & Ostrowski NL. (1998). Comparative distribution of 
vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain. 
Endocrinology 139, 5015-5033. 
 
Van der Ploeg LH, Martin WJ, Howard AD, Nargund RP, Austin CP, Guan X, 
Drisko J, Cashen D, Sebhat I, Patchett AA, Figueroa DJ, DiLella AG, 
Connolly BM, Weinberg DH, Tan CP, Palyha OC, Pong SS, MacNeil T, 
Rosenblum C, Vongs A, Tang R, Yu H, Sailer AW, Fong TM, Huang C, Tota 
MR, Chang RS, Stearns R, Tamvakopoulos C, Christ G, Drazen DL, Spar BD, 
Nelson RJ & MacIntyre DE. (2002). A role for the melanocortin 4 receptor in 
sexual function. Proc Natl Acad Sci U S A 99, 11381-11386. 
 
van Leengoed E, Kerker E & Swanson HH. (1987). Inhibition of post-partum 
maternal behaviour in the rat by injecting an oxytocin antagonist into the 
cerebral ventricles. J Endocrinol 112, 275-282. 
 
Veenema AH & Neumann ID. (2008). Central vasopressin and oxytocin release: 
regulation of complex social behaviours. Prog Brain Res 170, 261-276. 
List of references  
172 
 
Veening JG, de Jong TR, Waldinger MD, Korte SM & Olivier B. (2015). The role of 
oxytocin in male and female reproductive behavior. Eur J Pharmacol 753, 209-
228. 
 
Veinante P & Freund-Mercier MJ. (1997). Distribution of oxytocin- and vasopressin-
binding sites in the rat extended amygdala: a histoautoradiographic study. J 
Comp Neurol 383, 305-325. 
 
Velmurugan S, Brunton PJ, Leng G & Russell JA. (2010). Circulating secretin 
activates supraoptic nucleus oxytocin and vasopressin neurons via 
noradrenergic pathways in the rat. Endocrinology 151, 2681-2688. 
 
Verbalis JG, Stricker EM, Robinson AG & Hoffman GE. (1991). Cholecystokinin 
activates C-fos expression in hypothalamic oxytocin and corticotropin-
releasing hormone neurons. J Neuroendocrinol 3, 205-213. 
 
Vergoni AV, Poggioli R & Bertolini A. (1986). Corticotropin inhibits food intake in 
rats. Neuropeptides 7, 153-158. 
 
Vetter P, Roth A & Hausser M. (2001). Propagation of action potentials in dendrites 
depends on dendritic morphology. J Neurophysiol 85, 926-937. 
 
Wakerley JB & Lincoln DW. (1971). Intermittent release of oxytocin during suckling 
in the rat. Nat New Biol 233, 180-181. 
 
Wakerley JB & Lincoln DW. (1973). The milk-ejection reflex of the rat: a 20- to 40-
fold acceleration in the firing of paraventricular neurones during oxytocin 
release. J Endocrinol 57, 477-493. 
 
Waldherr M & Neumann ID. (2007). Centrally released oxytocin mediates mating-
induced anxiolysis in male rats. Proc Natl Acad Sci U S A 104, 16681-16684. 
 
Walf AA & Frye CA. (2007). The use of the elevated plus maze as an assay of 
anxiety-related behavior in rodents. Nat Protoc 2, 322-328. 
 
Walum H, Waldman ID & Young LJ. (2016). Statistical and Methodological 
Considerations for the Interpretation of Intranasal Oxytocin Studies. Biol 
Psychiatry 79, 251-257. 
List of references  
173 
 
Wan S, Browning KN, Coleman FH, Sutton G, Zheng H, Butler A, Berthoud HR & 
Travagli RA. (2008). Presynaptic melanocortin-4 receptors on vagal afferent 
fibers modulate the excitability of rat nucleus tractus solitarius neurons. J 
Neurosci 28, 4957-4966. 
 
Watson SJ & Akil H. (1979). The presence of two alpha-MSH positive cell groups in 
rat hypothalamus. Eur J Pharmacol 58, 101-103. 
 
Way SA & Leng G. (1992). Relaxin increases the firing rate of supraoptic neurones 
and increases oxytocin secretion in the rat. J Endocrinol 132, 149-158. 
 
Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R & Levine N. 
(1998). Synthetic melanotropic peptide initiates erections in men with 
psychogenic erectile dysfunction: double-blind, placebo controlled crossover 
study. J Urol 160, 389-393. 
 
Wessells H, Hruby VJ, Hackett J, Han G, Balse-Srinivasan P & Vanderah TW. (2003). 
Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2 induces penile erection via 
brain and spinal melanocortin receptors. Neuroscience 118, 755-762. 
 
Wessells H, Levine N, Hadley ME, Dorr R & Hruby V. (2000). Melanocortin receptor 
agonists, penile erection, and sexual motivation: human studies with 
Melanotan II. Int J Impot Res 12 Suppl 4, S74-79. 
 
Willets JM, Brighton PJ, Mistry R, Morris GE, Konje JC & Challiss RA. (2009). 
Regulation of oxytocin receptor responsiveness by G protein-coupled 
receptor kinase 6 in human myometrial smooth muscle. Mol Endocrinol 23, 
1272-1280. 
 
Williams JR, Insel TR, Harbaugh CR & Carter CS. (1994). Oxytocin administered 
centrally facilitates formation of a partner preference in female prairie voles 
(Microtus ochrogaster). J Neuroendocrinol 6, 247-250. 
 
Wilson JF. (1988). Low permeability of the blood-brain barrier to nanomolar 
concentrations of immunoreactive alpha-melanotropin. Psychopharmacology 
(Berl) 96, 262-266. 
 
List of references  
174 
 
Wilson JF, Anderson S, Snook G & Llewellyn KD. (1984). Quantification of the 
permeability of the blood-CSF barrier to alpha-MSH in the rat. Peptides 5, 
681-685. 
 
Witt DM & Insel TR. (1994). Increased Fos expression in oxytocin neurons following 
masculine sexual behavior. J Neuroendocrinol 6, 13-18. 
 
Xia Y & Wikberg JE. (1996). Localization of ACTH receptor mRNA by in situ 
hybridization in mouse adrenal gland. Cell Tissue Res 286, 63-68. 
 
Yanagimoto M, Honda K, Goto Y & Negoro H. (1996). Afferents originating from 
the dorsal penile nerve excite oxytocin cells in the hypothalamic 
paraventricular nucleus of the rat. Brain Res 733, 292-296. 
 
Yang CR, Senatorov VV & Renaud LP. (1994). Organum vasculosum lamina 
terminalis-evoked postsynaptic responses in rat supraoptic neurones in 
vitro. J Physiol 477, 59-74. 
 
Yang Y. (2011). Structure, function and regulation of the melanocortin receptors. Eur 
J Pharmacol 660, 125-130. 
 
Yang Y, Chen M, Lai Y, Gantz I, Georgeson KE & Harmon CM. (2002). Molecular 
determinants of human melanocortin-4 receptor responsible for antagonist 
SHU9119 selective activity. J Biol Chem 277, 20328-20335. 
 
Yoshida M, Iwasaki Y, Asai M, Takayasu S, Taguchi T, Itoi K, Hashimoto K & Oiso 
Y. (2006). Identification of a functional AP1 element in the rat vasopressin 
gene promoter. Endocrinology 147, 2850-2863. 
 
Young KA, Liu Y, Gobrogge KL, Wang H & Wang Z. (2014). Oxytocin reverses 
amphetamine-induced deficits in social bonding: evidence for an interaction 
with nucleus accumbens dopamine. J Neurosci 34, 8499-8506. 
 
Young LJ. (1999). Frank A. Beach Award. Oxytocin and vasopressin receptors and 
species-typical social behaviors. Horm Behav 36, 212-221. 
 
Young LJ, Lim MM, Gingrich B & Insel TR. (2001). Cellular mechanisms of social 
attachment. Horm Behav 40, 133-138. 
List of references  
175 
 
Young LJ & Wang Z. (2004). The neurobiology of pair bonding. Nat Neurosci 7, 1048-
1054. 
 
Young LJ, Wang Z, Donaldson R & Rissman EF. (1998). Estrogen receptor alpha is 
essential for induction of oxytocin receptor by estrogen. Neuroreport 9, 933-
936. 
 
Young WS, 3rd, Shepard E, Amico J, Hennighausen L, Wagner KU, LaMarca ME, 
McKinney C & Ginns EI. (1996). Deficiency in mouse oxytocin prevents milk 
ejection, but not fertility or parturition. J Neuroendocrinol 8, 847-853. 
 
Yulis CR, Peruzzo B & Rodriguez EM. (1984). Immunocytochemistry and 
ultrastructure of the neuropil located ventral to the rat supraoptic nucleus. 
Cell Tissue Res 236, 171-180. 
 
Yulis CR & Rodriguez EM. (1982). Neurophysin pathways in the normal and 
hypophysectomized rat. Cell Tissue Res 227, 93-112. 
 
Zaidi SM & Heller H. (1974). Can neurohypophysial hormones cross the blood-
cerebrospinal fluid barrier? J Endocrinol 60, 195-196. 
 
Zelena D, Langnaese K, Domokos A, Pinter O, Landgraf R, Makara GB & 
Engelmann M. (2009). Vasopressin administration into the paraventricular 
nucleus normalizes plasma oxytocin and corticosterone levels in Brattleboro 
rats. Endocrinology 150, 2791-2798. 
 
Zelena D, Pinter O, Langnaese K, Richter K, Landgraf R, Makara GB & Engelmann 
M. (2013). Oxytocin in Brattleboro rats: increased synthesis is contrasted by 
blunted intrahypothalamic release from supraoptic nucleus neurones. J 
Neuroendocrinol 25, 711-718. 
 
Zhang Y, Rodriguez AL & Conn PJ. (2005). Allosteric potentiators of metabotropic 
glutamate receptor subtype 5 have differential effects on different signaling 
pathways in cortical astrocytes. J Pharmacol Exp Ther 315, 1212-1219. 
 
Zhang ZH & Felder RB. (2004). Melanocortin receptors mediate the excitatory effects 
of blood-borne murine leptin on hypothalamic paraventricular neurons in 
rat. Am J Physiol Regul Integr Comp Physiol 286, R303-310. 
List of references  
176 
 
Zoccal DB, Furuya WI, Bassi M, Colombari DS & Colombari E. (2014). The nucleus 
of the solitary tract and the coordination of respiratory and sympathetic 
activities. Front Physiol 5, 238. 
 
Zoicas I, Slattery DA & Neumann ID. (2014). Brain oxytocin in social fear 
conditioning and its extinction: involvement of the lateral septum. 














































































































































































































1 Values expressed as the mean ± S.E.M. cells per 104 μm2, otherwise stated (OT %, percentage
of oxytocin neurones expressing Fos). Number of animals in parentheses. cAMG ‐ central
amygdala, NTS ‐ nucleus tractus solitarii, OLVT ‐ organum vasculosum lamina terminalis, OT
– oxytocin, PVN ‐ paraventricular nucleus, mPVN ‐magnocellular PVN, pPVN ‐ parvocellular



























































1 Values expressed as the mean ± S.E.M. cells per 104μm2, otherwise stated (OT %, percentage
of oxytocin neurones expressing Fos). number of animals in parentheses. AOB ‐ accessory
olfactory bulb, EPL ‐ external plexiform layer, MCL ‐ mitral cell layer, OT ‐ oxytocin, PVN ‐











































































1 Values expressed as the mean ± S.E.M. cells per 104 μm2, otherwise stated (OT %, percentage
of oxytocin neurones expressing Fos). Number of animals in parentheses. OT ‐ oxytocin, PVN
‐ paraventricular nucleus, mPVN ‐ magnocellular PVN, pPVN ‐ parvocellular PVN, SON ‐
supraoptic nucleus.
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